前往化源商城

3575-80-2 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: SNCA-p-activity-luciferase
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION

1; Cells; 4 uL; Dispense 1500 HEK-293-SNCA-luc cells/well into Greiner 1536-well white / solid bottom tissue culture treated plate. The plate was covered with metal lids with gas-exchange holes.
2; Incubate; 24 hours; Incubate at 37C, 5% CO2, 95% RH.
3; Compounds; 23 nL; Compounds and controls were transferred via a Kalypsys Pin Tool (Wako USA) equipped with a 1536-slotted pin array. The plate was covered with metal lids with gas-exchange holes.
4; Incubate; 24 hours; Incubate at 37C, 5% CO2, 95% RH.
5; Dispense; 1 uL; Dispense Gly-Phe-7-amino-4-trifluoromethylcoumarin (GF-AFC, prepared at 125 uM in PBS) was added. The plate was covered with metal lids with gas-exchange holes.
6; Incubate; 30 min; Incubate at 37C, 5% CO2.
7; Detector; Fluorescence; Measure fluorescence with ViewLux microplate reader (PerkinElmer) equipped with 405/10 excitation and 540/25 emission filters.
8; Dispense; 3 uL; Dispense ONE-Glo (PerkinElmer) lucifase detection reagent was added to each well. Plates were covered with metal lids with gas-exchange holes.
9; Incubate; 15 min; Incubate at room temperature.
10; Detector; Luminescence; Measure luminescence with ViewLux microplate reader (PerkinElmer) equipped with clear filters.

NOTES (numbers refer to sequence above)
1; HEK-293-SNCA-luc were cultured and suspended in phenol-red free DMEM (4.5 g/L glucose, 25 mM HEPES, cat #21063 (Thermo)).
3; Compounds were added to the assay plate in an 11-point intra plate dose response, 1:3 titration in DMSO with a final concentration range of xxx - yyy uM. Vehicle-only plates, with DMSO being pin-transferred to every well, were inserted at the beginning of screening runs to confirm expected assay performance. Activity was normalized to wells containing medium only (-100% activity, full inhibition) and SNCA-luc cells treated with DMSO vehicle control (0% activity), contained on the same plate as test samples.
10; Signals were analyzed, and dose-response curves were fit using the Hill equation. Compounds in curve classes -1.1, -1.2, -2.1, -2.2 in the SNCA-luc assay were considered active. Compounds were eliminated from further consideration if also active (curve class -1.1, -1.2, -1.3, -1.4, -2.1, -2.2, -2.3, -2.4) in the GF-AFC cytotoxicity assay.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000386857 uMActivity at 0.0001060182 uMActivity at 0.0001896372 uMActivity at 0.0004510146 uMActivity at 0.0007501981 uMActivity at 0.0009728036 uMActivity at 0.00288 uMActivity at 0.00508 uMActivity at 0.00871 uMActivity at 0.015 uMActivity at 0.026 uMActivity at 0.053 uMActivity at 0.079 uMActivity at 0.232 uMActivity at 0.457 uMActivity at 0.692 uMActivity at 1.068 uMActivity at 2.292 uMActivity at 3.859 uMActivity at 11.39 uMActivity at 17.02 uMActivity at 25.62 uMActivity at 57.25 uMActivity at 87.55 uMActivity at 183.4 uMActivity at 286.0 uMCompound QC
Inactive0-6.754.95490.97270.090117.540 0 0 18.940815.9527-1.59161.49698.9408QC'd by Sytravon
Inactive0-5.34.0950.99965.5-7.782340 0 0 1-11.1081-7.5736-7.73535.034-11.1081QC'd by Sytravon
Inactive0-5.154.95490.907-15.92079.540 0 0 117.87255.287413.9021-13.683917.8725QC'd by Sytravon
Activator35.481346.40950Single point of activity-4.452.5884145.9404-0.469131 0 0 035.59340.1678-0.39091.93335.593QC'd by Sytravon
Activator39.810772.26460Single point of activity-4.44.95490.951568.1912-4.073330 0 0 058.01175.8738-9.2278-8.522458.0117QC'd by Sytravon
Activator14.125445.33190Partial curve; partial efficacy; poor fit-4.852.40640.998240.7728-4.55912.41 0 0 040.0933-24.9557-3.884511.525440.0933QC'd by Sytravon
Inactive0-5.754.95490.9291-20.608633.154541 0 0 0-12.846445.456928.2161-28.42-12.8464QC'd by Sytravon
Inactive0-4.354.95490.855-24.2184-0.540 0 0 0-18.932-3.6477-2.4094.988-18.932QC'd by Sytravon
Inactive0-4.73.62720.862515-8.552340 0 0 014.477-2.951-13.7936-5.964614.477QC'd by Sytravon
Inactive0-6.74.95490.66373-16.86440 0 0 08.8169-15.726.3794-6.35998.8169QC'd by Sytravon
Inactive0-4.752.40640.999921.5-2.410141 0 0 020.218433.3778-2.42513.577120.2184QC'd by Sytravon
Inactive0-4.44.95490.81172.5-8.34540 0 0 01.096-8.966-5.5054-11.12091.096QC'd by Sytravon
Activator39.810738.79450Single point of activity-4.44.95490.624141.75572.961230 0 0 036.203921.355-6.3904-4.532536.2039QC'd by Sytravon
Inactive0-6.054.0950.9994-6.05182040 0 0 120.515619.73771.4122-6.293220.5156QC'd by Sytravon
Inactive0-5.24.095110.5-10.168341 0 0 1-15.988436.1362-10.14028.7939-15.9884QC'd by Sytravon
Inactive0-6.51.39050.9999-24.2410.274540 0 0 1-5.5981-4.3546-20.7587-23.9509-5.5981QC'd by Sytravon
Inactive0-6.84.95490.711-2.44592140 0 0 0-3.345317.3219-9.95495.5495-3.3453QC'd by Sytravon
Activator39.810747.8090Partial curve; partial efficacy; poor fit-4.44.95490.521250.23992.43092.40 0 0 043.472230.2363-10.9855-11.514343.4722QC'd by Sytravon
Activator22.387275.50810Partial curve; high efficacy; poor fit-4.651.96730.982996.532421.02432.30 0 0 086.498526.093216.336536.261386.4985QC'd by Sytravon
Inactive0-6.84.95490.7429-1-13.073840 0 0 01.8063-11.31150.8702-5.17571.8063QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: CYP273
Protocol: Tox21 Assay Protocol Summary:

Two ul of enzyme-substrate mix was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a BioRaptr Flying Reagent Dispenser (FRD, Beckman Coulter, Brea, CA). Compounds dissolved in DMSO and positive control (furafyllline) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at room temperature for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000075213 uM-Replicate_1Activity at 0.0000171744 uM-Replicate_1Activity at 0.0000689059 uM-Replicate_1Activity at 0.0001619730 uM-Replicate_1Activity at 0.0003751800 uM-Replicate_1Activity at 0.0007781017 uM-Replicate_1Activity at 0.00212 uM-Replicate_1Activity at 0.00657 uM-Replicate_1Activity at 0.017 uM-Replicate_1Activity at 0.038 uM-Replicate_1Activity at 0.085 uM-Replicate_1Activity at 0.191 uM-Replicate_1Activity at 0.435 uM-Replicate_1Activity at 1.330 uM-Replicate_1Activity at 4.074 uM-Replicate_1Activity at 10.46 uM-Replicate_1Activity at 23.64 uM-Replicate_1Activity at 52.95 uM-Replicate_1Activity at 115.2 uM-Replicate_1Activity at 299.6 uM-Replicate_1Activity at 1087.9 uM-Replicate_1Activity at 2306.0 uM-Replicate_1Activity at 5157.0 uM-Replicate_1Activity at 11530.0 uM-Replicate_1Activity at 25780.0 uM-Replicate_1Activity at 57660.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-3.5643-2.3504-2.9312-2.3657-2.8224-2.60180.03942.8539-0.9099-0.8614-3.0049-2.5808-0.7-3.5643QC'd by SIGMAInactive0
Inactive0004-4.9449-1.1401-4.88281.72781.7167-2.1117-5.69640.39330.89390.1314-2.73353.195-4.9521-4.9449QC'd by SIGMAInactive0
Inactive00042.7107-2.18841.39851.45820.7693-2.47871.522.89860.9702-0.02532.12932.77661.5392.7107QC'd by EnamineInactive0
Inactive0004-2.1522-2.3143-3.894-2.36983.0635-2.9724-0.6981.807-0.3874-2.23870.0851-4.19653.0171-2.1522QC'd by SIGMAInactive0
Inactive0-4.34892.25260.8543-15.2749-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-14.3957-1.8486-1.8251-1.3415-0.2999-5.8043-1.46250.1520.0394-2.6869-2.4228-2.2664-9.6519-14.3957QC'd by SIGMAInactive0-4.09892.18760.881
Inactive0-4.39891.34430.8661-18.2112-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-16.0093-2.34660.81450.3878-0.5249-2.2045-0.0596-0.3675-2.1137-2.5302-0.6582-8.8446-8.7305-16.0093QC'd by AcrosInactive0-4.19891.62660.9372
Inactive0-4.37131.3310.7782-33.4439-3.50340 0 0 0 0 0 0 0 0 0 0 0 0 0 0-29.5366-4.0189-0.7745-2.4487-0.7353-13.4714-1.9963-2.0808-1.5803-2.9931-5.0804-13.0346-7.2628-16.8143-29.5366QC'd by LightBiologicalsInactive0-4.37131.22210.9463
Inactive0-4.14891.62660.9461-28.1716-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-20.143-1.7608-0.23880.22480.5264-2.4986-0.1313-2.2365-0.2423-3.4362-3.0971-3.2181-11.2156-20.143QC'd by EnamineInhibitor79.640731.491610Partial curve; partial efficacy; poor fit-4.09892.58840.988
Inhibitor79.640737.878410Partial curve; partial efficacy; poor fit-4.09892.33320.6037-41.3784-3.5-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-31.14860.0477-0.2424-0.1109-17.1482-2.60430.09871.3021-8.8121-0.6811-2.6079-6.0005-11.8578-31.1486QC'd by LightBiologicalsInhibitor70.979933.811310Partial curve; partial efficacy; poor fit-4.14891.47870.9532
Inactive0-4.14891.3310.6595-35.6335-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-26.36121.8269-1.26512.0528-1.3342-1.1508-1.3078-0.329-8.12350.9213-0.3901-8.3475-13.4823-26.3612QC'd by LightBiologicalsInhibitor63.260940.716221Partial curve; partial efficacy-4.19891.55790.9889
Inhibitor31.7055100.219240Partial curve; high efficacy-4.49891.41630.9793-102.2947-2.0755-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-88.79751.59931.9578-0.4182-5.9156-12.3257-6.81250.6301-0.9357-7.8675-21.9718-39.1747-68.2733-88.7975QC'd by SIGMAInhibitor28.2576108.402740Partial curve; high efficacy-4.54891.24750.9984
Inactive0-4.44891.53860.9285-23.7863140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.48852.58192.144-0.92281.57780.3813-0.7273-0.01780.48032.4385-0.728-9.9293-11.8247-21.4885QC'd by SIGMAInactive0-4.39891.62590.9598
Inhibitor9.333739.896721Complete curve; partial efficacy-5.02992.04370.9899-39.89670-1.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-36.3129-0.2423-0.4463-0.29990.64780.36361.006-0.49871.2825-1.1546-7.8589-17.895-35.8398-36.3129QC'd by LightBiologicalsInhibitor11.750456.388421Partial curve; partial efficacy-4.92991.1110.9845
Inhibitor31.7055101.457340Partial curve; high efficacy-4.49891.1110.9982-102.7597-1.3024-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-82.349-1.7206-3.1014-1.0307-0.462-0.0614-0.5481-3.1286-4.6801-13.1432-23.5612-42.1146-67.192-82.349QC'd by SIGMAInhibitor25.184689.509140Partial curve; high efficacy-4.59891.37230.9943
Inactive0-4.39891.37230.9408-30.7143-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-27.2619-3.9038-4.25970.95220.2767-0.086-3.7725-0.0863-0.3476-4.4856-5.6587-11.4378-17.5999-27.2619QC'd by EnamineInactive0-4.39891.37230.9104
Inhibitor0.0291.537495Complete curve; high efficacy-7.69891.210.9985-95.5053-3.9679-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-96.9758-10.1145-26.2532-42.3865-67.4835-79.9456-90.8539-91.593-94.2489-95.4721-96.0956-96.1267-97.0582-96.9758QC'd by SIGMAInhibitor0.141694.840291Complete curve; high efficacy-6.84891.210.9987
Inhibitor70.979957.401421Partial curve; partial efficacy-4.14891.46410.9678-60.4859-3.0846-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-45.8227-1.5241-1.1304-2.119-3.4583-2.7138-4.9163-1.3699-5.0741-7.7268-8.2608-10.3758-24.1789-45.8227QC'd by TCIInhibitor63.260959.370621Partial curve; partial efficacy-4.19891.82650.9826
Inhibitor31.705588.458340Partial curve; high efficacy-4.49891.24750.9907-90.0614-1.6031-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-73.0646-2.1792-0.7242-0.9217-2.0267-1.1711-1.4022-1.5555-4.0648-12.1704-19.1709-32.2561-64.0802-73.0646QC'd by SIGMAInhibitor31.705586.838540Partial curve; high efficacy-4.49891.1110.9934
Inhibitor7.09899.944883Complete curve; high efficacy-5.14891.34430.9949-102.6257-2.681-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-98.8687-2.2636-1.9377-0.2674-0.3864-3.2139-8.5636-4.0834-14.5383-36.543-60.2337-91.3595-96.848-98.8687QC'd by TCIInhibitor5.638199.072784Complete curve; high efficacy-5.24891.62660.998
Inhibitor14.162399.52242Partial curve; high efficacy-4.84890.70.9894-100.6417-1.1197-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-88.2822-1.4919-2.9847-0.2649-1.6478-3.8502-2.8959-7.6423-18.6375-36.1235-44.1844-53.91-71.7844-88.2822QC'd by SIGMAInhibitor17.829395.774281Complete curve; high efficacy-4.74891.210.9995
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: P53600
Protocol: Tox21 Assay Protocol Summary:

The p53RE-bla cells were dispensed at 4,000 cells/5 ul/well in 1536-well black wall/clear bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 16 hours. After 1 uL of LiveBLAzerTM B/G FRET substrate was added using a Flying Reagent Dispenser, the plates were incubated at room temperature for 2 hours, and fluorescence intensity was measured by an Envision plate reader. For cell viability readout that measures cytotoxicity, 4 ul/well of CellTiter-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).
Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000043054 uM-Replicate_1Activity at 0.0000099513 uM-Replicate_1Activity at 0.0000394398 uM-Replicate_1Activity at 0.0000922287 uM-Replicate_1Activity at 0.0002147056 uM-Replicate_1Activity at 0.0004452702 uM-Replicate_1Activity at 0.00122 uM-Replicate_1Activity at 0.00376 uM-Replicate_1Activity at 0.00955 uM-Replicate_1Activity at 0.022 uM-Replicate_1Activity at 0.049 uM-Replicate_1Activity at 0.109 uM-Replicate_1Activity at 0.249 uM-Replicate_1Activity at 0.761 uM-Replicate_1Activity at 2.332 uM-Replicate_1Activity at 5.986 uM-Replicate_1Activity at 13.53 uM-Replicate_1Activity at 30.31 uM-Replicate_1Activity at 65.96 uM-Replicate_1Activity at 171.5 uM-Replicate_1Activity at 622.7 uM-Replicate_1Activity at 1320.0 uM-Replicate_1Activity at 2952.0 uM-Replicate_1Activity at 6600.0 uM-Replicate_1Activity at 14760.0 uM-Replicate_1Activity at 33000.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive000411.68960.1156-13.79419.96613.16310.7283-0.13048.42250.8152-0.10070.800321.2177-5.098911.6896QC'd by GVKInconclusive22.349231.210810Partial curve; partial efficacy; poor fit-4.65074.95490.8311
Inactive00044.1278-1.2132-0.531.1724-13.6008-15.8488-1.6086-19.5261-1.84034.6782.76125.28040.28044.1278QC'd by SequoiaInactive0
Inactive0004-9.80083.31944.9321-4.8812-12.78760.30429.0414-8.94990.223314.08858.8057-15.4411-4.9694-9.8008QC'd by TocrisInactive0
Inactive0004-1.97565.0865-1.7855-7.44442.244-1.822215.634118.165121.11031.735-10.98693.971310.803-1.9756QC'd by MicrosourceInactive0
Inactive00046.85951.21214.5834-1.147427.33062.48186.32539.01910.214520.70491.9499-9.1091-8.70446.8595QC'd by SIGMAInactive0
Inactive0-4.80072.09370.639333.4297-12.96840 0 0 0 0 0 0 0 0 0 0 1 0 0 025.4284-14.8066-9.0853-13.581-7.588-35.7992-8.9477-21.4634-0.5226-3.92488.5216-5.58437.506325.4284QC'd by MicrosourceInactive0
Inactive0004-15.007-3.1282-9.3591-0.59167.66516.92395.64735.12210.15582.5991-1.3526-6.47-0.785-15.007QC'd by MicrosourceInactive0
Inactive000424.0896-0.8446-9.61-6.08550.45112.491311.00488.98224.16252.593115.94870.8545-5.437324.0896QC'd by VitasInactive0
Inactive0004-17.67891.269819.24249.9274-7.42686.6741.6608-11.9547-6.5433-0.12947.7321-0.9298-3.0587-17.6789QC'd by SequoiaInactive0
Inactive0004-14.1816-14.82752.70742.3606-2.2355-4.2683-14.785-4.9866-14.55780.587-5.4301-8.78443.5884-14.1816QC'd by MicrosourceInactive0-9.20073.19250.6375
Inactive0004-1.2316-19.54044.6965-1.2942-1.67070.2407-15.5972-0.1313-8.4723-7.3738-1.20892.41540.8864-1.2316QC'd by SequoiaInactive0
Inactive00041.5567-5.753613.963810.2956-0.5580-1.68249.770620.988-2.01438.1577-7.9909-2.67841.5567QC'd by VitasInactive0
Inactive0-5.00071.96730.395926.0362-2.459340 0 0 0 0 0 0 0 0 1 0 0 0 0 10.23290.7504-0.0238-13.01490.91413.2757.6-0.817-14.514333.15894.5704-6.010126.66430.2329QC'd by VitasInactive0-7.85074.95490.3764
Inactive00040.4996-11.00798.4449-5.51661.0437-5.31884.2154-11.5318-0.68280.560410.3541-10.0764-3.39490.4996QC'd by SequoiaInactive0
Inactive0004-11.29821.6112-9.15080.0988-19.993-7.174916.2891-28.8965-0.2185-13.4455-15.182-7.4087.9797-11.2982QC'd by SIGMAInactive0
Cytotoxic0.001329.371420Complete curve; partial efficacy; poor fit-8.90074.95490.6762-1.930827.4406-1.40 0 0 0 0 0 0 0 0 0 0 0 0 0 02.084327.380322.2956-1.7991-14.5009-13.0557-1.27961.8292-4.68462.1858-2.80191.152812.67842.0843QC'd by MicrosourceInactive0
Cytotoxic22.349237.143520Single point of activity-4.65074.95490.6826-37.6249-0.4814-30 0 0 0 0 0 1 0 0 0 0 0 0 0 0-35.0886-10.0183-3.78480.92698.32995.971651.8329-7.9197-7.10119.7258-3.0119-1.82540.4137-35.0886QC'd by MicrosourceCytotoxic19.918841.056720Single point of activity-4.70074.50450.7845
Inactive0004-8.20534.878-0.8843.033-7.545116.823-9.3197.52683.3384-2.1505-2.9445-18.3014-0.1048-8.2053QC'd by SpecsInconclusive25.076243.037610Single point of activity-4.60074.95490.5622
Inactive000420.76650.814812.61279.9828-12.22150.44040.7956-15.56271.1625-6.82596.0669-0.0505-1.196720.7665QC'd by Prestwick Chemical; Inc.Inconclusive22.349234.562510Single point of activity-4.65074.0950.9286
Inconclusive8.897437.738210Single point of activity-5.05073.1320.718338.15130.413130 0 0 0 0 0 0 0 0 0 0 0 0 0 1-5.95941.40094.89037.6788-4.8095-4.8507-6.912-0.4163-7.58221.59434.88844.768442.6535-5.9594QC'd by MicrosourceInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: P53MS958
Protocol: Tox21 Assay Protocol Summary:

The p53RE-bla cells were dispensed at 4,000cells/3ul/well in 1536-well black-clear bottom plates. After the assay plates were incubated at 37 C, 5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate. Following compound addition, 3 uL of rat liver microsomes (Molecular Toxicology, Boone, NC) at final concentration of 0.5 mg/mL and 1uL of B-Nicotinamide adenine dinucleotide 2'-phosphate (NADPH) at final concentration of 0.5 mg/mL were transferred to the assay plate. The plates were incubated at 37 C for 16 hours. 1 uL of LiveBLAzer detection mixture was added to each well and the plates were incubated at room temperature in the dark for 2 h. Fluorescence intensity at 460 and 530 nm emission and 405 nm excitation were measured by an Envision plate reader. For cell viability readout that measures cytotoxicity, 4 ul/well of CellTiter-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000043235 uM-Replicate_1Activity at 0.0000098296 uM-Replicate_1Activity at 0.0000380988 uM-Replicate_1Activity at 0.0000933477 uM-Replicate_1Activity at 0.0002146311 uM-Replicate_1Activity at 0.0004426192 uM-Replicate_1Activity at 0.00122 uM-Replicate_1Activity at 0.00372 uM-Replicate_1Activity at 0.00957 uM-Replicate_1Activity at 0.022 uM-Replicate_1Activity at 0.049 uM-Replicate_1Activity at 0.109 uM-Replicate_1Activity at 0.249 uM-Replicate_1Activity at 0.768 uM-Replicate_1Activity at 2.332 uM-Replicate_1Activity at 5.986 uM-Replicate_1Activity at 13.53 uM-Replicate_1Activity at 30.31 uM-Replicate_1Activity at 65.96 uM-Replicate_1Activity at 171.5 uM-Replicate_1Activity at 622.7 uM-Replicate_1Activity at 1320.0 uM-Replicate_1Activity at 2952.0 uM-Replicate_1Activity at 6600.0 uM-Replicate_1Activity at 14760.0 uM-Replicate_1Activity at 33000.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive000415.4129-0.3878-0.18645.37348.8557-0.29272.5035-10.205-0.2227.988-2.2891.52765.497915.4129QC'd by ACCInactive0
Inactive0-9.30074.95490.81131-17.707840 0 0 0 0 0 0 0 0 0 0 0 0 0 01.0149-13.08993.2756-1.32141.18321.8535-0.3978-0.4282.5506-0.24571.49181.68870.55861.0149QC'd by ACCInactive0
Inactive00040.0279-7.8342-1.89942.16960.5638-6.7392.6266-0.50970.73195.3764-7.7238-0.06747.02780.0279QC'd by ACCInactive0
Inactive00041.38786.287211.3346-1.35856.9465-2.58585.0519-2.5689.0021.6411-1.72927.00831.07741.3878QC'd by ACCInactive0-5.45072.40640.4602
Inactive0004-6.0549-14.8117-16.0755-3.9155-14.9771-10.937-32.5334-11.9531.4447-12.5843-18.1191-11.5121-10.2319-6.0549QC'd by RTIInactive0
Inactive0004-22.5649-3.3758-16.2168-4.5428-4.51510.1292-2.6754-23.201-8.3262-3.0518-1.1305-3.6383-2.6115-22.5649QC'd by RTIInactive0-8.59910.80.691
Inactive0004-0.2302-3.0733-11.95531.9394-0.062-0.7676-9.0695-1.09531.199-3.6509-10.3544-18.6262-9.6473-0.2302QC'd by RTIInactive0-4.20294.95490.345
Inactive0004-31.97-9.3562-1.8629-4.3936-8.3595-10.443-39.3827-2.50720.54372.3156-5.5145-4.9746-4.5578-31.97QC'd by RTIInactive0
Cytotoxic48.936540.016120Single point of activity-4.31044.95490.9076-41.0161-1-30 0 0 0 0 0 0 0 0 0 0 0 0 0 10.8752-0.1555-0.1471-0.86110.5088-1.62211.8567-5.5667-4.26740.6449-1.1659-1.471-37.97790.8752QC'd by RTIInactive0
Inactive0-4.4812.25260.6231-17.4881-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-14.1568-8.0428-0.62356.2346-0.9991-1.44871.2877-1.82882.3924-2.4336-0.4068-0.0819-10.8685-14.1568QC'd by RTIInactive0
Inactive0-4.15464.95490.3365-27.53820.41540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.24640.0979-1.09382.89261.68642.0417-11.5049-1.00074.87532.0771-10.214919.6036-0.4282-21.2464QC'd by RTIInactive0-4.35463.92950.4572
Cytotoxic1.909462.99420Single point of activity-5.71914.95490.8427-65.284-2.29-30 0 0 0 0 0 0 0 0 0 0 1 1 1 121.2448-4.4527-11.9693-0.7569-1.67770.0603-12.88981.4183.8556-64.004-3.125819.149730.660221.2448QC'd by RTIInconclusive26.970339.101610Partial curve; partial efficacy-4.56912.40640.8048
Inactive0-5.73594.95490.4398-11.70950.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-18.5079-13.1487-1.13453.01137.6647-1.76074.95091.42740.7821-7.5706-10.5531-11.2568-1.1121-18.5079QC'd by RTIInactive0-5.13593.990.4729
Inactive0-4.91744.95490.4007150.513840 0 0 0 0 0 0 0 0 0 0 0 0 0 1-8.2124-6.4957-1.34376.24526.8209-1.5109-0.187612.48363.7645-4.0819-5.983812.929113.901-8.2124QC'd by RTIInactive0
Inactive0004-4.309910.7843-0.2327-5.32226.8375-6.64633.82231.011417.173-2.68034.8346-1.5527-1.3315-4.3099QC'd by RTIInactive0
Inactive0-4.78644.95490.4643-0.5-6.943640 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.3412-9.0513-3.5748-2.3634-8.2237-8.0106-6.3527-9.1377-10.7863-6.9009-9.556-4.63561.3663-2.3412QC'd by RTIInactive0
Inactive00043.8948-9.18-4.528-7.8262-5.28180.1213-2.8514-5.27810.14171.4481-10.28080.21445.40843.8948QC'd by RTIInactive0-4.27824.0450.5133
Inactive00040.9309-0.3627-0.7959-0.29194.6133-6.45136.07670.37295.22822.4365-0.3736-6.44071.19840.9309QC'd by RTIInactive0
Inactive00044.6175-2.446-2.97794.96498.591-3.7225-1.29327.6265.56985.46650.618212.56510.39614.6175QC'd by RTIInactive0
Inactive00041.16141.11370.8635-2.0253-1.3109-1.0103-7.7297-0.07730.3904-0.9231-0.2649-8.99091.4551.1614QC'd by RTIInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: P53MS482
Protocol: Please refer to other AIDs 1963578, 1963580, 720687, 720685, 720678 and 720681 for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the p53 with rat microsomes agonist mode assay (AID 1963578), cell viability counter screen (AID 1963580), and auto fluorescence counter screens (AID 720687, 720685, 720678, and 720681). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).
Activity SummaryRatio ActivityRatio Potency (uM)Ratio Efficacy (%)530 nm Activity530 nm Potency (uM)530 nm Efficacy (%)460 nm Activity460 nm Potency (uM)460 nm Efficacy (%)Viability ActivityViability Potency (uM)Viability Efficacy (%)Blue (460 nm) auto fluorescence outcomeSample Source
inactiveinactive0inactive0inactive0active antagonist37.95478669-56.89862383inactiveRohm and Haas
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactivePfaltz-Bauer
inactiveinactive0inactive0inactive0inactive0inactiveRadian International
inactiveinactive0inactive0inactive0inconclusive antagonistinactiveSpectrum Chemical
inactiveinactive0inconclusive agonistinactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactive0inactiveBattelle Northwest
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inconclusive agonistinactive0inactiveSIGMA
inactiveinactive0inactive0inactive0active antagonist11.47389904-137.559426inactiveTCI
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inconclusiveinactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveShanghai Xingling
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: P53344
Protocol: Tox21 Assay Protocol Summary:

The p53RE-bla cells were dispensed at 4,000 cells/5 ul/well in 1536-well black wall/clear bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 16 hours. After 1 uL of LiveBLAzerTM B/G FRET substrate was added using a Flying Reagent Dispenser, the plates were incubated at room temperature for 2 hours, and fluorescence intensity was measured by an Envision plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W530-Activity_Score-Replicate_1W530-Curve_Description-Replicate_1W530-Fit_LogAC50-Replicate_1W530-Fit_HillSlope-Replicate_1W530-Fit_R2-Replicate_1W530-Fit_InfiniteActivity-Replicate_1W530-Fit_ZeroActivity-Replicate_1W530-Fit_CurveClass-Replicate_1W530-Excluded_Points-Replicate_1W530-Max_Response-Replicate_1W530-Activity at 0.0000043054 uM-Replicate_1W530-Activity at 0.0000099513 uM-Replicate_1W530-Activity at 0.0000394398 uM-Replicate_1W530-Activity at 0.0000922287 uM-Replicate_1W530-Activity at 0.0002147056 uM-Replicate_1W530-Activity at 0.0004452702 uM-Replicate_1W530-Activity at 0.00122 uM-Replicate_1W530-Activity at 0.00376 uM-Replicate_1W530-Activity at 0.00955 uM-Replicate_1W530-Activity at 0.022 uM-Replicate_1W530-Activity at 0.049 uM-Replicate_1W530-Activity at 0.109 uM-Replicate_1W530-Activity at 0.249 uM-Replicate_1W530-Activity at 0.761 uM-Replicate_1W530-Activity at 2.332 uM-Replicate_1W530-Activity at 5.986 uM-Replicate_1W530-Activity at 13.53 uM-Replicate_1W530-Activity at 30.31 uM-Replicate_1W530-Activity at 65.96 uM-Replicate_1W530-Activity at 171.5 uM-Replicate_1W530-Activity at 622.7 uM-Replicate_1W530-Activity at 1320.0 uM-Replicate_1W530-Activity at 2952.0 uM-Replicate_1W530-Activity at 6600.0 uM-Replicate_1W530-Activity at 14760.0 uM-Replicate_1W530-Activity at 33000.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inactive10004-2.7054-0.742917.6324-5.7098-2.4442-8.8689-8.44923.85664.8951.316-4.2342-2.2173-1.3067-2.705410004-0.008
Inactive10004-9.2163-14.98060.5352-3.1889-1.87493.657-6.40320.83436.099515.97381.8503-6.6623-7.3549-9.2163100040.5551
Inconclusive15.82281.873510Partial curve; high efficacy-4.80071.46410.942883.86851.9952.11 0 0 0 0 0 0 0 0 0 0 0 0 0 063.7671-25.2350.72594.9823.8964-6.011-7.50423.0243-0.36318.58029.552814.338143.879163.767110-5.15071.41630.6697-11.5276040 0 0 0 0 0 0 0 0 0 0 0 0 0 0-9.41
Inactive10004-7.60360.157-0.8011-9.9636-13.0521-10.3016-8.2965-19.3101-11.1767-1.8658-10.3506-0.2558-4.7484-7.6036100040.7786
Inactive10004-1.25980.187213.2885.11046.52950.1337-12.0409-9.16955.1910.756-5.7729-4.064311.1384-1.2598100040.0274
Inactive10-4.79910.60.5308-18.20022.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-12.66682.13790.73361.997911.88191.0068-5.4624-1.91134.135-9.1428-3.5388-7.7512-8.3149-12.6668100042.1474
Inactive100040.120.6216.73751.29862.96138.4418-20.9196-8.36372.5119-0.9643-3.05170.98720.45280.12100040.1505
Inactive10004-3.34154.8601-0.05933.13132.492711.5913-1.4902-13.7451.9094-3.61140.17755.8982-1.925-3.3415100040.1916
Inactive100044.68764.03720.43261.7117-5.36330.01244.09393.29011.8675-5.35829.301-3.3996-6.65394.687610004-0.8649
Inactive1000414.45021.1662-13.4728-0.06892.7591-5.585-15.2304-11.60378.2866-5.55088.036-4.6022-4.845814.450210004-3.7942
Inactive10-4.60461.1110.576731.0459-6.10640 0 0 0 0 0 0 0 0 0 0 0 0 0 026.6548-7.6451-2.6127-0.4371-10.6818-11.93260.5693-21.22510.609-17.09791.011613.89869.803426.654810004-1.0538
Inconclusive15.166545.683610Partial curve; partial efficacy-4.81910.60.775941.0698-4.61382.20 0 0 0 0 0 0 0 0 0 0 0 0 0 032.1055-2.8274-2.73911.8943-2.4675-16.4634-3.3416-2.31647.09830.338415.525617.156218.43332.1055100040.1046
Inactive10-4.68594.50450.56518-4.235840 0 0 0 0 0 0 0 0 0 0 0 0 0 15.1259-0.5226-4.0178-6.8476-0.1323-11.918-14.7798-1.343-0.6951-0.0477-3.8234-0.157915.36455.125910004-0.8015
Inactive10004-2.57192.1271-15.6379-9.9458-0.0566-1.3009-10.3345-4.73090.7930.4322-6.21176.0155-0.1149-2.571910004-0.2737
Inactive10-4.429110.3508160.584740 0 0 0 0 0 0 0 0 0 0 0 0 0 014.03072.8758-1.4333-4.09618.1324-0.1788-1.8365-3.40460.96875.33925.74960.63436.788614.030710004-0.3011
Inactive10-5.88644.95490.460410-0.303340 0 0 0 0 0 0 0 0 0 0 0 0 0 014.81111.65651.78890.1435-7.595-1.069210.26810.1065-11.50277.37014.69215.95186.487814.811110004-6.6938
Inactive1000412.70575.94743.12190.9114-1.934610.27262.0269-12.6992-5.01885.3788-5.1369-2.868815.767612.705710004-1.5792
Inactive100048.0685-3.4653-4.85211.49384.676215.0539-6.5066-14.57680.9838-2.93245.02795.50265.54988.068510004-2.3647
Inactive100040.21273.5618-0.86484.668510.12697.869-0.11867.88796.91763.71724.3769.7145-1.76850.212710004-0.1916
Inactive1000415.68179.5665-3.95061.963.0139-1.30215.9929-15.24591.98272.56765.42287.37042.786215.681710004-3.34
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:tumor suppressor p53 [Homo sapiens]
External ID: P53MS233
Protocol: Tox21 Assay Protocol Summary:

The p53RE-bla cells were dispensed at 4,000cells/3ul/well in 1536-well black-clear bottom plates. After the assay plates were incubated at 37 C, 5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate. Following compound addition, 3 uL of human liver microsomes (XenoTech, Kansas City, KS) at final concentration of 0.5 mg/mL and 1uL of Beta-Nicotinamide adenine dinucleotide 2-phosphate (NADPH) at final concentration of 0.5 mg/mL were transferred to the assay plate. The plates were incubated at 37 C for 16 hours. 1 uL of LiveBLAzer detection mixture was added to each well and the plates were incubated at room temperature in the dark for 2 h. Fluorescence intensity at 460 and 530 nm emission and 405 nm excitation were measured by an Envision plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W530-Activity_Score-Replicate_1W530-Curve_Description-Replicate_1W530-Fit_LogAC50-Replicate_1W530-Fit_HillSlope-Replicate_1W530-Fit_R2-Replicate_1W530-Fit_InfiniteActivity-Replicate_1W530-Fit_ZeroActivity-Replicate_1W530-Fit_CurveClass-Replicate_1W530-Excluded_Points-Replicate_1W530-Max_Response-Replicate_1W530-Activity at 0.0000042859 uM-Replicate_1W530-Activity at 0.0000098296 uM-Replicate_1W530-Activity at 0.0000389118 uM-Replicate_1W530-Activity at 0.0000921325 uM-Replicate_1W530-Activity at 0.0002143310 uM-Replicate_1W530-Activity at 0.0004423865 uM-Replicate_1W530-Activity at 0.00121 uM-Replicate_1W530-Activity at 0.00372 uM-Replicate_1W530-Activity at 0.00955 uM-Replicate_1W530-Activity at 0.022 uM-Replicate_1W530-Activity at 0.049 uM-Replicate_1W530-Activity at 0.109 uM-Replicate_1W530-Activity at 0.249 uM-Replicate_1W530-Activity at 0.761 uM-Replicate_1W530-Activity at 2.332 uM-Replicate_1W530-Activity at 5.986 uM-Replicate_1W530-Activity at 13.53 uM-Replicate_1W530-Activity at 30.31 uM-Replicate_1W530-Activity at 65.96 uM-Replicate_1W530-Activity at 171.5 uM-Replicate_1W530-Activity at 622.7 uM-Replicate_1W530-Activity at 1320.0 uM-Replicate_1W530-Activity at 2952.0 uM-Replicate_1W530-Activity at 6600.0 uM-Replicate_1W530-Activity at 14760.0 uM-Replicate_1W530-Activity at 33000.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inactive10-5.20073.990.3607-2.5677740 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.945810.030110.74434.3442-5.05659.97422.951914.24288.764610.73796.49832.3813-4.5519-0.945810004.0000-0.4661
Inactive10-5.65074.95490.5456-1.9439840 0 0 0 0 0 0 0 0 0 0 0 0 0 15.08469.49733.81968.4513-0.619110.36259.433713.778210.27034.69635.4408-1.6199-1.45995.084610004.00001.5918
Inactive10-5.55070.20.470118-0.201840 0 0 0 0 0 0 0 0 0 0 0 0 0 011.2543-1.00153.75646.89974.79742.8342.87626.5347.24690.758412.16298.90029.7511.254310004.0000-5.5377
Inactive100041.163-3.51611.707-1.8835-3.46991.9890.10351.2453-2.9592-3.6379-2.9446-1.8761-0.93791.16310004.00000.1358
Inconclusive1000416.859332.73635.020523.23553.332115.0249-2.90566.9949.49478.34391.2576-2.0333-2.290216.859310004.00009.1878
Inconclusive10004-2.1455-0.55639.41727.7352.03946.42493.62662.90958.6089-4.7033-4.009520.11873.2965-2.145510004.00007.8923
Inactive10004-3.66575.64289.1238-0.71545.00783.34610.6894.02219.965210.092117.6894-0.24811.5526-3.665710004.000014.7162
Inconclusive100044.2675-5.79323.71026.399110.69910.51886.8431-0.265818.58843.903414.16020.41198.98754.267510004.00006.5135
Inactive100049.866218.26245.804817.49314.15489.82548.16059.947216.279414.177417.85510.539517.09199.866210004.0000-5.4950
Inactive10004-5.329712.331.7312-5.499611.4558-3.72499.28072.31575.44163.66498.36633.099311.8517-5.329710004.0000-5.3240
Inconclusive70.04772.348410Partial curve; high efficacy; poor fit-4.15460.80.6385105.628933.28052.30 0 0 0 0 0 0 0 0 0 0 0 0 0 080.211934.473140.812939.568732.405624.682727.567430.391541.000332.340943.744858.28146.303280.211910004.0000-2.1350
Inconclusive19.093534.34910Partial curve; partial efficacy; poor fit-4.71914.95490.7411-28.10156.2475-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 11.53110.97148.54297.49310.6748-2.691-2.1743-2.26359.19559.26333.86910.8178-29.03671.53110-5.01914.95490.734118.5000-1.04734.00000 0 0 0 0 0 0 0 0 0 0 0 0 0 11.7941
Inactive10-5.33594.95490.4604141.095140 0 0 0 0 0 0 0 0 0 0 0 0 0 024.7756-3.87228.9743-3.24331.4147-5.33746.5468-1.04071.0629-0.639615.012312.85582.944224.775610004.00004.5021
Inactive100047.41038.87323.5826-6.8276-3.40045.10857.125.99217.88590.76615.2069-2.5857-2.38937.410310004.0000-2.5566
Inactive10004-1.2866-1.8663.79256.244.97715.953813.60749.92898.28548.214414.36688.1213-0.9202-1.286610004.0000-3.9577
Inconclusive1000423.99170.9944-3.96381.687221.14372.265812.972312.03323.94191.4937-3.1913.4-3.920623.991710004.00006.2522
Inactive10004-4.56660.7965-6.9681-2.20180.034-1.99810.8299-0.3127-3.4977-3.3230.25471.8446-8.8778-4.566610004.00002.4663
Inactive10-7.02153.51170.347180.303440 0 0 0 0 0 0 0 0 0 0 0 0 0 010.5722-4.18564.19643.9575-4.3305-3.43177.7017.906311.39089.358710.9552-1.394.103110.572210004.00001.0750
Inactive10004-3.64221.972216.7669-4.364-3.7771-2.02811.2212-1.9042-4.0395-1.3596-5.395-2.4515-3.7855-3.642210004.00004.9536
Inactive1000416.4401-5.27783.8363-0.299718.8033-3.88715.63613.536316.4656.73621.28493.68095.811416.440110004.00004.3898
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: P53MS837
Protocol: Tox21 Assay Protocol Summary:

The p53RE-bla cells were dispensed at 4,000cells/3ul/well in 1536-well black-clear bottom plates. After the assay plates were incubated at 37 C, 5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate. Following compound addition, 3 uL of human liver microsomes (XenoTech, Kansas City, KS) at final concentration of 0.5 mg/mL and 1uL of B-Nicotinamide adenine dinucleotide 2'-phosphate (NADPH) at final concentration of 0.5 mg/mL were transferred to the assay plate. The plates were incubated at 37 C for 16 hours. 1 uL of LiveBLAzer detection mixture was added to each well and the plates were incubated at room temperature in the dark for 2 h. Fluorescence intensity at 460 and 530 nm emission and 405 nm excitation were measured by an Envision plate reader. For cell viability readout that measures cytotoxicity, 4 ul/well of CellTiter-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).
Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000042859 uM-Replicate_1Activity at 0.0000098296 uM-Replicate_1Activity at 0.0000389118 uM-Replicate_1Activity at 0.0000921325 uM-Replicate_1Activity at 0.0002143310 uM-Replicate_1Activity at 0.0004423865 uM-Replicate_1Activity at 0.00121 uM-Replicate_1Activity at 0.00372 uM-Replicate_1Activity at 0.00955 uM-Replicate_1Activity at 0.022 uM-Replicate_1Activity at 0.049 uM-Replicate_1Activity at 0.109 uM-Replicate_1Activity at 0.249 uM-Replicate_1Activity at 0.761 uM-Replicate_1Activity at 2.332 uM-Replicate_1Activity at 5.986 uM-Replicate_1Activity at 13.53 uM-Replicate_1Activity at 30.31 uM-Replicate_1Activity at 65.96 uM-Replicate_1Activity at 171.5 uM-Replicate_1Activity at 622.7 uM-Replicate_1Activity at 1320.0 uM-Replicate_1Activity at 2952.0 uM-Replicate_1Activity at 6600.0 uM-Replicate_1Activity at 14760.0 uM-Replicate_1Activity at 33000.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-0.81153.24171.7036-3.88633.70051.90923.46112.62383.42171.96184.5532-2.1817-2.0587-0.8115QC'd by SIGMAInactive0
Inactive00042.02641.27780.40633.132-0.96178.39740.80260.38625.08541.03870.96490.31392.19092.0264QC'd by Sigma DiscoveryCPRInactive0-6.03963.990.6227
Inactive0004-0.07830.8602-0.43130.77533.3389-7.07430.1475-4.9244-5.6061.28811.431-5.9165-1.58613.3747-0.0783QC'd by SIGMAInactive0-4.85182.12110.4048
Inactive0-8.53960.90.4382.5-17.2540 0 0 0 0 0 0 0 0 0 0 0 0 0 00.4242-11.5665-3.6679-0.6129-7.17834.78830.4184-0.157710.703511.6402-3.9345-0.5512-6.24530.4242QC'd by SIGMAInactive0-7.93964.95490.4551
Inactive0004-5.3318-1.94410.4522-8.3321.0107-0.1156-10.7826-10.8532-4.24710.20287.2076-6.6671-8.3789-5.3318QC'd by SIGMAInactive0
Inactive00040.6118-3.3835-2.5203-9.6183-0.5168-7.3565-1.9351-3.59144.7435-5.2628-2.1247-4.3417-14.53680.6118QC'd by SIGMAInactive0
Inactive0004-5.3821-1.5125-3.5484-1.106-5.2777-3.6383-5.511-10.9006-6.9604-1.92230.6192-4.5677-4.7296-8.0223QC'd by SIGMAInactive0-8.2680.30.4015
Inactive00040.87320.4702-0.8794-0.6340.6861-1.04133.7723-12.8167-6.05652.7542-1.535-7.9041-5.49780.8732QC'd by SIGMAInactive0
Inactive0-6.83964.95490.55124-4.470340 0 0 0 0 0 0 0 0 0 0 0 0 0 01.0676-1.3224-9.1419-1.1865-3.6159-5.2485-8.195310.19175.79951.09081.49983.96712.02971.0676QC'd by SIGMAInactive0-6.78964.95490.3599
Inactive0004-1.0220.210.2513-2.37471.3717-0.50383.9894-1.7888-6.79872.53691.01664.19945.5844-1.022QC'd by SIGMAInactive0-6.38964.95490.3471
Inactive0004-1.4059-3.132-7.66070.7238-4.33320.32411.33020.24797.5234-14.4771-13.01446.36361.2275-1.4059QC'd by RocheInactive0
Inactive0-4.33964.95490.3429-10.88620.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-9.07183.4287-0.5118-4.4669-2.302-2.17713.30782.8439-1.01244.2267-6.21353.9872-0.6916-9.0718QC'd by TCIInactive0
Inactive0004-0.68310.0297-0.9593-0.7386-2.2052-1.3291-4.3626-5.62091.9907011.30340.7086-3.1047-0.6831QC'd by SIGMAInactive0-5.48964.95490.3751
Inactive0-5.93961.78850.35820-3.229640 0 0 0 0 0 0 0 0 0 0 0 0 0 00.3463-2.7679-2.538-3.6541-2.975-8.1080.403-4.8358-1.7099-1.45512.2456-0.5792-0.4960.3463QC'd by SIGMAInactive0
Inactive0004-11.95511.4361-7.8259-8.6263-1.52171.5909-12.8729-11.017-6.8916-3.5531-4.5898-4.7446-6.1302-11.9551QC'd by LightBiologicalsInactive0
Inactive0004-9.9242-1.6531-3.70011.0424-7.9893.6152-5.8328-1.3701-2.0464-3.8438-5.7091-2.1285-5.1644-9.9242QC'd by SIGMAInactive0-4.33963.67720.3682
Cytotoxic40.77972.441840Partial curve; high efficacy-4.38963.92950.8982-74.5596-2.1178-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-64.8179-2.60644.2761-5.9881-1.3877-6.5057-2.59266.3601-8.70221.2883-0.5997-1.9403-18.4593-64.8179QC'd by TCICytotoxic51.337734.492820Single point of activity-4.28964.95490.8014
Inactive0004-14.5026-3.1743.642-4.3769-9.3023-7.6508-8.2832-19.8532-7.861711.7122-6.9451-14.94643.8797-14.5026QC'd by SIGMAInactive0
Inactive0004-2.2222-0.98421.4931-1.41171.1017-10.6336-4.34-12.0027-8.0387-2.805-8.872512.3039-3.6772-2.2222QC'd by SIGMAInactive0
Inactive0-7.33964.95490.52824.5-2.771840 0 0 0 0 0 0 0 0 0 0 0 0 0 01.0674-3.5855-4.2141.2009-4.39320.913.422214.0382.72535.26962.21886.31271.41211.0674QC'd by RocheInactive0-4.73964.0950.6096
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:tumor suppressor p53 [Homo sapiens]
External ID: P53MS898
Protocol: Tox21 Assay Protocol Summary:

The p53RE-bla cells were dispensed at 4,000cells/3ul/well in 1536-well black-clear bottom plates. After the assay plates were incubated at 37 C, 5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate. Following compound addition, 3 uL of rat liver microsomes (Molecular Toxicology, Boone, NC) at final concentration of 0.5 mg/mL and 1uL of Beta-Nicotinamide adenine dinucleotide 2-phosphate (NADPH) at final concentration of 0.5 mg/mL were transferred to the assay plate. The plates were incubated at 37 C for 16 hours. 1 uL of LiveBLAzer detection mixture was added to each well and the plates were incubated at room temperature in the dark for 2 h. Fluorescence intensity at 460 and 530 nm emission and 405 nm excitation were measured by an Envision plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W530-Activity_Score-Replicate_1W530-Curve_Description-Replicate_1W530-Fit_LogAC50-Replicate_1W530-Fit_HillSlope-Replicate_1W530-Fit_R2-Replicate_1W530-Fit_InfiniteActivity-Replicate_1W530-Fit_ZeroActivity-Replicate_1W530-Fit_CurveClass-Replicate_1W530-Excluded_Points-Replicate_1W530-Max_Response-Replicate_1W530-Activity at 0.0000043397 uM-Replicate_1W530-Activity at 0.0000099416 uM-Replicate_1W530-Activity at 0.0000388206 uM-Replicate_1W530-Activity at 0.0000933245 uM-Replicate_1W530-Activity at 0.0002146562 uM-Replicate_1W530-Activity at 0.0004427766 uM-Replicate_1W530-Activity at 0.00122 uM-Replicate_1W530-Activity at 0.00372 uM-Replicate_1W530-Activity at 0.00957 uM-Replicate_1W530-Activity at 0.022 uM-Replicate_1W530-Activity at 0.049 uM-Replicate_1W530-Activity at 0.109 uM-Replicate_1W530-Activity at 0.249 uM-Replicate_1W530-Activity at 0.768 uM-Replicate_1W530-Activity at 2.332 uM-Replicate_1W530-Activity at 5.987 uM-Replicate_1W530-Activity at 13.55 uM-Replicate_1W530-Activity at 30.33 uM-Replicate_1W530-Activity at 65.98 uM-Replicate_1W530-Activity at 172.8 uM-Replicate_1W530-Activity at 616.1 uM-Replicate_1W530-Activity at 1320.0 uM-Replicate_1W530-Activity at 2952.0 uM-Replicate_1W530-Activity at 6600.0 uM-Replicate_1W530-Activity at 14760.0 uM-Replicate_1W530-Activity at 33000.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inactive10004-0.0766-0.0658-2.15293.9062-0.3999-1.37385.63961.2637-2.85641.76041.55167.3112-1.1534-0.076610004.0000-0.5396
Inactive10004-9.26574.0277-6.0118-0.0071-1.8112.0788-0.1063-9.81183.02231.6158-3.4131-0.3905-0.1348-9.265710004.0000-0.7395
Inconclusive17.752636.150110Partial curve; partial efficacy-4.75072.40640.95137.51.34992.20 0 0 0 0 0 0 0 0 0 0 0 0 0 030.754-1.3751.59181.76342.18881.4238-0.72522.56751.81642.88342.28283.111216.001330.75410-4.70072.40640.9040-16.0184-1.00004.00000 0 0 0 0 0 0 0 0 0 0 0 0 0 0-12.5153
Inactive10004-0.8668-1.48543.1589-1.5267-0.3498-0.9828-1.6965-4.30540.34461.0195-3.8892-0.0431-3.4971-0.866810004.00002.1550
Inactive100040.4687-0.3692-2.2383-2.0699-1.1088-1.1038-1.892-3.7217-0.3761-2.9675-7.199-1.25980.5490.468710004.0000-4.3810
Inactive100040.4126-1.2865-0.5387-2.298-1.8546-1.5264-1.5856-1.7954-2.1107-10.0252-3.0851-2.8249-1.38430.412610004.00000.0966
Inactive10-8.75291.53860.542-3.90151040 0 0 0 0 0 0 0 0 0 0 0 0 0 10.10826.8455-0.6219-1.9403-3.2657-2.4784-1.636-6.3641-2.7947-6.0758-3.8759-3.1216-2.63750.108210004.0000-1.7240
Inactive10004-2.64841.2797-2.7761-6.4353-4.779-1.4021-0.3446-1.6237-1.1309-5.3966-0.90140-0.5502-2.648410004.00004.8834
Inactive10004-0.1792-0.474-1.4694-0.8953-0.4709-0.74150.1743-4.2804-1.4515-8.5725-1.40966.8573-0.4899-0.179210004.00000.3507
Inactive10-5.2314.95490.63782.5-6.309340 0 0 0 0 0 0 0 0 0 0 0 0 0 03.5172-6.7601-8.0367-0.7524-8.9539-6.7515-6.0875-9.8411-8.2478-4.204-0.20621.74341.04493.517210004.00007.8280
Inactive10-5.25464.95490.73888-2.536240 0 0 0 0 0 0 0 0 0 0 0 0 0 011.2916-1.1337-0.9738-3.7502-3.5438-3.92812.0571-0.3539-3.0856-2.45181.10275.54624.50711.291610004.00000.2257
Inactive10-4.71910.80.3767-22.1814-240 0 0 0 0 0 0 0 0 0 0 0 0 0 1-7.9565-2.4609-4.7653-0.7909-4.3968-2.1758-2.0522-3.5012-2.3448-13.94742.318-16.8178-12.5058-7.956510004.0000-0.5576
Inactive10-5.38594.95490.609313-3.112140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.9382-2.1013-5.1202-0.9168-6.4291-0.2473-7.5114-1.6150.7413-1.600515.74921.42750.7564-0.938210004.00003.5229
Inactive10004-2.5193-0.5943-0.7208-2.3194-2.31182.0984-4.0928-2.1388-3.1827-4.05230.0794-0.2907-0.4065-2.519310004.00002.1690
Inactive10-4.97912.72020.55856-4.095340 0 0 0 0 0 0 0 0 0 0 0 0 0 08.8855-0.6587-4.6588-0.4651-5.4882-3.2508-2.652-4.0762-6.6845-6.0914-4.67266.54320.29268.885510004.00008.4566
Inactive100040.3919-1.19260.06151.2782-3.2151-0.8299-0.6638-3.5934-2.2676-3.964912.1718-12.289-2.3960.391910-4.28643.13200.766711.50000.55584.00000 0 0 0 0 0 0 0 0 0 0 0 0 0 08.8922
Inactive100041.3115-1.013-0.5151-0.4031-1.1603-0.0285-0.1807-1.90091.5472-3.20528.574-14.1104-2.36981.311510004.00000.7374
Inactive100041.2453-0.1374-0.3605-3.4935-1.2563-2.4487-0.2616-0.72990.0304-4.47-0.75345.7775-0.09731.245310004.00001.2743
Inactive100040.0274-0.9052-3.7849-3.6459-0.6677-0.01462.1795-6.8978-0.8919-5.2845-0.8362-13.15210.1420.027410004.0000-2.5213
Inactive10004-2.4878-3.5001-2.6738-5.3379-5.5521-3.88740.4423-5.0105-3.9092-8.9672-0.5005-7.892-0.4544-2.487810004.00000.0360
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: OBG420
Protocol: Assay Protocol Summary:

1,000 cells in 4 uL of media were dispensed into white, solid bottom 1536-well plates using a Multidrop Combi (Thermo Scientific). The Assay plates were incubated for 16 hours at 37 C with 5% CO2 in assay plates, followed by the addition of 23 nL of DMSO or drug dissolved in DMSO. Each compound was assayed in five concentrations (0.092, 0.46, 2.3, 11.5, and 57.5 uM), using the automated Wako 1536 Pin Tool workstation and incubated at 37 C with 5% CO2 48 hours. 4 uL of ATPlite, the ATP monitoring reagent, was then added to the each well of the assay plates using the Multidrop Combi reagent dispenser followed by incubation for 15 minutes at room temperature. The resulting luminescence was measured using the ViewLux plate reader.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, cytotoxic compounds are considered active and show up as apparent inhibitors, which are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0002299000 uMActivity at 0.0009353959 uMActivity at 0.00184 uMActivity at 0.00468 uMActivity at 0.00919 uMActivity at 0.016 uMActivity at 0.027 uMActivity at 0.051 uMActivity at 0.092 uMActivity at 0.155 uMActivity at 0.256 uMActivity at 0.462 uMActivity at 0.846 uMActivity at 1.283 uMActivity at 2.310 uMActivity at 4.246 uMActivity at 6.551 uMActivity at 11.58 uMActivity at 25.26 uMActivity at 38.52 uMActivity at 57.54 uMActivity at 116.1 uMActivity at 221.6 uMActivity at 288.3 uMPanel IDPanel Name
Inactive0.089120.43770-7.054.95490.524316-4.437740 0 0 0 013.1195-1.614723.02214.923222.436413.11953PA-1
Inactive0.501219.5120-6.34.50450.98372.5-17.01240 0 0 0 04.6148-17.0933-15.1392.02030.96314.61484SKOV3
Inactive0.089110.17840-7.054.95490.4664-7.67842.540 0 0 0 0-7.22470.9983-11.3986-10.48-0.961-7.22475C33A
Inactive000046.8018-1.79437.92887.71697.15576.80186JEG-3
Inactive0.6315.87540-6.24.95490.65335-0.875440 0 0 0 04.99780.7404-1.97958.09512.36074.99787Es-2
Inactive00004-1.56592.9339-4.8958-4.79511.5969-1.56598Hek293T
Inactive0.08919.9950-7.054.95490.3786-7.4952.540 0 0 0 0-5.41281.1477-11.5205-0.3743-12.9125-5.41289Tov112D
Inactive00004-3.29573.83081.4062-4.436-2.7163-3.295710Tov-21-G
Inactive0.707914.66040-6.154.95490.999411.5-3.160440 0 0 0 11.8313-3.0503-3.035511.111111.20241.831311OV90
Inactive2.511911.03920-5.61.62590.99184.5-6.539240 0 0 0 04.3244-5.7563-6.6993-3.04413.02174.324412CASKI
Inactive000044.00029.26091.730716.16898.27064.00021CAOV3
Inactive0.112.42240-71.64360.8881-1.922410.540 0 0 0 0-4.51867.76070.4819-0.6217-0.7957-4.51862HeLa
Inactive000049.02713.25131.741213.527517.68579.0273PA-1
Inactive0.3162180-6.54.44950.963772540 0 0 0 119.687125.203421.51315.01739.427119.68714SKOV3
Inactive000040.33690.4452-0.91255.72924.440.33695C33A
Inactive0.063110.50-7.24.95490.8451212.540 0 0 0 01.087910.83860.19022.46194.63951.08796JEG-3
Inactive0.50129.55980-6.34.95490.95170-9.559840 0 0 0 0-0.0179-8.4158-10.46650.9667-1.2439-0.01797Es-2
Inactive0.063114.81190-7.24.95490.534-5.8119940 0 0 0 10.28146.5861-12.75991.4268-6.08970.28148Hek293T
Inactive8.91258.5410-5.054.0450.6148-0.54140 0 0 0 07.75193.7595-4.2009-0.57340.66357.75199Tov112D
Inactive000041.0625-0.46660.2533-1.2691-7.13331.062510Tov-21-G
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: HERG01
Protocol: NCGC Assay Protocol Summary:

HERG assay (FluxORTM thallium flux assay) was initially developed by Invitrogen/Molecular Probes, and then miniaturized into 1536-well plate in a homogeneous format by NCGC. This assay measures the activity of potassium channel using thallium dye (FluxOR) flux as surrogate measurement for potassium into the cells with a FDSS-7000 kinetic plate reader (Hamamatsu Corp., Hamamatsu City, Japan). The hERG ion channel is transduced into mammalian cells (U2OS) using a baculovirus (Bacmam) construct harboring the hERG K+ ion channel. So far we screened LOPAC1280 library (Sigma), the NTP collection of 1408 compounds, and the NCGC Pharmaceutical Collection (NPC), in which many well defined HERG blockers are present. The rank order potencies of many of these compounds are similar to that of other HERG assays (membrane potential, Rb+ flux, patch clamp, etc). This quick and homogeneous assay is also found to be sensitive, specific, and robust.

Using the FluxORTM thallium flux assay, the activity of potassium channel using thallium dye (FluxOR) flux as surrogate measurement for potassium into the cells was measured in the U2OS cell line transduced with hERG K+ ion channel using a baculovirus (Bacmam) using Opti-MEM medium (Invitrogen) containing 2% fetal calf serum (FCS, HyCone) following loading buffer addition, compound treatment for around 10 minutes and finally adding stimulation buffer. The assay was performed in black clear Kalypsys 1536-well plates. In the screen, Astemizole was used as positive controls. Library compounds were measured for their ability to cause hERG channel blockage in the cell line, as reflected by a decrease in fluorescence intensity, in a concentration-dependent manner. Data were normalized to the controls for basal activity (DMSO only) and 100% inhibition (5uM Astemizole). AC50 values were determined from concentration-response data modeled with the standard Hill equation.

qHTS protocol for hERG-U2OS cellular assay

[Step] [Parameter] [Value] [Description]

1. Day 1: Replace medium in 70-80% confluent T225 flask with 2.5 mL of hERG-BacMam virus plus 12.5 mL of phosphate buffered saline (PBS) (corresponding roughly to a multiplicity of infection ratio of 100 virus particles/cell)
2. Incubation: 4 hrs @ room Temperature in Dark
3. Reagent; Remove virus; wash once with 25 ml DPBS
4. Reagent; 35 ml culture medium
5. Incubation; 37oC overnight
6. Day2: Reagent; 3 uL; 2000 U2OS cells/well
7. Time; 4 hr; 37oC incubation
8. Loading buffer; 1 uL; 0.7X;
9. Incubation: 1hr @ RT in Dark.
10. Compounds; 23 nL; 0.59 nM to 92 uM
11. Controls; 23 nL; Astemizole 1.4 nM to 92 uM
12. Time; 10min; 37oC incubation
13. Read fluorescence Intensity on FDSS for 10 Sec with 1 sec interval
14. Reagent; 1 uL; stimulation buffer
15. Read fluorescence Intensity on FDSS for 2 min with 1 sec interval
16. Detection; Fluorescence Intensity; FDSS
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0001000000 uMActivity at 0.0003000000 uMActivity at 0.0006116734 uMActivity at 0.00133 uMActivity at 0.00297 uMActivity at 0.00673 uMActivity at 0.015 uMActivity at 0.033 uMActivity at 0.075 uMActivity at 0.167 uMActivity at 0.369 uMActivity at 0.412 uMActivity at 0.836 uMActivity at 1.842 uMActivity at 2.061 uMActivity at 4.179 uMActivity at 9.216 uMActivity at 20.61 uMActivity at 46.08 uMActivity at 92.17 uMCompound QC
Inactive04.0950.5622-0.5-17.405541 0 0 0 0 0 1 0 0 0 0 0 0 04.0358-8.1088-16.5879-0.7265-5.65844.3730.1327-9.70320.36854.1527-0.141-3.5272-0.9713-9.32034.0358QC'd by NIEHS/NTP
Activator15.848952.39750Single point of activity-4.80.40.510848.9806-3.416930 0 0 0 0 1 0 0 0 0 0 1 0 1 038.06212.0116-8.9739-7.06230-7.0944-39.2396018.733825.780800-59.539411.623748.215338.0621QC'd by NIEHS
Inactive04-1.0832-10.89741.0031-11.058-11.8883.65680.91825.31740.029-1.48932.17113.0788-19.8367-2.8584-1.0832QC'd by NIEHS/NTP
Inactive042.45982.223-1.63678.778-0.11389.22693.440711.6742-2.146511.8823-1.8078-2.0833.78254.49092.4598QC'd by NIEHS
Inactive01.85790.45754.5-21.089940 0 0 0 0 0 0 0 0 0 0 0 0 012.886-15.90830.10180.3771-0.02467.9993-3.79713.097311.63728.3022-2.66639.3202-2.3421-0.285412.886QC'd by NIEHS/NTP
Inactive04.95490.5492-6.77071.540 0 0 0 0 0 0 0 0 0 1 0 0 11.3669-1.0856-0.77651.12421.70580.7901-1.98696.09015.26593.2331-7.9279-28.3694-1.3017-10.22551.3669QC'd by NIEHS/NTP
Inactive04-5.5826-4.0359-4.4476-11.3473-11.9097-1.5507-10.1535-3.36261.3234-0.4426-13.9824-5.2512-18.0387-15.3022-5.5826QC'd by NIEHS/NTP
Inhibitor39.810751.900420Partial curve; partial efficacy-4.43.990.9828-50.13811.7623-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0-49.45943.1993-0.02692.7134-1.98075.29460.2133-0.1387-0.26252.47080.17772.53720.4925-30.4729-49.4594QC'd by NIEHS/NTP
Inactive02.33320.6977-10.8456140 0 0 0 0 0 1 0 0 0 0 1 0 1-1.1266-1.46111.2528-0.03690.02955.5889-3.03576.75064.5747-1.4797-0.1821-9.6414-1.4402-9.8713-1.1266QC'd by NIEHS/NTP
Inactive0414.60080.5397-1.6708-0.4130.96947.4259-2.25855.08697.9351-2.4752-5.6365.39961.849-2.487114.6008QC'd by NIEHS/NTP
Inactive00.70.5791-8.9231440 0 0 0 0 0 1 0 0 0 0 0 0 12.80633.51535.19381.41166.33634.612.742912.44016.0481-0.14110.3707-1.47812.4968-5.76932.8063QC'd by NIEHS/NTP
Inactive04-17.8369-10.5115-2.5586-8.8158-26.0957-0.4819-9.7892-2.01490.27332.7166-17.2183-0.47591.0932-12.7028-17.8369QC'd by NIEHS/NTP
Inactive04.95490.4427-9.7222-1.541 0 1 0 0 0 0 0 0 0 0 0 0 0-13.1018-5.53920.00687.73370.45884.0455-12.3759-6.57240.92181.9145-11.3469-7.6261-8.5179-8.6226-13.1018QC'd by NIEHS/NTP
Inactive03.1320.7434-16.07841.540 0 0 0 0 0 0 0 0 0 0 0 0 13.99653.3921-1.15561.97152.01773.8894-2.6092.87572.72384.1025-3.54462.1635-3.6983-12.9823.9965QC'd by NIEHS/NTP
Inactive047.53724.3881-20.20115.5178-1.37582.0045-1.44014.9593-2.11221.3726-3.0011-3.06771.18832.18177.5372QC'd by NIEHS/NTP
Inactive0411.45250.2692-0.1403-0.3748-11.74892.8347-5.054616.89840.0513.829-3.6094-0.51978.0326-1.547611.4525QC'd by NIEHS/NTP
Inactive049.99361.71397.16916.3352-0.34329.148-5.8673-1.564112.6111.82378.2616-0.66541.73632.63199.9936QC'd by NIEHS/NTP
Inactive0410.2340.52521.3877-1.9626-0.9425.6494-0.276911.70528.3766.8657-0.149-0.19442.6788-6.419210.234QC'd by NIEHS/NTP
Activator22.387233.89380Complete curve; partial efficacy; poor fit-4.652.25260.715133.99630.10251.40 0 0 0 0 0 0 0 0 0 0 0 0 025.52240.4272-0.9219-0.128-2.10618.1765-1.5863-10.226512.16486.8628-0.3193-6.515517.608732.268925.5224QC'd by NIEHS/NTP
Inactive049.98485.58260.0396-1.5504-1.30043.2953.988212.27428.06469.11922.031.29227.4225-2.99749.9848QC'd by NIEHS/NTP
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Severe acute respiratory syndrome coronavirus 2
External ID: CHEMBL4303805
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL4303835
ChEMBL Target Name: SARS-CoV-2
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: SARS-CoV-2 Screening Data
Standard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
Inhibition=-11.52%Outside typical range
Inhibition=5.09%
Inhibition=-1.71%
Inhibition=3.69%
Inhibition=22.47%
Inhibition=8.51%
Inhibition=-6.86%
Inhibition=-6.18%
Inhibition=-2.07%
Inhibition=3.91%
Inhibition=-5.9%
Inhibition=-2.45%
Inhibition=-5.55%
Inhibition=6.31%
Inhibition=-1.08%
Inhibition=12.7%
Inhibition=0.37%
Inhibition=8.88%
Inhibition=11.63%
Inhibition=-1.96%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL1614670
Protocol: N/A
Comment: Journal: Drug Metab Dispos
Year: 2008
Volume: 36
Issue: 7
First Page: 1385
Last Page: 1405
DOI: 10.1124/dmd.108.020479
Standard TypeStandard RelationStandard ValueStandard Units
Vdss=0.73L.kg-1
Vdss=2.6L.kg-1
Vdss=1.6L.kg-1
Vdss=0.096L.kg-1
Vdss=0.32L.kg-1
Vdss=1.6L.kg-1
Vdss=2.1L.kg-1
Vdss=6.1L.kg-1
Vdss=1.9L.kg-1
Vdss=12L.kg-1
Vdss=0.8L.kg-1
Vdss=1L.kg-1
Vdss=3.1L.kg-1
Vdss=3.2L.kg-1
Vdss=1.2L.kg-1
Vdss=13L.kg-1
Vdss=45L.kg-1
Vdss=0.37L.kg-1
Vdss=1.5L.kg-1
Vdss=4.1L.kg-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL1614671
Protocol: N/A
Comment: Journal: Drug Metab Dispos
Year: 2008
Volume: 36
Issue: 7
First Page: 1385
Last Page: 1405
DOI: 10.1124/dmd.108.020479
Standard TypeStandard RelationStandard ValueStandard Units
CL=4.7mL.min-1.kg-1
CL=18mL.min-1.kg-1
CL=2.5mL.min-1.kg-1
CL=1.3mL.min-1.kg-1
CL=5.1mL.min-1.kg-1
CL=2.4mL.min-1.kg-1
CL=8.3mL.min-1.kg-1
CL=9.7mL.min-1.kg-1
CL=31mL.min-1.kg-1
CL=13mL.min-1.kg-1
CL=16mL.min-1.kg-1
CL=0.38mL.min-1.kg-1
CL=13mL.min-1.kg-1
CL=15mL.min-1.kg-1
CL=0.7mL.min-1.kg-1
CL=8.2mL.min-1.kg-1
CL=20mL.min-1.kg-1
CL=0.65mL.min-1.kg-1
CL=2.1mL.min-1.kg-1
CL=13mL.min-1.kg-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL1614673
Protocol: N/A
Comment: Journal: Drug Metab Dispos
Year: 2008
Volume: 36
Issue: 7
First Page: 1385
Last Page: 1405
DOI: 10.1124/dmd.108.020479
Standard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
MRT=2.6hr
MRT=2.4hr
MRT=11hr
MRT=1.2hr
MRT=1hr
MRT=11hr
MRT=4.2hr
MRT=10hr
MRT=1hr
MRT=15hr
MRT=1hr
MRT=44hr
MRT=4hr
MRT=3.6hr
MRT=27hr
MRT=26hr
MRT=38hr
MRT=9.5hr
MRT=12hr
MRT=5.3hr
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL1614674
Protocol: N/A
Comment: Journal: Drug Metab Dispos
Year: 2008
Volume: 36
Issue: 7
First Page: 1385
Last Page: 1405
DOI: 10.1124/dmd.108.020479
Standard TypeStandard RelationStandard ValueStandard Units
T1/2=2hr
T1/2=2hr
T1/2=8.9hr
T1/2=1.4hr
T1/2=1.1hr
T1/2=8.6hr
T1/2=3.8hr
T1/2=7.3hr
T1/2=1.69hr
T1/2=16hr
T1/2=0.78hr
T1/2=42hr
T1/2=3.6hr
T1/2=2.5hr
T1/2=26hr
T1/2=26hr
T1/2=36hr
T1/2=13hr
T1/2=9.6hr
T1/2=5.6hr
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Replicase polyprotein 1ab
External ID: CHEMBL4495582
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL4523582
ChEMBL Target Name: Replicase polyprotein 1ab
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned

Data Source: SARS-CoV-2 Screening Data
Standard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
Inhibition=13.77%
Inhibition=2.35%
Inhibition=21.17%
Inhibition=18.36%
Inhibition=5.381%
Inhibition=18.17%
Inhibition=10.15%
Inhibition=29.56%
Inhibition=18.27%
Inhibition=11.42%
Inhibition=15.4%
Inhibition=7.437%
Inhibition=-3.216%
Inhibition=18%
Inhibition=1.021%
Inhibition=16.4%
Inhibition=2.544%
Inhibition=19.11%
Inhibition=26.15%
Inhibition=5.133%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: CYP3A7681
Protocol: Assay Protocol Summary:

Two ul of enzyme-substrate mix was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). Compounds dissolved in DMSO, and positive control (ketoconazole) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at room temperature for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000073560 uMActivity at 0.0000367800 uMActivity at 0.0000735600 uMActivity at 0.0001677464 uMActivity at 0.0003678000 uMActivity at 0.0007363003 uMActivity at 0.00153 uMActivity at 0.00368 uMActivity at 0.00723 uMActivity at 0.00914 uMActivity at 0.018 uMActivity at 0.039 uMActivity at 0.092 uMActivity at 0.191 uMActivity at 0.460 uMActivity at 0.910 uMActivity at 1.182 uMActivity at 2.302 uMActivity at 4.834 uMActivity at 11.49 uMActivity at 23.94 uMActivity at 57.45 uMActivity at 115.4 uMActivity at 193.5 uMActivity at 288.3 uMCompound QC
Inhibitor1.0964121.524587Complete curve; high efficacy-5.960.60.996-99.00122.5235-1.10 0 0 0 0 0 0 0-91.416421.20118.089711.55633.2362-23.6097-54.3722-70.1237-91.4164QC'd by GVK
Inactive00041.30296.4095.7452-8.127411.434512.7995.91137.13891.3029QC'd by Vitas
Inhibitor0.05596.749490Complete curve; high efficacy-7.260.60.9836-74.157422.592-1.10 0 0 0 0 0 0 0-78.849512.345912.9899-11.4013-37.5586-53.042-61.5426-65.313-78.8495QC'd by Bosche
Inactive0004-9.339-4.094-2.86744.5071-4.4459-5.3433-2.46713.5091-9.339QC'd by BIOMOL
Inactive0-6.614.95490.77852.5-6.094140 0 0 0 0 0 0 1-8.7946-5.07-2.6335-5.97-10.49513.49112.05881.9174-8.7946QC'd by SIGMA
Inhibitor34.671339.82710Single point of activity-4.462.30310.825-41.327-1.5-30 0 0 0 0 0 0 0-31.93923.6009-5.26172.22954.1407-8.6455-6.9529-4.2362-31.9392QC'd by Microsource
Inactive040 0 0 0 0 0 0 0-13.898620.649216.42211.68939.501116.6467-2.6177-2.1673-13.8986QC'd by Vitas
Inhibitor15.487178.566741Partial curve; partial efficacy-4.810.80.995-76.6721.8947-2.20 0 0 0 0 0 0 0-58.08492.73420.67454.0214-0.609-3.975-12.9528-31.6593-58.0849QC'd by Sequoia
Inactive000426.644512.4429-0.644219.37847.33520.35134.22857.434426.6445QC'd by Microsource
Inactive0-5.92134.95490.79423.5-5.645240 0 0 0 0 0 1-9.4213-2.1113-8.4544-4.6822-8.22654.16062.7472-9.4213QC'd by Tocris
Inactive0004-2.8012-11.1342-2.1920-10.8176-0.6934-3.3166-1.4979-2.8012QC'd by SIGMA
Inactive0-5.764.95490.510428.8996-2.44840 1 0 0 0 0 0 1-2.30523.7377-36.8683-4.4543-19.5675-9.380122.243229.0984-2.305QC'd by Vitas
Inhibitor12.301887.401142Partial curve; high efficacy-4.910.60.9549-73.550113.8509-2.10 0 0 0 0 0 0 0-54.873522.14538.368412.13289.0141-1.3852-8.6537-22.9862-54.8735QC'd by Microsource
Inhibitor27.540450.239310Single point of activity-4.561.75290.9401-50.16480.0744-30 0 0 0 0 0 0 0-39.142.8036-3.03351.3596-6.01625.1159-1.7887-9.2175-39.14QC'd by Microsource
Inactive0-5.310.60.8041-16.01361740 0 0 0 0 0 0 0-11.67817.682513.435821.75976.519717.4375-0.6278-0.9036-11.678QC'd by Enzo
Inhibitor15.487177.547110Partial curve; partial efficacy; poor fit-4.811.1110.829-67.10610.4411-2.40 0 0 0 0 0 0 0-53.05410.743524.16552.70531.738225.7669-4.8999-19.2859-53.0541QC'd by Bosche
Inactive0-6.361.46410.8922-22.47584.540 0 0 0 0 0 0 0-25.49972.54256.30397.767-1.9911-6.3102-26.2299-15.2464-25.4997QC'd by Microsource
Inactive0-4.511.96730.4991426.540 0 0 0 0 0 0 016.846225.531732.670220.285228.569325.635926.981725.029716.8462QC'd by GVK
Inhibitor0.870947.278824Complete curve; partial efficacy-6.064.95490.9676-45.67661.6021-1.20 0 0 0 0 0 0 1-20.51278.27430.9756-1.5573-1.30970.8922-49.683-41.1152-20.5127QC'd by Enzo
Inactive0-6.064.95490.4399-0.676240 0 0 0 0 0 0 1-0.0131.95381.5464-4.31350.312-2.768216.93540.8252-0.013QC'd by Sequoia
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: ADRB2293
Protocol: Tox21 Assay Protocol Summary:

CHO-ADRB2 cells were dispensed at 1,000/well in 4uL assay medium into white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a Multidrop Combi dispenser (ThermoFisher Scientific, Waltham, MA). The assay plates were incubated at 37C and 5% CO2 for an overnight (18-20hr). Then positive control and test compounds dissolved in DMSO were transferred to the assay plates at 23nL using a Pintool station (Wako, San Diego, CA). Following the compound and positive control transfer, 1uL stimulation mix containing 100uM IBMX and 25uM Ro-20-1724 was added to each well of the assay plates using BioRAPTR Flying Reagent Dispenser (FRD, Beckman Coulter, Brea, CA). The assay plates were incubated at room temperature for 0.5hr. Then 2.5ul each d2-labled cAMP and anti-cAMP-cryptate solutions were added separately to each well of the assay plates using an FRD and the assay plates were incubated at room temperature for 1hr. The fluorescence signal was measured at two different wavelengths (665nm and 615nm) using an Envision plate reader (Perkin Elmer, Shelton, CT). Data were expressed as the ratio of 665 nm/615 nm.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W530-Activity_Score-Replicate_1W530-Curve_Description-Replicate_1W530-Fit_LogAC50-Replicate_1W530-Fit_HillSlope-Replicate_1W530-Fit_R2-Replicate_1W530-Fit_InfiniteActivity-Replicate_1W530-Fit_ZeroActivity-Replicate_1W530-Fit_CurveClass-Replicate_1W530-Excluded_Points-Replicate_1W530-Max_Response-Replicate_1W530-Activity at 0.0000060039 uM-Replicate_1W530-Activity at 0.0000138057 uM-Replicate_1W530-Activity at 0.0000545120 uM-Replicate_1W530-Activity at 0.0001296300 uM-Replicate_1W530-Activity at 0.0003003888 uM-Replicate_1W530-Activity at 0.0006194162 uM-Replicate_1W530-Activity at 0.00172 uM-Replicate_1W530-Activity at 0.00522 uM-Replicate_1W530-Activity at 0.013 uM-Replicate_1W530-Activity at 0.030 uM-Replicate_1W530-Activity at 0.068 uM-Replicate_1W530-Activity at 0.153 uM-Replicate_1W530-Activity at 0.349 uM-Replicate_1W530-Activity at 1.067 uM-Replicate_1W530-Activity at 3.267 uM-Replicate_1W530-Activity at 8.386 uM-Replicate_1W530-Activity at 18.95 uM-Replicate_1W530-Activity at 42.46 uM-Replicate_1W530-Activity at 92.41 uM-Replicate_1W530-Activity at 240.3 uM-Replicate_1W530-Activity at 872.4 uM-Replicate_1W530-Activity at 1849.0 uM-Replicate_1W530-Activity at 4135.0 uM-Replicate_1W530-Activity at 9246.0 uM-Replicate_1W530-Activity at 20670.0 uM-Replicate_1W530-Activity at 46230.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inconclusive10004-1.9035-1.1923-2.0332-1.0619-12.6616-0.78820.0664-11.7887-6.4513-11.6244-1.9076-2.0225-3.2172-1.90350Single point of activity-5.61024.95490.9089-45.54365-30 0 0 0 0 0 0 0 0 0 0 1 1 1 126.2694
Inactive10004-1.20222.7609-0.01530.9955-0.41571.63592.32520.5928-0.99092.84790.1279-0.03861.8432-1.202210004-31.8285
Inhibitor0.994556.503510004-2.90612.33111.736-3.60126.00595.10040.6447-1.71252.76160.832-1.74680.48220.191-2.90610Single point of activity-6.00242.25260.6374-44.503512-31 0 0 0 0 0 0 0 0 0 1 1 1 1 18.1326
Inconclusive10004-1.3710.9506-2.91191.52635.1535.55271.52731.54971.7024.269902.5531-6.3366-1.37110004-25.7768
Inactive10004-4.2769-0.95591.72782.6067.9793-4.5417-5.96084.89575.48863.60130.2343-3.1649-0.1676-4.276910004-8.7462
Inhibitor8.758121.9554100041.30884.730914.16229.43255.624-1.95912.73144.32472.41837.8238-5.8845-5.16396.60721.30880Single point of activity-5.05761.10.6955-89.934132.0212-30 0 0 0 0 0 0 0 1 0 0 0 0 1 1-23.4699
Inconclusive0.002425.78310Complete curve; partial efficacy; poor fit-8.61330.80.8235-3.7909-29.57391.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.4664-19.6302-7.473-8.9859-9.0898-8.3146-0.2424-6.5275-6.0557-3.3866-1.82-2.8939-4.0012-2.466410004-30.4385
Inactive10004-7.3264-1.5887-10.9052-0.9831-6.53-5.410.9435-5.6079-0.699-2.0867-3.2569-4.2536-2.16180.5621-7.326410-7.92771.80790.6047-24.965740 0 0 0 0 0 0 0 0 0 0 0 0 0 1-31.1667
Inconclusive10004-0.76813.03751.73091.12096.2561-0.0974-8.24190.864-0.54561.50994.4639-1.16054.7076-0.76810Single point of activity-4.95763.1320.706-69.1601-0.5-30 0 0 0 0 0 1 0 0 0 1 1 0 1 1-35.5326
Inconclusive10-5.8521.69240.3729-0.5701440 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.18373.34480.978.50642.5766.04151.76024.88511.9267-0.2988-0.0183-1.0279-1.3405-0.183710-8.8024.95490.41826-43.08340 0 0 1 0 0 0 0 0 0 0 0 0 0 022.5365
Inconclusive10-9.12574.44950.3776-1-17.747540 0 0 0 0 0 0 0 0 0 0 0 0 0 02.0705-13.4218-2.2278-1.534-1.45313.8095-2.4909-1.0374-13.5396-0.16050.0263-0.09952.04422.0705100046.6627
Inconclusive10Partial curve; partial efficacy; poor fit-4.15594.95490.9512-25.9952-1-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.246-1.2286-0.8428-1.2278-0.5805-1.8719-0.06640.8961-0.8452-1.9038-2.1419-3.3814-0.974-21.24610-5.25594.95490.5517-28.362-240 0 0 0 0 0 0 0 0 1 1 0 0 0 1-3.0491
Inconclusive10004-2.6403-1.5203-3.2668-0.3318-5.31293.2585-4.0841-4.30851.19516.0144-4.8227-2.25281.5709-2.64030Partial curve; high efficacy; poor fit-5.16334.95490.4313-80.8838-1.5-2.30 0 0 0 0 0 0 0 0 0 0 0 1 1 1-1.3949
Inactive10004-0.26721.230113.62434.24763.99616.594517.55362.17369.11160.1969-3.48061.5252-2.0777-0.267210-5.31244.95490.3735-19.39133.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-1.3739
Inactive10004-5.77735.11124.0288-1.9434-1.021412.92192.34717.4846-2.0121.291-2.74985.90195.369-5.777310004-4.4961
Inconclusive10004-15.4564-4.51941.21191.7588-11.93060.5255-1.2623.2933-2.6412-3.3809-1.071-2.7851-1.8097-15.456410-4.66420.70.437326.1319-6.859441 0 0 0 1 0 0 0 0 0 0 0 0 0 10.7866
Inactive100045.20961.56415.30634.99462.482-1.21514.35076.00556.2785-0.47860.86696.1344.32315.209610004-35.4391
Inactive100042.47121.4625-2.9807-1.69247.24483.0542-12.2145-8.3996-2.4864.052-1.4266-1.5593-0.16762.4712100043.4572
Inactive10-4.91021.46410.523614.5-0.475640 0 0 0 0 0 0 0 0 0 0 0 0 0 013.887.5564-7.4796-3.3029-4.4182-3.7928-2.6927-0.11982.6654-1.01760.301216.57859.432213.88100043.7428
Inactive100040.5160.0357.1699-4.87981.4861-5.9734-8.5349-6.6743-1.7256-1.1817-1.1379-5.50792.8730.51610004-5.7554
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: ADRB2713
Protocol: Tox21 Assay Protocol Summary:

CHO-ADRB2 cells were dispensed at 1,000/well in 4uL assay medium into white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a Multidrop Combi dispenser (ThermoFisher Scientific, Waltham, MA). The assay plates were incubated at 37C and 5% CO2 for an overnight (18-20hr). Then positive control and test compounds dissolved in DMSO were transferred to the assay plates at 23nL using a Pintool station (Wako, San Diego, CA). Following the compound and positive control transfer, 1uL agonist-stimulation mix containing 1nM Isoproterenol HCl, 100uM IBMX and 25uM Ro-20-1724 was added to each well of the assay plates using BioRAPTR Flying Reagent Dispenser (FRD, Beckman Coulter, Brea, CA). The assay plates were incubated at room temperature for 0.5hr. Then 2.5ul each d2-labled cAMP and anti-cAMP-cryptate solutions were added separately to each well of the assay plates using an FRD and the assay plates were incubated at room temperature for 1hr. The fluorescence signal was measured at two different wavelengths (665nm and 615nm) using an Envision plate reader (Perkin Elmer, Shelton, CT). Data were expressed as the ratio of 665 nm/615 nm.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W530-Activity_Score-Replicate_1W530-Curve_Description-Replicate_1W530-Fit_LogAC50-Replicate_1W530-Fit_HillSlope-Replicate_1W530-Fit_R2-Replicate_1W530-Fit_InfiniteActivity-Replicate_1W530-Fit_ZeroActivity-Replicate_1W530-Fit_CurveClass-Replicate_1W530-Excluded_Points-Replicate_1W530-Max_Response-Replicate_1W530-Activity at 0.0000060039 uM-Replicate_1W530-Activity at 0.0000137707 uM-Replicate_1W530-Activity at 0.0000545120 uM-Replicate_1W530-Activity at 0.0001296300 uM-Replicate_1W530-Activity at 0.0003002588 uM-Replicate_1W530-Activity at 0.0006197232 uM-Replicate_1W530-Activity at 0.00170 uM-Replicate_1W530-Activity at 0.00522 uM-Replicate_1W530-Activity at 0.013 uM-Replicate_1W530-Activity at 0.030 uM-Replicate_1W530-Activity at 0.068 uM-Replicate_1W530-Activity at 0.153 uM-Replicate_1W530-Activity at 0.349 uM-Replicate_1W530-Activity at 1.067 uM-Replicate_1W530-Activity at 3.267 uM-Replicate_1W530-Activity at 8.386 uM-Replicate_1W530-Activity at 18.95 uM-Replicate_1W530-Activity at 42.46 uM-Replicate_1W530-Activity at 92.41 uM-Replicate_1W530-Activity at 240.3 uM-Replicate_1W530-Activity at 872.4 uM-Replicate_1W530-Activity at 1849.0 uM-Replicate_1W530-Activity at 4135.0 uM-Replicate_1W530-Activity at 9246.0 uM-Replicate_1W530-Activity at 20670.0 uM-Replicate_1W530-Activity at 46230.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inhibitor26.603267.916510004-6.3959-9.65890.68632.7866-13.8272-6.7622-5.1896-0.7481-5.27594.03470.82940.1619-7.9826-6.39590Partial curve; partial efficacy-4.57512.04790.7981-71.9165-4-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-55.9973
Inactive10-4.62514.44950.3528-7.16493.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-6.38749.90032.8880.83753.8232-0.0972-3.85071.63986.05136.86712.68588.8472-0.8502-6.3874100041.575
Inactive10-6.97511.47810.3563-3.5961240 0 0 0 0 0 0 0 0 0 0 0 0 0 10.93160.12450.04624.37542.76350.5086-0.9132-2.76892.6163-8.8301-3.1415-5.9818-0.09820.9316100041.7546
Inactive10004-0.2652-5.20890.1059-0.2104-5.15230.33386.5915-0.1964-2.77990.7841-0.7171-11.48410.0954-0.265210004-13.1319
Inactive100042.5869-2.9649-3.11563.2094-2.83759.1891-4.0873-2.306-3.35572.25610.25920.4568-2.76022.586910004-1.7942
Inactive10-8.42514.95490.42-1.5675840 0 0 0 0 0 0 0 0 0 0 0 0 0 13.10992.05513.45141.5277-1.18820.19451.17012.6784-0.2053-6.4479-0.458-3.6987-4.65953.109910-6.57510.50.3897-7.94783.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-8.9647
Inactive100041.98244.9364-3.0777-2.52245.8788-4.393-2.1514-6.5660.2639-2.3165-0.97250.1618.67231.9824100046.8262
Inactive100043.1910.64224.5969-8.3735-6.2557-10.06561.9483-0.0245-0.5998-6.34343.4655-0.97126.44013.19110-6.42514.95490.47171-6.555840 0 0 0 0 0 0 0 0 0 0 0 0 0 01.4044
Inactive100043.06910.94732.7335-0.3539-2.50762.6313-2.14111.34421.3076-1.59431.5055-0.4395-0.98173.0691100041.074
Inactive100040.03460.7513-5.05642.3416-3.78150.6279-8.57720.96422.5971-5.43511.94880.0125-4.35290.0346100041.8201
Inactive100040.6895-3.70214.9864-1.54015.41435.0376-4.7424-5.3192-0.37944.4337-3.11858.58982.10140.6895100040.0062
Inactive100041.35410.6932-6.5104-4.10014.12961.40140.1852-2.5615-2.9103-6.16262.11950.64771.75491.354110004-0.079
Inactive10004-0.9612-2.32050.75015.3012-0.3654-0.41856.8872-1.988210.93541.3283-3.35076.4187-0.5006-0.961210-8.87513.06540.39511.5-6.166340 0 0 0 0 0 0 0 0 0 0 0 0 0 05.4117
Inactive10-4.97510.70.3315-10.872-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-7.76180.98150.1-0.85683.8492-10.310.16961.4622-0.195-5.3525-2.1777-5.7002-7.2375-7.761810-7.52514.95490.3969-2.9301540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-3.0376
Inactive10-5.12514.95490.8156-9.2611-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-8.12810.0145-0.6779-1.47220.3898-1.23510.5729-4.44590.86280.7235-0.3998-7.3742-9.8009-8.128110004-2.0593
Inactive100046.04370.32725.2199-1.386516.5133-4.78731.16280.41731.29560.90511.13123.78936.19046.0437100040.8526
Inactive10004-5.2833-3.6332-8.5443-7.987-8.28162.6995-7.1202-2.40580.91532.5108-1.3669-7.4886-7.4328-5.2833100046.8517
Inhibitor29.8493106.094510-5.47512.84730.42146.5-2.542840 0 0 0 0 0 0 0 0 0 0 0 0 0 1-3.2442-0.53315.2895-5.86780.6544-0.4618-5.09910.1718-8.184-9.20241.59976.35576.1854-3.24420Partial curve; high efficacy-4.52512.12110.9077-108.0945-2-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-81.8897
Inactive10-6.02514.95490.40980-4.031340 0 0 0 0 0 0 0 0 0 0 0 0 0 02.6436-7.1138-4.8994-1.2953-3.42690.0695-5.181-8.7761-5.8014-2.75760.2413-0.1351-2.45232.643610004-7.8883
Inactive10004-5.3863-7.35993.98542.9754-2.40971.18239.4234-0.41260.864-0.3003-2.479-0.03810.1317-5.386310004-9.0143
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: APP-Toga-CHIKV-nsp2-p
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Control / Compound; 20 nL; Echo 655 acoustic dispenser, Greiner 1536-well solid bottom black plate.
2; Enzyme; 4 uL; BioRAPTR FRD liquid dispenser (Beckman Coulter).
3; Incubation; 15 min; room temperature.
4; Reagent; 4 uL; 2.5 uM Peptide 2 substrate.
5; Incubation; 1 hr; room temperature.
6; Detection; Fluorescence; WiewLux microplate reader (PerkinElmer), 525 nm excitation, 598/25 nm emission.

NOTES (numbers refer to sequence numbers above).
1. Briefly, 20 nL DMSO, positive control ZnAc (20nM final concentration), and test compounds were transferred into a 1,536-well solid bottom black plate (789176-F, Greiner One) via Echo 655 acoustic dispenser (Beckman Coulter). For primary screens, compounds were tested at 7 concentrations, 1:3 dilution points ranging from 25 uM to 34 nM. Follow-up confirmatory screens were carried out at 11 concentrations, 1:3 dilution points from 25 uM to 0.42 nM.
2. Four uL nsP2pro enzyme mix (150 nM final concentration) in 10 mM Tris-HCl pH 8.0 with 0.01% Tween 20 assay buffer was dispensed into the plate using a BioRAPTR FRD liquid dispenser (Beckman Coulter).
3. The plate was incubated at room temperature (protected from light) for 15 min
4. Four microliter of peptide 2 substrate (2.5 uM final concentration) in assay buffer was added to the plate.
5. After 1 hour, plates were immediately read on a ViewLux high-throughput CCD imager (Exposure = 10 sec, Gain = High, Speed = Slow, Binning = 2X). The above assay was also incorporated in the NCATS HTS facility41, which allowed for robotic liquid and compound dispensing, microplate handling, and fluorescence reading..

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000040000 uMActivity at 0.0000163452 uMActivity at 0.0000320000 uMActivity at 0.0000806082 uMActivity at 0.0001439601 uMActivity at 0.0003895389 uMActivity at 0.0007288991 uMActivity at 0.00154 uMActivity at 0.00290 uMActivity at 0.00454 uMActivity at 0.00833 uMActivity at 0.021 uMActivity at 0.041 uMActivity at 0.095 uMActivity at 0.199 uMActivity at 0.321 uMActivity at 0.689 uMActivity at 1.028 uMActivity at 2.684 uMActivity at 5.101 uMActivity at 10.05 uMActivity at 24.85 uMActivity at 39.21 uMActivity at 78.39 uMActivity at 125.0 uMCompound QC
Inactive000458.411643.591625.884333.42079.110921.639545.688610.891128.395531.312738.991441.655858.4116QC'd by Sytravon
Inactive0004-12.6805-10.7548-9.5107-10.6418-15.9997-12.6805QC'd by Sytravon
Inactive0004-7.1462-9.2235-11.8601-6.118-12.2196-7.1462QC'd by Sytravon
Inactive0-4.754.95490.6661-22.0013-240 0 0 0 0-18.751-10.987-0.99352.3561.2583-18.751QC'd by Sytravon
Inactive0004-11.1249-10.2692-11.5229-11.032-13.325-11.1249QC'd by Sytravon
Inactive0-4.81.88510.5555-23.9168-5.408840 0 0 0 0-18.264-13.0121-2.8407-6.6548-7.1687-18.264QC'd by Sytravon
Inactive0-6.354.95490.9083-3.1815-14.928340 0 0 0 1-10.2909-13.1276-17.0236-1.4012-4.6174-10.2909QC'd by Sytravon
Inactive0-5.950.40.9812-20.7272-0.994240 0 0 0 0-16.0227-4.9952-8.1266-9.7286-14.3153-16.0227QC'd by Sytravon
Inactive0-6.54.95490.6409-9.2158-16.601140 0 0 0 1-12.7654-16.3342-16.1896-6.0131-13.084-12.7654QC'd by Sytravon
Inactive00041.9752.61033.4198-3.47481.76241.975QC'd by Sytravon
Inactive0004-8.2223-0.1456-4.3339-1.582-3.6253-8.2223QC'd by Sytravon
Inactive0-7.254.95490.602-10.0715240 0 0 0 0-12.60110.2325-14.2262-4.5441-8.7364-12.6011QC'd by Sytravon
Inactive0-4.754.50450.9809-24.6554-10.844240 0 0 0 0-22.2129-9.8702-10.3098-11.7375-10.6121-22.2129QC'd by Sytravon
Inactive0-4.754.95490.8409-13.5514240 0 0 0 0-11.2928-1.92764.61061.33364.0275-11.2928QC'd by Sytravon
Inactive0-5.20.50.9077-28.8252-9.445240 0 0 0 0-23.1876-10.7877-12.0613-16.7104-16.3414-23.1876QC'd by Sytravon
Inactive0004-18.3436-16.2788-21.7212-19.8613-16.6894-18.3436QC'd by Sytravon
Inactive0004-5.4025-9.518-0.16940.2848-4.8162-5.4025QC'd by Sytravon
Inactive0004-23.1229-14.0834-13.5556-16.7644-18.8145-23.1229QC'd by Sytravon
Inactive0-4.953.29750.9426-35.5663-15.226240 0 0 0 0-34.2687-12.6885-18.3414-14.0693-16.4909-34.2687QC'd by Sytravon
Inactive0-4.754.95490.7952-15.6253-4.893240 0 0 0 0-13.8544-4.3645-8.5252-3.661-3.9903-13.8544QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: DRD2945
Protocol: Tox21 Assay Protocol Summary:

DRD2-Hek293 cells were dispensed at 600 cells/3uL/well in 1536-well white plates using a Multidrop Dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 24 h, 1 uL of Ro20-1724 at final concentration of 0.1 mM was transferred to the assay plate by a Flying Reagent Dispenser. Following Ro20-1724 addition, 23 nL of compound dissolved in DMSO, positive controls or DMSO only was added to the assay plates via Wako pintool station. The assay plates were incubated at room temperature for 10 min. Next, 1 uL of mixture of NKH477 (final concentration at 200 nM) and quinpirole (final concentration at 12 nM) was added into the plates. After the assay plates were incubated at room temperature for an additional 30 min, 2.5 ul/well of cAMP-d2 and 2.5 ul/well of anti-cAMP-cryptate were added respectively into the assay plates using a Flying Reagent Dispenser. The plates were incubated at room temperature for 1 h. The fluorescence intensity in the plates was measured at 340 nm excitation and 665 & 620 nm emission by an Envision plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W530-Activity_Score-Replicate_1W530-Curve_Description-Replicate_1W530-Fit_LogAC50-Replicate_1W530-Fit_HillSlope-Replicate_1W530-Fit_R2-Replicate_1W530-Fit_InfiniteActivity-Replicate_1W530-Fit_ZeroActivity-Replicate_1W530-Fit_CurveClass-Replicate_1W530-Excluded_Points-Replicate_1W530-Max_Response-Replicate_1W530-Activity at 0.0000060292 uM-Replicate_1W530-Activity at 0.0000139277 uM-Replicate_1W530-Activity at 0.0000552087 uM-Replicate_1W530-Activity at 0.0001297661 uM-Replicate_1W530-Activity at 0.0003003480 uM-Replicate_1W530-Activity at 0.0006206701 uM-Replicate_1W530-Activity at 0.00170 uM-Replicate_1W530-Activity at 0.00522 uM-Replicate_1W530-Activity at 0.013 uM-Replicate_1W530-Activity at 0.030 uM-Replicate_1W530-Activity at 0.068 uM-Replicate_1W530-Activity at 0.153 uM-Replicate_1W530-Activity at 0.348 uM-Replicate_1W530-Activity at 1.074 uM-Replicate_1W530-Activity at 3.280 uM-Replicate_1W530-Activity at 8.379 uM-Replicate_1W530-Activity at 18.94 uM-Replicate_1W530-Activity at 42.46 uM-Replicate_1W530-Activity at 92.41 uM-Replicate_1W530-Activity at 242.9 uM-Replicate_1W530-Activity at 865.8 uM-Replicate_1W530-Activity at 1849.0 uM-Replicate_1W530-Activity at 4135.0 uM-Replicate_1W530-Activity at 9246.0 uM-Replicate_1W530-Activity at 20670.0 uM-Replicate_1W530-Activity at 46230.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inactive100043.78813.72091.98610.20610.59235.59482.53080.60822.30311.88620.3033-2.23441.87823.788110004-12.0188
Inactive100040.30120.52940.6626-2.6038-0.5572-0.6631-4.33661.0325-2.759-0.3338-0.3287-1.63422.49720.3012100042.5444
Inactive10004-6.3367-0.20894.28190.94444.1311-1.1259-2.3025-0.8518-3.0168-0.69982.3696-1.04735.4453-6.336710-4.87513.51170.6776-24.2714-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 12.914
Inactive10004-1.1765-2.02963.5024-1.9703-0.15791.9613-0.75732.76970.8721.72771.1044-0.05681.933-1.176510-6.12514.95490.4361-5.3789240 0 0 0 0 0 0 0 0 0 0 0 0 0 116.187
Inactive10-4.44014.95490.7066-19.0899240 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.90474.8233-2.51545.04834.70586.1601-0.2063-0.8092-0.6546-4.17011.85590.3717-17.5749-0.904710-4.49014.95490.471515.5-4.348640 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.0917
Inconclusive10-6.62354.95490.7986-0.6511040 0 0 0 0 0 0 0 0 0 0 0 0 0 0-3.63988.774811.18327.61489.427810.847712.24230.7218-1.8373-2.18071.01625.3861-1.696-3.639810004-1.5758
Inactive100041.33252.41660.0324-1.17531.0360.22312.63193.94840.94140.00221.27583.2279-2.80021.332510004-3.3592
Inactive10-6.37992.72020.319-1.29553.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-3.3155.53032.4743-0.4098-0.05774.777410.7719-2.01031.7767-1.0637-1.2042.5912-3.5795-3.31510-6.32994.95490.42623.5-6.413140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.295
Inactive100041.11512.34553.30752.55170.31210.86413.3572-5.8070.82230.74510.4398-3.3457-5.97791.115110-7.08462.04790.54874-12.505140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-9.5005
Inactive100041.63771.2371-1.25830.3296-1.6140.7175-1.114-0.0071-2.3580.54470.1386-1.0325-0.62621.637710004-2.264
Inactive100041.1729-5.37470.0618-1.16140.2075-0.5657-2.68830.98772.79770.48074.20440.5734-4.58271.172910-7.72874.95490.3377-4.06432.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-5.4636
Inhibitor50.887851.364110004-0.0970.4130.80160.55140.49890.17153.02080.70020.7634-4.9454-3.23730.4082-4.1558-0.0970Partial curve; partial efficacy-4.29343.06540.7755-53.8641-2.5-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-47.2455
Inactive100047.09728.61190.86441.2866-1.15580.06177.65980.00716.608-1.8979-2.1702-0.918410.71347.097210-4.66014.44950.5285-18.6347-340 0 0 0 0 0 0 0 0 0 0 0 0 0 0-16.5019
Inactive100040.4698-1.0082-3.0359-1.3764-2.8847-2.1219-1.72584.0502-6.0703-2.72140.76450.6902-0.23090.469810004-4.9773
Inactive100045.8424.59930.09510.5509-0.07364.4281-2.8904-1.95170.0719-0.5266-2.90590.46610.03965.84210-4.15331.210.5077-31.931240 0 0 0 0 0 0 0 0 0 0 0 0 0 0-23.2758
Inconclusive100042.20030.65450.18076.1358-0.38062.10074.9512-0.01961.9422-1.56120.41822.5985-2.1292.200310-6.56052.72020.4244-1.5-9.440940 0 0 0 0 0 0 0 0 0 0 0 0 0 1-12.2578
Inhibitor31.4373115.3525100049.71694.21783.58235.13815.09542.57424.22143.54180.04322.4418-1.71227.3565-0.25439.71690Partial curve; high efficacy-4.50261.24750.9516-117.8525-2.5-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-103.3794
Inactive100041.7529-5.7942-2.1210.23431.62890.87140.2124-5.88470.01861.5276-1.9768-1.2986-3.43591.752910-8.09594.95490.48860.5917840 0 0 0 0 0 0 0 0 0 0 0 0 0 00.6765
Inactive100043.39870.6520.80240.3115-3.13092.1040.4118-2.7174-3.73120.0892-0.14594.0124-0.74333.398710-8.74514.95490.45570.928714.540 0 0 0 0 0 0 0 0 0 0 0 0 0 00.1127
Inactive100045.282.1409-0.18040.24510.4128-3.92832.74470.34230.07910.359-0.25380.8178-2.33135.2810004-1.3082
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: DRD2180
Protocol: Tox21 Assay Protocol Summary:

DRD2-Hek293 cells were dispensed at 600 cells/3uL/well in 1536-well white plates using a Multidrop Dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 24 h, 1 uL of Ro20-1724 at final concentration of 0.1 mM was transferred to the assay plate by a Flying Reagent Dispenser. Following Ro20-1724 addition, 23 nL of compound dissolved in DMSO, positive controls or DMSO only was added to the assay plates via Wako pintool station. The assay plates were incubated at room temperature for 10 min. Next, 1 uL of NKH477 at 200nM was added into the plates. After the assay plates were incubated at room temperature for an additional 30 min, 2.5 ul/well of cAMP-d2 and 2.5 ul/well of anti-cAMP-cryptate were added respectively into the assay plates using a Flying Reagent Dispenser. The plates were incubated at room temperature for 1 h. The fluorescence intensity in the plates was measured at 340 nm excitation and 665 & 620 nm emission by an Envision plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W530-Activity_Score-Replicate_1W530-Curve_Description-Replicate_1W530-Fit_LogAC50-Replicate_1W530-Fit_HillSlope-Replicate_1W530-Fit_R2-Replicate_1W530-Fit_InfiniteActivity-Replicate_1W530-Fit_ZeroActivity-Replicate_1W530-Fit_CurveClass-Replicate_1W530-Excluded_Points-Replicate_1W530-Max_Response-Replicate_1W530-Activity at 0.0000060039 uM-Replicate_1W530-Activity at 0.0000137707 uM-Replicate_1W530-Activity at 0.0000545120 uM-Replicate_1W530-Activity at 0.0001296300 uM-Replicate_1W530-Activity at 0.0003002588 uM-Replicate_1W530-Activity at 0.0006189798 uM-Replicate_1W530-Activity at 0.00171 uM-Replicate_1W530-Activity at 0.00522 uM-Replicate_1W530-Activity at 0.013 uM-Replicate_1W530-Activity at 0.030 uM-Replicate_1W530-Activity at 0.068 uM-Replicate_1W530-Activity at 0.153 uM-Replicate_1W530-Activity at 0.349 uM-Replicate_1W530-Activity at 1.067 uM-Replicate_1W530-Activity at 3.267 uM-Replicate_1W530-Activity at 8.386 uM-Replicate_1W530-Activity at 18.95 uM-Replicate_1W530-Activity at 42.46 uM-Replicate_1W530-Activity at 92.41 uM-Replicate_1W530-Activity at 240.3 uM-Replicate_1W530-Activity at 872.4 uM-Replicate_1W530-Activity at 1849.0 uM-Replicate_1W530-Activity at 4135.0 uM-Replicate_1W530-Activity at 9246.0 uM-Replicate_1W530-Activity at 20670.0 uM-Replicate_1W530-Activity at 46230.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inactive10-9.17434.95490.4482-3.18846.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-1.07816.0843-0.8272-3.4248-7.0165-0.7165-1.5939-6.0807-6.8337-3.16772.3771-1.0033-5.7858-1.5510004-2.7583
Inactive10-4.56371.86170.317890.084640 0 0 0 0 0 0 0 0 0 0 0 0 0 10.0842-0.0855-0.2953-0.78052.34661.2131-0.54523.1167-3.3842-0.91893.75641.40566.4780.084210004-4.2236
Inactive100042.61982.3466-0.37735.5914.99152.11680.87533.1726-0.17420.9304-1.192-0.56531.70682.619810004-6.2418
Inactive100046.3560.92680.5680.6444-3.3685.672.3853-0.05552.7361-3.48357.347-3.04965.74596.356100043.4789
Inactive100041.38231.31710.97261.5261-8.2713-38.61011.4699-0.6371-5.1128-8.1546-1.1688-0.5786-0.66451.3823100048.8154
Inactive10004-2.5144-2.361-1.80391.85040.1129-6.2676-1.336-3.9127-3.9292-2.7130.026-2.79-2.1424-2.514410004-9.9999
Inactive100048.63938.07697.9985-2.61410.32086.27480.56646.16683.97512.40730.27918.65336.08258.6393100040.6824
Inactive10004-4.5511-0.5715-12.6079-5.3348-1.7778-1.64430.7428-13.8301-1.3699-2.6117-9.8602-7.4651-3.7149-4.5511100044.8975
Inactive10004-8.9924-2.5393-12.2689-12.3285-8.4096-5.3726-7.3661-8.2488-6.5273-10.2917-10.0818-0.9401-19.8028-8.992410-4.56374.95490.6441100.364840 0 0 0 0 0 0 0 0 0 0 0 0 0 08.3824
Inactive100040.5065-4.7724-1.7416-5.05921.11050.443-0.1512-1.416-1.4307-0.5117-7.58251.11541.19672.93930.5065100042.402
Inactive100040.07942.87210.18864.94540.2886-2.1392-1.7328-1.01662.15434.9444.9611.73843.84360.079410-5.06374.95490.4347-3.07543.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.2874
Inactive10-4.61644.0950.4209-7.778140 0 0 0 0 0 0 0 0 0 0 0 0 0 12.11662.02-0.42232.25972.48460.06621.20842.5829-1.68581.7929-0.6289-1.1-6.89832.116610-4.11644.95490.5915-20.3885-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-15.3238
Inactive10004-7.0632-0.8623-1.7916-4.2652-5.9669-19.4504-1.91220.824-2.2999-5.5153-0.4675-5.37812.0763-7.063210-8.81374.95490.73241-15.784740 0 0 0 0 0 0 0 0 0 0 0 0 0 03.2717
Inactive100045.45724.7104-1.6933-3.19594.97480.59361.7222-0.1931.27552.5585-4.68520.39195.48635.457210-9.04334.95490.6699-0.51411.540 0 0 0 0 0 0 0 0 0 0 0 0 0 01.4299
Inactive10004-5.15337.6944-0.2819-6.74360.13834.2317-8.8165.28882.3311.64635.25816.3561-1.5635-5.153310-8.71374.44950.67941.5-14.151240 0 0 0 0 0 0 0 0 0 0 0 0 0 01.5537
Inactive100047.48515.0097.9161-5.82395.4781-0.20210.73765.95164.1964-6.02863.1953-2.5872.51947.4851100042.0117
Inactive100047.63123.15953.60054.23419.422-0.7563.62193.93153.42863.89981.27179.0227-0.49517.631210004-6.9865
Inactive10-5.36374.95490.3650.132640 0 0 0 0 0 0 0 0 0 0 0 0 0 111.41172.26859.495711.56072.32788.75936.01856.48955.66755.3341-2.80674.5233-1.542111.411710004-1.6128
Inactive100042.8507-1.44118.21990.12610.2712-2.1386-1.41324.99742.20190.50950.32360.58160.98078.83382.8507100040.3148
Inactive10004-3.5331.7914-3.9103-4.2814-4.8026-0.23944.0174-2.4595-1.52260.851.611-2.87492.3635-3.53310004-4.1257
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: CHRM1834
Protocol: Assay Protocol Summary:

CHRM1-CHO cells were dispensed at 1000 cells/3uL/well in 1536-well black-clear bottom plates using a Multidrop Dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 18 h, 3 uL of Dye Loading Buffer was transferred to the assay plate by a Flying Reagent Dispenser. The assay plates were incubated at 37 C for 1h. For agonist mode, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pin tool. The fluorescence intensity in the plates was measured using FDSS 7000EX kinetic plate reader for 2 min at 1 sec intervals. The fluorescence intensity in the plates was measured using FDSS 7000EX kinetic plate reader for 3 min at 1 sec intervals. Each test compound was measured at 15 concentrations in three independent runs.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152025 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive00040.27-0.01710.2452-0.00120.080.07230.2279-0.64050.02840.0796-0.0665-0.0639-0.02560.27QC'd by SigmaAldrichInactive0
Inactive00040.3979-0.06510.78140.003-0.08590.1712-0.03250.09370.0666-0.442-0.6501-0.7181-1.19180.3979QC'd by Toronto ResearchInactive0
Inactive00040.50960.13750.02540.15070.01870.023-0.0882-0.04940.26750.23570.15260.0353-0.51360.5096QC'd by SigmaAldrichInactive0
Inactive00042.53080.77180.56770.1541-0.18960.0586-0.0992-0.19140.07380.69750.14260.09660.34082.5308QC'd by SIGMAInactive0
Inactive0004-1.14720.10470.25460.15670.13560.05240.35320.1530.0574-0.6714-0.19020.1471-1.2293-1.1472QC'd by SIGMAInactive0
Inactive00040.14630.0224-0.33040.05520.09030.0693-0.08240.1615-0.03260.09990.3798-0.07420.35760.1463QC'd by SIGMAInactive0
Inactive0004-0.0699-0.94060.80630.77990.03390.7610.03490.21810.49060.0890.2004-0.0501-0.0028-0.0699QC'd by SIGMAInactive0
Inactive00041.83420.1116-0.00320.11720.23360.2218-0.15310.0723-0.0177-0.04750.0390.36720.25951.8342QC'd by SigmaAldrichInactive0
Inactive00041.2961-0.0487-0.113-0.27430.0322-0.18530.2616-0.01810.4137-0.05260.35890.45560.61241.2961QC'd by SigmaAldrichInactive0
Inactive0004-0.17021.55020.53860.099-0.1571-0.2841-0.4676-0.23710.2585-0.29890.42120.2244-0.329-0.1702QC'd by SIGMAInactive0-4.24844.95490.9849
Inactive00040.617-0.0348-0.0116-0.15060.12690.09220.04280.13080.67190.54110.05040.04340.07380.617QC'd by SigmaAldrichInactive0
Inactive00040.08250.10830.13780.04780.2340.03580.0664-0.12370.0503-0.01640.11520.24270.00820.0825QC'd by SIGMAInactive0
Inactive00040.29450.04740.51170.20190.25530.09380.3703-0.06840.1512-0.01270.2949-0.07560.07070.2945QC'd by SigmaAldrichInactive0
Inactive0004-0.47420.19480.86240.64810.36120.4680.4992-0.19240.7415-0.0520.3014-0.4759-0.7733-0.4742QC'd by SIGMAActivator4.888238.3142Complete curve; partial efficacy-5.31084.95490.9876
Inactive0004-0.10730.05280.15780.0556-0.06520.094-0.0707-0.09840.15540.01480.06-0.683-0.0854-0.1073QC'd by SIGMAInactive0
Inactive0004-0.38280.7081.10930.27520.50230.35130.5920.2070.31280.31150.00490.15090.0186-0.3828QC'd by SIGMAInactive0
Inactive00043.19140.05370.0627-0.0199-0.91560.34450.1644-0.0051-0.06990.12160.44840.16630.14663.1914QC'd by Spectrum ChemicalInactive0
Inactive0-8.86033.990.97980.24231740 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.08198.09170.91440.3470.2061.69190.27670.2627-0.1985-0.0993-0.2147-0.0596-0.0858-0.0819QC'd by SIGMAInactive0
Inactive00040.11330.20950.15290.2804-0.00250.29590.57160.22840.33210.03070.11970.07720.34590.1133QC'd by SigmaAldrichInactive0
Inactive00040.53410.02420.21240.18710.04730.10960.04040.0920.12340.01120.1629-0.07080.20290.5341QC'd by SigmaAldrichInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: CHRM1997
Protocol: Tox21 Assay Protocol Summary:

CHRM1-CHO cells were dispensed at 1000 cells/3uL/well in 1536-well black-clear bottom plates using a Multidrop Dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 18 h, 3 uL of Dye Loading Buffer was transferred to the assay plate by a Flying Reagent Dispenser. The assay plates were incubated at 37 C for 1h. For antagonist mode, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pin tool. After 5 min incubation at room temperature, 1.5 uL of acetylcholine at 50nM was added to each well. The fluorescence intensity in the plates was measured using FDSS 7000EX kinetic plate reader for 3 min at 1 sec intervals. Each test compound was measured at 15 concentrations in three independent runs.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000039960 uM-Replicate_1Activity at 0.0000091663 uM-Replicate_1Activity at 0.0000362847 uM-Replicate_1Activity at 0.0000862850 uM-Replicate_1Activity at 0.0001998674 uM-Replicate_1Activity at 0.0004124603 uM-Replicate_1Activity at 0.00113 uM-Replicate_1Activity at 0.00347 uM-Replicate_1Activity at 0.00893 uM-Replicate_1Activity at 0.020 uM-Replicate_1Activity at 0.045 uM-Replicate_1Activity at 0.102 uM-Replicate_1Activity at 0.232 uM-Replicate_1Activity at 0.710 uM-Replicate_1Activity at 2.174 uM-Replicate_1Activity at 5.582 uM-Replicate_1Activity at 12.62 uM-Replicate_1Activity at 28.26 uM-Replicate_1Activity at 61.51 uM-Replicate_1Activity at 159.9 uM-Replicate_1Activity at 580.7 uM-Replicate_1Activity at 1231.0 uM-Replicate_1Activity at 2752.0 uM-Replicate_1Activity at 6155.0 uM-Replicate_1Activity at 13760.0 uM-Replicate_1Activity at 30770.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-2.1781-14.6077-15.74035.874-6.19418.893-5.649710.7344-0.67673.7136-6.5739-2.1499-21.2783-2.1781QC'd by SIGMAInactive0
Inactive0-6.1260.30.4906-11.7304-33.739340 0 0 0 0 0 0 0 0 0 0 0 0 0 0-16.5369-31.6558-25.1796-28.7381-31.0798-26.2723-27.0785-30.5027-26.1541-8.1086-12.2914-19.9415-24.8788-16.5369QC'd by SIGMAInactive0
Inactive000415.11824.3534-3.1877-2.3826-5.7413-2.494211.75430.97083.76215.91024.486711.0592-5.946515.1182QC'd by SIGMAInactive0
Inactive0-8.52620.80.37567.5-8.95740 0 0 0 0 0 0 0 0 0 0 0 0 0 1-7.0338-3.64071.60920.62293.187712.91231.74593.92468.020910.518311.639515.6309-5.7975-7.0338QC'd by SIGMAInactive0
Inactive0-6.0263.990.37841.5-16.326140 0 0 0 0 0 0 0 0 0 0 0 0 0 07.701-23.9593-2.61690.34194.1756-23.8273-28.1884-27.1927-13.1416-3.4634-3.930911.7786-7.39137.701QC'd by SIGMAInactive0-7.4761.3310.4129
Inactive0-8.87624.95490.4467-2.89869.540 0 0 0 0 0 0 0 0 0 0 0 0 0 11.2264.0632-6.2638-6.4961-4.2253-3.5816-3.9002-1.843-3.68491.19333.89413.4558-6.99891.226QC'd by SIGMAInactive0
Inactive000417.853-4.4191-4.34458.438221.648-5.45146.6976-11.093111.255112.5287-7.84059.850416.079317.853QC'd by SIGMAInactive0
Inhibitor14.929466.177610Single point of activity-4.8264.44950.89-59.67766.5-30 0 0 0 0 0 0 0 0 0 0 0 0 0 1-15.344512.41639.71031.67098.92985.04529.81652.21698.6338-9.05192.0403-8.8885-59.3874-15.3445QC'd by CrescentInhibitor14.929443.584610Partial curve; partial efficacy; poor fit-4.8261.24750.7244
Inactive0004-12.3393-5.4707-7.76841.2125-0.9372-2.8638-4.8159-2.7306-8.3906-9.8909-5.1158-7.2832-3.7752-12.3393QC'd by CrescentInactive0
Inactive0004-12.39951.73690.337212.25698.1175-3.8979-0.5168-2.9245-1.5012-11.34040.83976.57380.9346-12.3995QC'd by CrescentInactive0
Inactive0-7.4764.95490.44240.4896-18.399340 0 0 0 0 0 0 0 0 0 0 0 0 0 0-4.4979-11.8174-3.4832-35.6655-28.5631-0.27183.2831-4.3744-4.3198.29879.438-3.47050.9414-4.4979QC'd by SIGMAInactive0
Inactive000411.53510.193311.9123-7.312714.60326.2774-3.41324.3898-1.954310.42329.88493.05612.716611.5351QC'd by SIGMAInactive0
Inhibitor0.594430.146810Partial curve; partial efficacy; poor fit-6.2263.92950.7596-31.1468-1-2.40 0 0 0 0 0 0 0 0 0 1 1 1 1 19.5925-8.13272.24441.75489.3564-5.7864-0.27772.5376-21.72486.41512.81351.15442.42899.5925QC'd by SIGMAInactive0
Inactive0-5.2763.990.4615-5.34586.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.30194.76232.487611.73962.3257-6.645112.017214.48989.03815.5870.4265-6.2237-6.9549-2.3019QC'd by SIGMAInactive0-4.3764.95490.5619
Inactive00042.05448.146913.882312.5534-5.61650.912412.01381.37735.791415.21471.24863.25714.80342.0544QC'd by SIGMAInactive0
Inhibitor8.395486.565182Complete curve; high efficacy-5.0762.25260.9515-80.06516.5-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-75.405-0.47175.053514.06375.580411.760223.03491.4555-1.71019.2627-17.022-54.0908-79.057-75.405QC'd by SIGMAInactive0-4.3764.95490.4538
Inactive00041.3209-3.56471.30272.7209-12.34330.54250.6416-2.4475-9.1264-0.7083-1.51823.5135-1.75421.3209QC'd by SIGMAInactive0
Inactive00040.14032.2597-2.059213.664116.96353.773113.14130.69514.996-1.62290.30745.6118.65320.1403QC'd by SIGMAInactive0
Inactive0-5.58383.990.6268-0.5-10.788840 0 0 0 0 0 0 0 0 0 0 0 0 0 0-1.6985-10.3141-12.3897-15.0539-7.0521-6.4389-18.9907-5.2846-10.0691-6.4352-0.26281.1904-1.6416-1.6985QC'd by SIGMAInactive0
Inactive000410.66146.5582-3.2554-3.2146-2.04712.598611.13443.1739-1.526-0.57044.82454.971210.532110.6614QC'd by SIGMAInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: CRE506
Protocol: Tox21 Assay Protocol Summary:
CRE-bla Hek 293T cells were suspended in assay medium (DMEM containing 10% dialyzed FBS, 0.1 mM NEAA, 1 mM sodium pyruvate and 25 mM HEPES) and dispensed at 2,000 cells/4 uL /well into 1536-well black wall/clear bottom plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37 C/5% CO2 for 18 hrs, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pintool workstation (Kalypsys, San Diego, CA), followed by addition of 1 only was transferred to the assay plate by a Pintool station (Kalypsys, San Diego, CA), followed by addition of 1 uL of 1.25uM NKH477 (0.25 uM as final concentration) in assay medium using a Flying Reagent Dispenser (Aurora Discovery, San Diego, CA). The plates were incubated at 37 C and 5% CO2 for 3 hrs. Then 1 uL of LiveBLAzer B/G FRET substrate (Invitrogen, Carlsbad, CA) was added to each well using Bioraptr Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). The plates were incubated at room temperature for 2 h.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).
Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W530-Activity_Score-Replicate_1W530-Curve_Description-Replicate_1W530-Fit_LogAC50-Replicate_1W530-Fit_HillSlope-Replicate_1W530-Fit_R2-Replicate_1W530-Fit_InfiniteActivity-Replicate_1W530-Fit_ZeroActivity-Replicate_1W530-Fit_CurveClass-Replicate_1W530-Excluded_Points-Replicate_1W530-Max_Response-Replicate_1W530-Activity at 0.0000060039 uM-Replicate_1W530-Activity at 0.0000137707 uM-Replicate_1W530-Activity at 0.0000545120 uM-Replicate_1W530-Activity at 0.0001296798 uM-Replicate_1W530-Activity at 0.0003000028 uM-Replicate_1W530-Activity at 0.0006177381 uM-Replicate_1W530-Activity at 0.00171 uM-Replicate_1W530-Activity at 0.00519 uM-Replicate_1W530-Activity at 0.013 uM-Replicate_1W530-Activity at 0.030 uM-Replicate_1W530-Activity at 0.068 uM-Replicate_1W530-Activity at 0.153 uM-Replicate_1W530-Activity at 0.349 uM-Replicate_1W530-Activity at 1.067 uM-Replicate_1W530-Activity at 3.267 uM-Replicate_1W530-Activity at 8.391 uM-Replicate_1W530-Activity at 18.95 uM-Replicate_1W530-Activity at 42.44 uM-Replicate_1W530-Activity at 92.40 uM-Replicate_1W530-Activity at 240.3 uM-Replicate_1W530-Activity at 872.4 uM-Replicate_1W530-Activity at 1849.0 uM-Replicate_1W530-Activity at 4135.0 uM-Replicate_1W530-Activity at 9246.0 uM-Replicate_1W530-Activity at 20670.0 uM-Replicate_1W530-Activity at 46230.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inactive10004-7.0159-0.28761.01321.44170.0888-9.1268-1.0522-7.4421-2.13092.3-0.6113-7.015910004-3.4056
Inactive10004-3.011-1.145-2.4844-1.55333.485-0.204-2.4902-1.54362.3767-6.3498-2.685-3.011100040.7393
Inactive10004-0.47-2.8951-3.2523-3.7349-2.26785.50733.05993.31041.24725.2625-0.1696-0.4710004-1.555
Inactive10004-0.09036.7111-0.5976-0.3144-0.47654.1544-6.4709-0.4438-7.8642.2606-1.579-0.0903100040.228
Inconclusive10004-0.2489-6.5215-0.8591-0.5168-7.3815-0.3741.3251-4.3898-1.81870-5.0418-0.24890Single point of activity-4.94454.95490.8866-44.0901-1.7908-30 0 0 0 0 0 0 0 0 0 1 12.9202
Inactive10004-5.6294-14.3173-2.7201-11.2343-4.43723.4425-5.249628.2483-6.79752.1333-6.1463-5.629410-8.24452.33320.5422-2-14.519340 0 0 0 0 0 0 0 0 0 0 1-7.0593
Inactive10004-4.8656-4.3458-5.475-4.89231.908812.6287-0.6734-6.886-6.7235-12.2506-0.9244-4.865610004-0.1056
Inactive100042.05360.3109-7.7771-4.05191.735913.82374.1529-1.641-6.3339-7.8549-1.84152.053610-8.54450.20.35041.5-15.408240 0 0 0 0 0 0 0 0 0 0 01.5023
Inactive100041.8357-3.8712-4.59684.9056-2.4421-0.4821-0.70024.091-5.05424.7764-0.18731.835710-6.84454.95490.3731-1.2664840 0 0 0 0 0 0 0 0 0 0 0-6.472
Inconclusive10-8.44454.95490.4825-0.97971140 0 0 0 0 0 0 0 0 0 0 0-2.985812.2192-7.4831-2.76110.9594.608-1.19161.5553-4.61891.86440.8695-2.98580Complete curve; partial efficacy; poor fit-8.44454.95490.854-2.188620-1.40 0 0 0 0 0 0 0 0 0 0 0-3.7347
Inactive10-7.69454.95490.30740-6.674740 0 0 0 0 0 0 0 0 0 0 16.9665-0.2746-13.4789-0.7541.4976-6.63441.89750.04562.39343.2814-4.07626.966510004-1.252
Inactive10004-0.47391.766-10.94371.36752.373-9.08121.0872-1.62221.10851.03521.2078-0.473910004-1.5827
Inactive10-4.44452.40640.9192-16.0230.540 0 0 0 0 0 0 0 0 0 0 0-13.76922.63221.58520.43591.6531-1.4042-0.73890.9511-0.33230.0369-10.5155-13.769210-4.19454.95490.57139-3.14940 0 0 0 0 0 0 0 0 0 0 07.2634
Inactive100048.62161.66121.39551.5105-8.28851.1474-1.52842.0426-0.73990.4137-1.85788.621610004-2.0298
Inactive10004-4.4756-0.29490.23863.43141.14790.7678-0.0067-0.6507-5.9741-0.2067-0.9416-4.475610004-3.061
Inactive100045.8601-2.39410.0423-2.0754.7846.2997-0.85951.393-3.01113.55965.32115.860110004-9.2067
Inconclusive10-4.24454.95490.427210.5-2.309340 0 0 0 0 0 0 0 0 0 0 09.5331-2.85560-1.2063-0.52341.9291-1.3959-2.6682-0.0439-13.5911-0.2019.533110-4.19454.95490.4089-3.448340 0 0 0 0 0 0 0 0 0 0 07.6869
Inactive10-4.28664.95490.72825.5-1.172640 0 0 0 0 0 0 0 0 0 0 023.3828-8.06053.02756.3622-3.8991.2563-5.1797-5.777-0.78790.19013.771823.382810-4.18664.95490.6532-22.1907-340 0 0 0 0 0 0 0 0 0 0 0-18.4923
Inconclusive100045.4646-3.9154-3.2006-6.41313.52925.1932-1.12710.5761-20.3247-0.5782-7.18015.464610004-5.264
Activator45.240774.820710-7.89454.95490.36863-7.172940 0 0 0 0 0 0 0 0 0 0 1-4.09-4.1888-10.14418.5838-1.725112.80163.66663.2286-2.06960.7385-1.1706-4.090Partial curve; high efficacy-4.34453.06540.983172.728-2.09272.10 0 0 0 0 0 0 0 0 0 0 064.1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: CRE623
Protocol: Tox21 Assay Protocol Summary:
CRE-bla Hek 293T cells were suspended in assay medium (DMEM containing 10% dialyzed FBS, 0.1 mM NEAA, 1 mM sodium pyruvate and 25 mM HEPES) and dispensed at 2,000 cells/5 uL /well into 1536-well black wall/clear bottom plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37 C/5% CO2 for 18 hrs, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pintool workstation (Kalypsys, San Diego, CA). After the plates were incubated at 37 C/5% CO2 for 3 hrs, 1 uL of LiveBLAzer B/G FRET substrate (Invitrogen, Carlsbad, CA) was added to each well using Bioraptr Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). The plates were incubated at room temperature for 2 h.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).
Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W530-Activity_Score-Replicate_1W530-Curve_Description-Replicate_1W530-Fit_LogAC50-Replicate_1W530-Fit_HillSlope-Replicate_1W530-Fit_R2-Replicate_1W530-Fit_InfiniteActivity-Replicate_1W530-Fit_ZeroActivity-Replicate_1W530-Fit_CurveClass-Replicate_1W530-Excluded_Points-Replicate_1W530-Max_Response-Replicate_1W530-Activity at 0.0000060039 uM-Replicate_1W530-Activity at 0.0000137707 uM-Replicate_1W530-Activity at 0.0000545120 uM-Replicate_1W530-Activity at 0.0001296300 uM-Replicate_1W530-Activity at 0.0003002588 uM-Replicate_1W530-Activity at 0.0006197232 uM-Replicate_1W530-Activity at 0.00170 uM-Replicate_1W530-Activity at 0.00522 uM-Replicate_1W530-Activity at 0.013 uM-Replicate_1W530-Activity at 0.030 uM-Replicate_1W530-Activity at 0.068 uM-Replicate_1W530-Activity at 0.153 uM-Replicate_1W530-Activity at 0.349 uM-Replicate_1W530-Activity at 1.067 uM-Replicate_1W530-Activity at 3.267 uM-Replicate_1W530-Activity at 8.386 uM-Replicate_1W530-Activity at 18.95 uM-Replicate_1W530-Activity at 42.46 uM-Replicate_1W530-Activity at 92.41 uM-Replicate_1W530-Activity at 240.3 uM-Replicate_1W530-Activity at 872.4 uM-Replicate_1W530-Activity at 1849.0 uM-Replicate_1W530-Activity at 4135.0 uM-Replicate_1W530-Activity at 9246.0 uM-Replicate_1W530-Activity at 20670.0 uM-Replicate_1W530-Activity at 46230.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inactive10004-0.9548-0.4195-0.08090.01770.7848-1.9753-7.8495-0.2201-5.8525-0.1843-6.667-6.1435-0.8948-0.9548100040.4943
Inconclusive33.491535.467210Single point of activity-4.47514.95490.843234-1.467230 0 0 0 0 0 0 0 0 0 0 0 0 0 031.5847-0.2053.1711-0.15032.02621.8413-4.6774-6.6393-0.2496-0.3165-2.4959-5.1038-6.43831.5847100040.7055
Fluorescent21.1317233.52310Partial curve; high efficacy-4.67511.66040.9916233.382-0.14082.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0187.9080.2599-1.6287-1.3781-0.2984-4.561-5.7662-0.1876-0.89793.775318.200944.8649106.298187.90810004-7.3866
Inactive10-9.12514.95490.3604-3.3986940 0 0 0 0 0 0 0 0 0 0 0 0 0 0-3.97486.1565-4.2866-4.2034-1.1608-2.7993-8.2488-3.77590.147-6.6878-0.72651.7247-4.6409-3.9748100040.7006
Inactive10004-2.523-0.126-0.55750.26870.577-0.4465-1.82971.4459-0.8687-0.2229-1.2617-1.1583-2.804-2.523100040.1481
Inactive10004-3.3158-2.46060.8744-2.4805-1.96530.2783-2.1155-3.1759-0.73280.0273-2.7411-1.1742-2.5861-3.3158100040.3542
Inactive10004-6.3298-3.0655-0.5983-3.9559-3.2297-0.1472-0.9072-0.8472-0.4548-2.3342-4.8197-0.9701-5.2874-6.3298100040.0515
Inactive10004-1.6718-2.7534-3.0434-3.2368-0.5266-0.94970.8324-0.4991-0.1271-2.3961-5.9765-2.88891.3265-1.671810004-0.8308
Inactive100040.2704-0.01130.2093-0.13591.8534-1.9442-1.318-1.36660.26060.3476-0.5964-4.328-0.650.2704100040.2962
Inactive100046.1074-1.09610.1205-0.9377-0.83138.31174.16744.893111.21568.51340.08540.32950.12876.107410004-1.6275
Inconclusive66.265742.352310Partial curve; partial efficacy; poor fit-4.17872.18760.744138.0307-4.32152.40 0 0 0 0 0 0 0 0 0 0 0 0 0 029.2246-1.7761-13.0089-0.6771-0.1398-0.17050.3188-8.468-7.9781-16.97650.4529-0.721710.880929.224610004-3.7076
Fluorescent28.616390.842810Partial curve; high efficacy-4.54341.10.981890.3256-0.51722.10 0 0 0 0 0 0 0 0 0 0 0 0 0 071.8878-4.4616-0.0053-3.23970.62975.4330.79530.3464.285511.413917.470133.335455.296271.8878100044.8243
Inconclusive34.66854.985810Partial curve; partial efficacy-4.46011.10.947255.96930.98352.20 0 0 0 0 0 0 0 0 0 0 0 0 0 046.8430.3409-1.0852-0.7636-0.33174.23040.81593.05980.71718.24410.756619.145128.547346.84310004-3.0992
Inactive100040.2088-0.50992.4533-1.9209-0.41840.4617-1.05255.94946.28828.7636-0.5450.9216-2.79590.208810004-1.4861
Inconclusive49.734642.262210Partial curve; partial efficacy-4.303310.807245.23142.96912.20 0 0 0 0 0 0 0 0 0 0 0 0 0 039.7015-0.61882.84480.88810.00942.76685.875211.958.22448.9497.06849.448122.15539.701510004-4.3489
Inconclusive30.869639.274510Partial curve; partial efficacy-4.51052.63840.979938.9369-0.33752.20 0 0 0 0 0 0 0 0 0 0 0 0 0 038.3807-0.22181.8163-0.7660.9433-1.62850.7273-1.86440.5114-1.39731.36159.830428.899138.380710004-3.1002
Inconclusive62.725631.99510Partial curve; partial efficacy; poor fit-4.20263.24750.808229-2.9952.40 0 0 0 0 0 0 0 0 0 0 0 0 0 023.8094-4.1625-1.3901-1.5226-0.3825-8.32920.3951-6.4986-0.4749-5.7267-0.3547-1.45245.496723.809410004-4.0375
Inactive10-4.39591.69240.5803-7.38343.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-7.8195-0.15651.02455.34581.68774.78684.9925.87394.32077.04250.0148-0.2167-0.2419-7.8195100040.8078
Inactive10-5.99513.92950.3374-3.0208240 0 0 0 0 0 0 0 0 0 0 0 0 0 0-6.7098-0.61051.9344.08050.45173.65393.7594-0.97033.256-6.2855-0.62940.2278-0.9853-6.7098100040.5022
Inactive10-4.06410.80.6276240.821840 0 0 0 0 0 0 0 0 0 0 0 0 0 017.14390.83390.9785-2.37282.60513.2312-0.1354-1.67722.75114.08237.28953.67335.072317.143910004-1.6432
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: P53MS574
Protocol: Please refer to other AIDs 1963577 and 1963579 for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the p53 with human microsomes agonist mode assay (AID 1963577), cell viability counter screen (AID 1963579), and auto fluorescence counter screens (AID 720687, 720685, 720678, and 720681). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Activity SummaryRatio ActivityRatio Potency (uM)Ratio Efficacy (%)530 nm Activity530 nm Potency (uM)530 nm Efficacy (%)460 nm Activity460 nm Potency (uM)460 nm Efficacy (%)Viability ActivityViability Potency (uM)Viability Efficacy (%)Blue (460 nm) auto fluorescence outcomeSample Source
active agonistactive agonist1.217408778.37631949inconclusive agonistactive agonist0.64630334178.39811596inactive0inactiveLightBiologicals
active agonistactive agonist0.43195290759.28553099active agonist0.91292773444.30993466active agonist0.55433172482.63203296inactive0inactiveLightBiologicals
active agonistactive agonist1.92946276175.72635936inconclusive agonistactive agonist1.39241833793.4523553inactive0inactiveLightBiologicals
active agonistactive agonist0.90676599358.50333518active agonist0.30731181552.96240355active agonist0.50725702284.98953543inactive0inactiveLightBiologicals
active agonistactive agonist0.46322605451.84457808active agonist0.58316704959.08400159active agonist0.56121117687.34471148inactive0inconclusiveCrescent
active agonistactive agonist3.97431503881.35179825inconclusive antagonist6.298864848-55.06041593inconclusive agonistactive antagonist8.897383087-112.1712623inactiveMicrosource
active agonistactive agonist2.57297994471.82694939inconclusive agonistactive agonist1.5623190775.01686917inactive0inactiveLightBiologicals
active agonistactive agonist0.96702210456.88216128inconclusive agonistactive agonist0.813647772.2886186inactive0inactiveLightBiologicals
active agonistactive agonist2.16489282570.10936057inconclusive agonist0.16234405951.55911786active agonist0.78301437374.08029793inactive0inactiveSIGMA
active agonistactive agonist1.18648510457.37963601active agonist2.1099020365.82498706active agonist1.30595723699.20329811inactive0inactiveSequoia
active agonistactive agonist0.94245861853.83876935inactive0active agonist1.12011416783.34522444inactive0inactivePharmaron
active agonistactive agonist1.13670862258.22057975active agonist0.38813471546.97356994active agonist0.69021197284.87369086inactive0inactiveSigmaAldrich
active agonistactive agonist1.37140703260.17931711inconclusive agonist8.16895252360.48218607active agonist3.94003160970.47314257inactive0inactiveFisher
active agonistactive agonist1.30131434158.4681202inconclusive agonistactive agonist0.88657513973.04049532inactive0inconclusiveSIGMA
active agonistactive agonist0.43195290746.46415354active agonist1.02432176549.29568673active agonist0.57601845974.36852288inactive0Sigma Chemical Company
active agonistactive agonist2.1099020362.60069161inconclusive agonistactive agonist1.20947145569.12030947inactive0inactiveSIGMA
active agonistactive agonist3.97431503876.85083297inconclusive agonist0.0792980148.75406392active agonist1.844713627108.3175397inactive0inactiveChemos
active agonistactive agonist4.07789839875.41728704inconclusive agonistactive agonist5.54331724488.76279206inactive0inactiveLightBiologicals
active agonistactive agonist3.23918983670.70756618inconclusive agonistactive agonist4.40321340175.21515029inactive0inactiveLightBiologicals
active agonistactive agonist3.84978433576.47198713inconclusive agonistactive agonist2.29317078985.70280133inactive0inactiveSIGMA
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: P53654
Protocol: Please refer to other AIDs 1963582 and 1963581 for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the p53 agonist mode assay (AID 1963582), cell viability counter screen (AID 1963581), and auto fluorescence counter screens (AID 720687, 720685, 720678, and 720681). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).
Activity SummaryRatio ActivityRatio Potency (uM)Ratio Efficacy (%)530 nm Activity530 nm Potency (uM)530 nm Efficacy (%)460 nm Activity460 nm Potency (uM)460 nm Efficacy (%)Viability ActivityViability Potency (uM)Viability Efficacy (%)Blue (460 nm) auto fluorescence outcomeSample Source
active agonistactive agonist0.047234823152.29472inactive0active agonist0.037519953136.8633354inactive0GVK
active agonistactive agonist0.844238379220.2162354inconclusive antagonistactive agonist0.512623398104.6191287inactive0inactiveToronto Research
active agonistactive agonist0.012094715104.4361664inconclusive agonistactive agonist0.011201142144.4467864active antagonist0.397431504-70.21237763inactiveSelleck
active agonistactive agonist1.209471455180.1226065inactive0active agonist0.606171653113.571674inconclusive agonistinactiveSequoia
active agonistactive agonist2.778239835211.6412216inconclusive agonist48.4659132967.35167123active agonist5.13376992205.3954222inactive0inconclusiveSigmaAldrich
active agonistactive agonist13.57817889353.547094active antagonist13.06696898-36.85413308active agonist12.57500577253.5649028active agonist2.9828481548.90133363inactiveMicrosource
active agonistactive agonist0.13570492993.31141224inconclusive antagonist0.188045216-22.20736842active agonist0.14101401985.04743995inactive0inactiveSequoia
active agonistactive agonist0.16450339394.32096258inconclusive antagonistactive agonist0.36827722384.98769167inconclusive agonistinactivePrestwick
active agonistactive agonist9.486435714254.9932329active antagonist5.985536287-48.49725447active agonist8.136476998139.346131inactive0inactivePharma
active agonistactive agonist8.399671273237.8402483active antagonist1.410140188-48.09733887active agonist7.071445409180.865123inconclusiveinactiveMicrosource
active agonistactive agonist0.09129277384.95609526inactive0active agonist0.05437964977.70981018inactive0inconclusiveAcros
active agonistactive agonist4.38376925182.3000923active antagonist5.111099704-51.21597367active agonist3.48215169122.7336497inactive0inactiveSigmaAldrich
active agonistactive agonist1.993004104142.3810228inconclusive antagonistactive agonist5.202054047130.3026231inactive0inconclusiveSIGMA
active agonistactive agonist0.500619997103.8418341inactive0active agonist0.856725169155.0303204inconclusive antagonist0.562341325-43.25974821inactiveVitas
active agonistactive agonist0.12094714681.97009147inconclusive agonistactive agonist0.103735871123.2085258active antagonist0.70674426-72.37265734inactiveSequoia
active agonistactive agonist2.815193123137.0716961active antagonist3.159593015-33.41462647active agonist2.15199632892.29790016inactive0inactiveMicrosource
active agonistactive agonist0.61789561391.22925261inactive0active agonist1.809596631101.0029829inactive0inconclusiveSIGMA
active agonistactive agonist0.55433172483.79635801inactive0active agonist1.39241833788.81361331inactive0inactiveSIGMA
active agonistactive agonist0.43195290778.01689897inconclusive agonistactive agonist0.37766180899.59298459active agonist0.51337699277.40150829inactiveRoche
active agonistactive agonist2.605727258108.4007283inconclusive agonistactive agonist1.916883076121.5082983active antagonist2.507623262-38.90785093inactiveMicrosource
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: HTR2A603
Protocol: Assay Protocol Summary:

HTR2A-CHO cells were dispensed at 2000 cells/3uL/well in 1536-well black-clear bottom plates using a Multidrop Dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 18 h, 3 uL of Dye Loading Buffer was transferred to the assay plate by a Flying Reagent Dispenser. The assay plates were incubated at 37 C for 1h. For agonist mode, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pin tool. The fluorescence intensity in the plates was measured using FDSS 7000EX kinetic plate reader for 2 min at 1 sec intervals.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049636 uM-Replicate_1Activity at 0.0000112894 uM-Replicate_1Activity at 0.0000451294 uM-Replicate_1Activity at 0.0001083383 uM-Replicate_1Activity at 0.0002490219 uM-Replicate_1Activity at 0.0005090755 uM-Replicate_1Activity at 0.00139 uM-Replicate_1Activity at 0.00429 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.128 uM-Replicate_1Activity at 0.292 uM-Replicate_1Activity at 0.874 uM-Replicate_1Activity at 2.651 uM-Replicate_1Activity at 7.023 uM-Replicate_1Activity at 15.88 uM-Replicate_1Activity at 35.56 uM-Replicate_1Activity at 76.84 uM-Replicate_1Activity at 198.7 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0-5.67131.10.547980.819540 0 0 0 0 0 0 0 0 0 0 0 0 0 08.7235-1.7246-0.79674.02471.9622-1.14673.4822-1.5146-1.8176.06554.31945.62146.74618.7235QC'd by ACCInactive0
Inactive00040.71362.84913.15472.62081.73272.79433.62882.21110.9461-1.0072-0.4977-1.0290.49570.7136QC'd by ACCInactive0-6.67134.95490.4722
Activator23.9145533.488243Partial curve; high efficacy-4.62131.98870.987537.0293.54082.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0406.84010.49816.65853.85970.56377.39464.5987-3.71610.781112.19813.264681.5331158.4589406.8401QC'd by ACCActivator18.9959357.953744Partial curve; high efficacy-4.72131.34430.9586
Inactive0004-3.33330.3686-2.1838-0.97840.28920.0634-2.0419-0.18710.061-3.3304-2.6853-2.00990.2108-3.3333QC'd by ACCInactive0
Inactive00043.36520.94171.36941.3511-0.11411.40170.29941.14555.12170.75433.87762.18824.52673.3652QC'd by RTIInactive0
Inactive0-4.96951.88510.9211-14.6405140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-13.45042.42870.3370.34840.7070.60323.1373-1.09171.7571-3.2954-1.1568-10.861-12.9725-13.4504QC'd by RTIInactive0-4.41952.18760.6553
Activator0.075282.249290Complete curve; high efficacy-7.12350.80.98879.7492-2.51.10 0 0 0 0 0 0 0 0 0 0 0 0 0 080.83461.78786.13089.925819.761739.591652.77160.918266.105569.033480.327881.334383.594680.8346QC'd by RTIActivator0.474788.523888Complete curve; high efficacy-6.32350.90.9909
Activator0.265393.198289Complete curve; high efficacy-6.57630.80.995589.1185-4.07971.10 0 0 0 0 0 0 0 0 0 0 0 0 0 090.5676-0.8998-0.035-0.36238.222717.297432.011448.365862.041171.971786.9385.895983.583490.5676QC'd by RTIActivator0.026577.546693Complete curve; high efficacy-7.57630.90.987
Inactive0-4.13091.24750.8779-16.497-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-14.58080.1628-0.5762-1.1136-0.2048-0.368-0.8819-0.8283-2.0195-1.2058-1.9466-7.6162-7.0211-14.5808QC'd by RTIInactive0
Inactive0004-6.6585-1.8147-3.036-2.7414-2.9382-3.1098-0.24922.1427-2.6629-0.1939-2.7488-1.4566-8.5268-6.6585QC'd by RTIInactive0
Inactive0004-3.4757-0.43290.3326-0.84020.0544-2.7307-0.3172-1.3413-2.0597-1.0047-1.1604-1.2522-8.0139-3.4757QC'd by RTIInactive0-4.0751.10.6917
Activator57.586431.97110Partial curve; partial efficacy; poor fit-4.23974.95490.909830-1.9712.40 0 0 0 0 0 0 0 0 0 0 0 0 0 024.7904-1.4056-0.3633-0.0089-3.0195-0.599-0.5758-0.7948-0.4323-4.1986-5.0136-5.39250.354724.7904QC'd by RTIInactive0
Activator62.154948.383510Single point of activity-4.20654.95490.969648.1294-0.254130 0 0 0 0 0 0 0 0 0 0 0 0 0 039.8328-0.49521.4760.66241.9344-0.3395-0.7123-1.4037-1.73662.2992-2.7117-1.43311.585639.8328QC'd by RTIActivator55.395689.54741Partial curve; high efficacy-4.25652.58840.9752
Inactive0004-1.5545-1.6566-2.6838-1.6155-1.2771-2.8033-0.7992-2.2086-2.1165-1.43662.10792.0395-0.1964-1.5545QC'd by RTIInactive0
Inactive0-6.44991.96730.9648-15.489-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-11.8883-0.1006-0.005-1.1316-1.8411-1.5843-1.4803-6.9758-12.1972-15.4653-17.0742-15.8774-16.437-11.8883QC'd by RTIInactive0-7.24990.90.9292
Inactive0-6.7574.95490.7181-12.0035140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-11.7465-0.46011.86560.11251.6950.44190.0198-17.5030.0822-10.7704-15.9134-13.7319-15.7608-11.7465QC'd by RTIInactive0-6.6074.95490.7096
Inactive0-5.39891.62660.717541440 0 0 0 0 0 0 0 0 0 0 0 0 0 02.18889.749913.244215.360917.054711.082914.114214.655317.559610.40557.12343.60218.61112.1888QC'd by RTIInactive0
Activator0.00149.315210Complete curve; high efficacy; poor fit-8.99190.40.646890.475241.161.30 0 0 0 0 0 0 0 0 0 0 0 0 0 087.673963.476275.320673.937776.90881.009883.341778.7232103.994589.298187.72991.364785.620587.6739QC'd by RTIActivator5.0E-480.912699Complete curve; high efficacy-9.29190.60.7869
Activator1.440861.767884Complete curve; high efficacy-5.84141.47870.990864.30992.54211.10 0 0 0 0 0 0 0 0 0 0 0 0 0 062.09883.60835.35485.57370.9311-2.04832.24227.913418.225242.68557.609265.591966.455462.0988QC'd by RTIActivator1.616683.116985Complete curve; high efficacy-5.79140.80.9937
Inactive0-5.36041.96730.3672-14.2663-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-12.6859-5.5953-3.7533-2.9145-1.4897-2.1001-2.8826.1673-6.0115-4.3461-9.4884-15.1664-14.9205-12.6859QC'd by RTIInactive0-5.56044.0950.9954
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: HTR2A875
Protocol: Tox21 Assay Protocol Summary:

HTR2A-CHO cells were dispensed at 2000 cells/3uL/well in 1536-well black-clear bottom plates using a Multidrop Dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 18 h, 3 uL of Dye Loading Buffer was transferred to the assay plate by a Flying Reagent Dispenser. The assay plates were incubated at 37 C for 1h. For antagonist mode, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pin tool. After 5 min incubation at room temperature, 1.5 uL of 4-Iodo-2,5-dimethoxy-alpha-methylbenzeneethanamine hydrochloride (DOI) at 4nM was added to each well. The fluorescence intensity in the plates was measured using FDSS 7000EX kinetic plate reader for 3 min at 1 sec intervals.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000039737 uM-Replicate_1Activity at 0.0000090357 uM-Replicate_1Activity at 0.0000361304 uM-Replicate_1Activity at 0.0000867348 uM-Replicate_1Activity at 0.0001993648 uM-Replicate_1Activity at 0.0004075545 uM-Replicate_1Activity at 0.00112 uM-Replicate_1Activity at 0.00343 uM-Replicate_1Activity at 0.00899 uM-Replicate_1Activity at 0.020 uM-Replicate_1Activity at 0.046 uM-Replicate_1Activity at 0.103 uM-Replicate_1Activity at 0.233 uM-Replicate_1Activity at 0.700 uM-Replicate_1Activity at 2.122 uM-Replicate_1Activity at 5.622 uM-Replicate_1Activity at 12.72 uM-Replicate_1Activity at 28.47 uM-Replicate_1Activity at 61.52 uM-Replicate_1Activity at 159.1 uM-Replicate_1Activity at 580.7 uM-Replicate_1Activity at 1231.0 uM-Replicate_1Activity at 2752.0 uM-Replicate_1Activity at 6155.0 uM-Replicate_1Activity at 13760.0 uM-Replicate_1Activity at 30770.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-7.2061-3.526-9.9489-2.97267.0388-5.0617-5.7675-3.6219-0.0251-2.7206-1.11990.8657-10.4359-7.2061QC'd by SIGMAInactive0
Inactive00046.13445.64138.53264.04038.44095.441410.92884.31674.82284.80260.47619.71629.14296.1344QC'd by WaterstoneInactive0-8.6263.06540.5917
Inactive00042.3205-1.4158-3.9188-1.2064-7.0528-5.2123-2.2684-6.0073-2.0124-4.3471-2.4408-5.7061-1.99452.3205QC'd by SIGMAInactive0
Inactive00040.29564.40161.67061.4091-1.97283.5850.63440.38270.4984-2.7333.67393.46242.37810.2956QC'd by LightBiologicalsInactive0
Inactive0004-6.96170.1347-10.9722-11.3789-0.9886-3.2185-2.6238-5.3048-2.66760.8444-8.24951.4346-0.1703-6.9617QC'd by LightBiologicalsInactive0
Inactive0-4.9264.95490.47717-3.149540 0 0 0 0 0 0 0 0 0 0 0 0 0 08.9844-4.3701-1.7004-8.87464.1299-5.48120.94572.1614-3.6786-2.2479-8.06382.37734.41318.9844QC'd by SIGMAInactive0
Inactive00042.7598-1.388-10.7501-2.243-7.1709-7.7234-0.86450.53450.11642.5902-8.76125.54313.50742.7598QC'd by LightBiologicalsInactive0
Inactive0-5.65821.46410.408-4.6092240 0 0 0 0 0 0 0 0 0 0 0 0 0 10.78232.28384.9364.2099-4.16470.83986.4512-0.0288-0.01385.2677-3.4901-4.5008-2.3051-5.0910.7823QC'd by SIGMAInactive0
Inactive00043.79320.7208-1.6962-3.28710.9942-4.8215.321-4.7996-0.71224.43679.43390.65277.89283.7932QC'd by SIGMAInactive0
Inactive00041.00171.7707-1.3919-0.9574.20364.12342.9095-0.1743.60228.54267.03274.49020.66171.0017QC'd by TCIInhibitor0.167523.871710Single point of activity-6.7764.95490.6462
Inactive00041.3141-0.92173.5166-2.30331.6783.27250.5745-9.0E-41.5868-0.40153.79654.99052.65621.3141QC'd by SIGMAInactive0
Inactive0-5.62610.41615-3.772340 0 0 0 0 0 0 0 0 0 0 0 0 0 06.036-2.1149-5.697-13.97690.09992.219-1.9463-2.9706-3.34883.16550.39146.03741.34256.036QC'd by SIGMAInactive0
Inhibitor9.419843.686410Single point of activity-5.0264.95490.8559-47.6864-4-30 0 0 0 0 0 0 0 0 0 0 0 0 1 1-4.2356-9.8138-9.423-4.05922.411-1.0589-7.4879-2.3574-4.7276-3.6806-4.4603-38.39886.5491-4.2356QC'd by LightBiologicalsInactive0-7.0260.20.4384
Inactive0004-0.06471.12492.86741.33545.11772.14-1.44271.18032.9089-1.5124-0.02495.72685.9847-0.0647QC'd by LightBiologicalsInhibitor47.210925.535310Partial curve; partial efficacy; poor fit-4.3264.95490.7127
Inactive0-6.42610.55530.5-8.527640 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.5555-7.8118-8.811-10.011-6.4119-10.1734-6.8978-2.0059-5.3563.4401-1.34733.18-0.9271-0.5555QC'd by LightBiologicalsInactive0
Inactive00041.97624.76444.171228.06640.678-1.83649.05051.55284.31155.40685.86384.23756.04841.9762QC'd by SIGMAInactive0
Inactive0004-2.38713.6232-0.273903.5491.08915.48920.99120.71813.3244-2.86665.65283.6147-2.3871QC'd by LightBiologicalsInactive0
Inactive000413.15252.6229-1.041215.1602-2.820813.804212.821710.52165.190911.06815.40983.05368.005213.1525QC'd by SIGMAInactive0
Inactive0-5.2761.10.6487-16.0176-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-15.848-6.15315.9102-2.0982-1.5437-3.338-2.63271.5609-0.7495-10.8518-7.7926-9.3193-14.5467-15.848QC'd by LightBiologicalsInactive0-4.6261.3310.6582
Inactive00040.0466-2.72680.2154-0.12984.7191-1.4011-1.10474.8769-0.64661.98962.8818-2.35198.50421.5602QC'd by AcrosInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: Ebola screen2_EMI141217_green
Protocol: This 1536-well plate assay was adapted from the original 6-wells assay with a modification that eliminated cell wash steps. HeLa cells were plated at 750 cells/well in 3 microl of assay medium (DMEM + 10% FBS) in 1536-well assay plates and incubated for 16 hours at 37 degrees C and 5% CO2. Compounds in the 1536-well drug source plates were added to the 1536-well assay plates in a volume of 23 nl/well via a NX-TR pintool station (WAKO Scientific Solutions, San Diego, CA). Following 1-hour incubation at 37 degrees C with 5% CO2, 1 microl/well of VLP solution was added to the assay plates using a BioRapTR FRD dispenser (the VLP solution was diluted in Opti-MEM to a final concentration of 1:16). Plates were then spinoculated by centrifugation at 1500 rpm at 4 degrees C for 45 minutes followed by incubation at 37 degrees C with 5% CO2 for 4.5 hours. The CCF2-AM beta-lactamase substrate was prepared at 6x concentration following the manufacturer's instruction which was added to assay plates at 1 microl/well. Following a 2-hour incubation at room temperature, dual fluorescence intensities (Ex1 = 405+/-20, Em1 = 460+/-20, and Ex2 = 405+/-20, Em2 = 530+/-20 nm) were measured in an EnVision plate reader (PerkinElmer, Boston, MA). The ratio of fluorescence intensities (Em1/Em2) was calculated to represent the beta-lactamase activity that is proportional to the amount of VLP entry into the host cells.
Comment: The activity score was determined using both AC50, Efficacy and curve class. For a given compound j:
Activity is defined as the ability to inhibit viral entry.

If curve class = 4, activity score = 0 and outcome is set to 1. Compounds of this class have no significant activity points.
If efficacy is negative, activity score = 0 and outcome is set to 1. Compounds with negative efficacies, promote viral entry.

For all other curve classes:

Activity score(j) = [100*((max(Ac50)-Ac50(j))/(max(Ac50)-min(Ac50))) + 100*(1-(max(efficacy)-efficacy(j))/(max(efficacy)-min(efficacy))) ]/2

Compounds with Activity scores > 80% are deemed active, and the activity outcome is set to 2.

Refer to the following recent publication for more detail regarding active compounds:

Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs

Jennifer Kouznetsova, Wei Sun, Carles Marti nez-Romero, Gregory Tawa, Paul Shinn, Catherine Z Chen,
Aaron Schimmer, Philip Sanderson, John C McKew, Wei Zheng and Adolfo Garci a-Sastre

Emerging Microbes and Infections (2014) 3, e84; doi:10.1038/emi.2014.88
NCGC sample numberSample NameSupplierAC50 (uM)Curve Class2EfficacyChannel
4trans-Aconitic acidSpecs0.6314-10.976Green
10NEROLMicrosource12.58934-28.228Green
3Phenol redLabotest0.7079419.263Green
4Aminoquinuride dihydrochlorideLabotest0.7079418Green
3Pyridoxamine DihydrochlorideBosche15.84894-11.767Green
7CarzenideLabotest0.631411.002Green
9PridinolSpecs102.236.664Green
3L-LeucineBosche0.8913414.333Green
6FenticlorVitas3.16234-28.657Green
6CHLORPROTHIXENE HYDROCHLORIDEMicrosource39.8107-3-98.319Green
8BenzbromaroneLabotest1.7783416.5Green
8Phosphonoacetic acidSIGMA14-15.333Green
17DomperidoneMicrosource25.11892.3125.472Green
4PifexoleBionet0.6314-9.778Green
15WY-14643SIGMA3.9811419.845Green
14OXAPROZINMicrosource39.8107418.153Green
6Topotecan hydrochloridePrestwick31.622851429.488Green
12AZELAIC ACIDMicrosource10417.221Green
13AmoxapineEnzo8.91252.394.86Green
14R-(+)-AtenololVitas104-16.344Green
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: Ebola screen2_EMI141217_ratio
Protocol: This 1536-well plate assay was adapted from the original 6-wells assay with a modification that eliminated cell wash steps. HeLa cells were plated at 750 cells/well in 3 microl of assay medium (DMEM + 10% FBS) in 1536-well assay plates and incubated for 16 hours at 37 degrees C and 5% CO2. Compounds in the 1536-well drug source plates were added to the 1536-well assay plates in a volume of 23 nl/well via a NX-TR pintool station (WAKO Scientific Solutions, San Diego, CA). Following 1-hour incubation at 37 degrees C with 5% CO2, 1 microl/well of VLP solution was added to the assay plates using a BioRapTR FRD dispenser (the VLP solution was diluted in Opti-MEM to a final concentration of 1:16). Plates were then spinoculated by centrifugation at 1500 rpm at 4 degrees C for 45 minutes followed by incubation at 37 degrees C with 5% CO2 for 4.5 hours. The CCF2-AM beta-lactamase substrate was prepared at 6x concentration following the manufacturer's instruction which was added to assay plates at 1 microl/well. Following a 2-hour incubation at room temperature, dual fluorescence intensities (Ex1 = 405+/-20, Em1 = 460+/-20, and Ex2 = 405+/-20, Em2 = 530+/-20 nm) were measured in an EnVision plate reader (PerkinElmer, Boston, MA). The ratio of fluorescence intensities (Em1/Em2) was calculated to represent the beta-lactamase activity that is proportional to the amount of VLP entry into the host cells.
Comment: The activity score was determined using both AC50, Efficacy and curve class. For a given compound j:
Activity is defined as the ability to inhibit viral entry.

If curve class = 4, activity score = 0 and outcome is set to 1. Compounds of this class have no significant activity points.
If efficacy is negative, activity score = 0 and outcome is set to 1. Compounds with negative efficacies, promote viral entry.

For all other curve classes:

Activity score(j) = [100*((max(Ac50)-Ac50(j))/(max(Ac50)-min(Ac50))) + 100*(1-(max(efficacy)-efficacy(j))/(max(efficacy)-min(efficacy))) ]/2

Compounds with Activity scores > 80% are deemed active, and the activity outcome is set to 2.

Refer to the following recent publication for more detail regarding active compounds:

Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs

Jennifer Kouznetsova, Wei Sun, Carles Marti nez-Romero, Gregory Tawa, Paul Shinn, Catherine Z Chen,
Aaron Schimmer, Philip Sanderson, John C McKew, Wei Zheng and Adolfo Garci a-Sastre

Emerging Microbes and Infections (2014) 3, e84; doi:10.1038/emi.2014.88
NCGC sample numberSample NameSupplierAC50 (uM)Curve Class2EfficacyChannel
4trans-Aconitic acidSpecs40ratio
10NEROLMicrosource0.6314-18.609ratio
3Phenol redLabotest8.9125411.059ratio
4Aminoquinuride dihydrochlorideLabotest19.95262.395.842ratio
3Pyridoxamine DihydrochlorideBosche44.66844-13.116ratio
7CarzenideLabotest40ratio
9PridinolSpecs28.18382.3104.274ratio
3L-LeucineBosche0.79434-27.61ratio
6FenticlorVitas15.84892.459.259ratio
6CHLORPROTHIXENE HYDROCHLORIDEMicrosource3.16231.370.654ratio
8BenzbromaroneLabotest7.9433419.539ratio
8Phosphonoacetic acidSIGMA7.943349.28ratio
17DomperidoneMicrosource25.1189387.928ratio
4PifexoleBionet3.54814-20.543ratio
15WY-14643SIGMA3.9811-3-98.934ratio
14OXAPROZINMicrosource39.8107416.681ratio
6Topotecan hydrochloridePrestwick7.94332.183.464ratio
12AZELAIC ACIDMicrosource40ratio
13AmoxapineEnzo102.1101.678ratio
14R-(+)-AtenololVitas40ratio
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: Ebola screen2_EMI141217_blue
Protocol: This 1536-well plate assay was adapted from the original 6-wells assay with a modification that eliminated cell wash steps. HeLa cells were plated at 750 cells/well in 3 microl of assay medium (DMEM + 10% FBS) in 1536-well assay plates and incubated for 16 hours at 37 degrees C and 5% CO2. Compounds in the 1536-well drug source plates were added to the 1536-well assay plates in a volume of 23 nl/well via a NX-TR pintool station (WAKO Scientific Solutions, San Diego, CA). Following 1-hour incubation at 37 degrees C with 5% CO2, 1 microl/well of VLP solution was added to the assay plates using a BioRapTR FRD dispenser (the VLP solution was diluted in Opti-MEM to a final concentration of 1:16). Plates were then spinoculated by centrifugation at 1500 rpm at 4 degrees C for 45 minutes followed by incubation at 37 degrees C with 5% CO2 for 4.5 hours. The CCF2-AM beta-lactamase substrate was prepared at 6x concentration following the manufacturer's instruction which was added to assay plates at 1 microl/well. Following a 2-hour incubation at room temperature, dual fluorescence intensities (Ex1 = 405+/-20, Em1 = 460+/-20, and Ex2 = 405+/-20, Em2 = 530+/-20 nm) were measured in an EnVision plate reader (PerkinElmer, Boston, MA). The ratio of fluorescence intensities (Em1/Em2) was calculated to represent the beta-lactamase activity that is proportional to the amount of VLP entry into the host cells.
Comment: The activity score was determined using both AC50, Efficacy and curve class. For a given compound j:
Activity is defined as the ability to inhibit viral entry.

If curve class = 4, activity score = 0 and outcome is set to 1. Compounds of this class have no significant activity points.
If efficacy is negative, activity score = 0 and outcome is set to 1. Compounds with negative efficacies, promote viral entry.

For all other curve classes:

Activity score(j) = [100*((max(Ac50)-Ac50(j))/(max(Ac50)-min(Ac50))) + 100*(1-(max(efficacy)-efficacy(j))/(max(efficacy)-min(efficacy))) ]/2

Compounds with Activity scores > 80% are deemed active, and the activity outcome is set to 2.

Refer to the following recent publication for more detail regarding active compounds:

Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs

Jennifer Kouznetsova, Wei Sun, Carles Marti nez-Romero, Gregory Tawa, Paul Shinn, Catherine Z Chen,
Aaron Schimmer, Philip Sanderson, John C McKew, Wei Zheng and Adolfo Garci a-Sastre

Emerging Microbes and Infections (2014) 3, e84; doi:10.1038/emi.2014.88
NCGC sample numberSample NameSupplierAC50 (uM)Curve Class2EfficacyChannel
4trans-Aconitic acidSpecs104-14.43blue
10NEROLMicrosource40blue
3Phenol redLabotest39.81074-13.607blue
4Aminoquinuride dihydrochlorideLabotest22.38722.395.429blue
3Pyridoxamine DihydrochlorideBosche40blue
7CarzenideLabotest40blue
9PridinolSpecs31.6228398.957blue
3L-LeucineBosche0.3981-1.4-35.007blue
6FenticlorVitas102.251.546blue
6CHLORPROTHIXENE HYDROCHLORIDEMicrosource3.16231.390.071blue
8BenzbromaroneLabotest11.2202418.74blue
8Phosphonoacetic acidSIGMA7.9433411.21blue
17DomperidoneMicrosource39.8107390.852blue
4PifexoleBionet3.54814-15.204blue
15WY-14643SIGMA3.9811-3-135.758blue
14OXAPROZINMicrosource44.668448.931blue
6Topotecan hydrochloridePrestwick0.6314-18.88blue
12AZELAIC ACIDMicrosource1.1224-15.036blue
13AmoxapineEnzo14.12542.190.875blue
14R-(+)-AtenololVitas40blue
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:NON-PROTEIN TARGET
External ID: CHEMBL3137722
Protocol: N/A
Comment: Journal: Gastroenterol Clin Biol
Year: 2004
Volume: 28
Issue: 8-9
First Page: 720
Last Page: 759
DOI: 10.1016/s0399-8320(04)95062-2

Target ChEMBL ID: CHEMBL3879801
ChEMBL Target Name: NON-PROTEIN TARGET
ChEMBL Target Type: NON-MOLECULAR - Target has not been defined at a molecular level, only the non-molecular entity which is affected (e.g., organism, cell line etc)
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueActivity Comment
Hepatotoxicity (moderate)=0references out of a total of 1
Hepatotoxicity (moderate)=61references out of a total of 69
Hepatotoxicity (moderate)=2references out of a total of 5
Hepatotoxicity (moderate)=7references out of a total of 27
Hepatotoxicity (moderate)=13references out of a total of 13
Hepatotoxicity (moderate)=1references out of a total of 1
Hepatotoxicity (moderate)=114references out of a total of 132
Hepatotoxicity (moderate)=15references out of a total of 23
Hepatotoxicity (moderate)=1references out of a total of 1
Hepatotoxicity (moderate)=3references out of a total of 9
Hepatotoxicity (moderate)=4references out of a total of 34
Hepatotoxicity (moderate)=1references out of a total of 5
Hepatotoxicity (moderate)=18references out of a total of 53
Hepatotoxicity (moderate)=1references out of a total of 1
Hepatotoxicity (moderate)=1references out of a total of 14
Hepatotoxicity (moderate)=3references out of a total of 5
Hepatotoxicity (moderate)=3references out of a total of 3
Hepatotoxicity (moderate)=3references out of a total of 16
Hepatotoxicity (moderate)=29references out of a total of 123
Hepatotoxicity (moderate)=1references out of a total of 4
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:NON-PROTEIN TARGET
External ID: CHEMBL3137723
Protocol: N/A
Comment: Journal: Gastroenterol Clin Biol
Year: 2004
Volume: 28
Issue: 8-9
First Page: 720
Last Page: 759
DOI: 10.1016/s0399-8320(04)95062-2

Target ChEMBL ID: CHEMBL3879801
ChEMBL Target Name: NON-PROTEIN TARGET
ChEMBL Target Type: NON-MOLECULAR - Target has not been defined at a molecular level, only the non-molecular entity which is affected (e.g., organism, cell line etc)
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
Hepatotoxicity (moderate)=0%
Hepatotoxicity (moderate)=42.2%
Hepatotoxicity (moderate)=0%
Hepatotoxicity (moderate)=25%
Hepatotoxicity (moderate)=8.3%
Hepatotoxicity (moderate)=5%
Hepatotoxicity (moderate)=46.4%
Hepatotoxicity (moderate)=7.7%
Hepatotoxicity (moderate)=0%
Hepatotoxicity (moderate)=26%
Hepatotoxicity (moderate)=22%
Hepatotoxicity (moderate)=0%
Hepatotoxicity (moderate)=5.8%
Hepatotoxicity (moderate)=6%
Hepatotoxicity (moderate)=7.1%
Hepatotoxicity (moderate)=32%
Hepatotoxicity (moderate)=12.8%
Hepatotoxicity (moderate)=19%
Hepatotoxicity (moderate)=90%
Hepatotoxicity (moderate)=37%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: DT40657
Protocol: Tox21 Assay Protocol Summary:

300 DT40 mutant cells in 5 uL/well were dispensed into white, solid-bottom 1536-well plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37 C/5% CO2 for approximately 0.5 hour, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred into the assay plate by a pintool work station (Kalypsys, San Diego, CA). The assay plates were incubated at 37 C/5% CO2 for 40 hours. After 5 uL per well of CellTiter-Glo reagent was added into each well of the assay plates, the plates were incubated for 30 min at room temperature and the luminescence intensity of the plates was measured using a ViewLux (PerkinElmer, Shelton, CT) plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000044240 uM-Replicate_1Activity at 0.0000098920 uM-Replicate_1Activity at 0.0000221200 uM-Replicate_1Activity at 0.0000618460 uM-Replicate_1Activity at 0.0001391192 uM-Replicate_1Activity at 0.0002694481 uM-Replicate_1Activity at 0.0005944760 uM-Replicate_1Activity at 0.00124 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00617 uM-Replicate_1Activity at 0.014 uM-Replicate_1Activity at 0.031 uM-Replicate_1Activity at 0.069 uM-Replicate_1Activity at 0.154 uM-Replicate_1Activity at 0.343 uM-Replicate_1Activity at 0.767 uM-Replicate_1Activity at 1.711 uM-Replicate_1Activity at 3.817 uM-Replicate_1Activity at 8.535 uM-Replicate_1Activity at 18.17 uM-Replicate_1Activity at 31.39 uM-Replicate_1Activity at 68.35 uM-Replicate_1Activity at 94.96 uM-Replicate_1Activity at 260.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive043.01123.097-15.61374.831817.24522.68492.87025.838-1.15092.4566-15.0143-1.83128.71463.75322.72683.0112QC'd by Sigma DiscoveryCPRInactive0
Inactive04-2.1785-10.892-15.6985-0.69210.4103-15.63332.8403-15.8637-6.5703-13.149-26.3626.1142-10.7498-15.5641-24.2196-2.1785QC'd by Sigma DiscoveryCPRCytotoxic68.589691.523642Partial curve; high efficacy-4.16373.24750.8975-95.1787
Inactive04-10.4836-24.2062-15.4625-22.1853-17.0029-23.7071-26.4511-5.4538-39.9631-45.6107-35.4677-32.0907-29.217-24.9641-27.9971-10.4836QC'd by Sigma DiscoveryCPRCytotoxic61.130629.401520Partial curve; partial efficacy; poor fit-4.21371.88510.8107-31.9015
Inactive04-4.59729.3751-8.1926-3.89550.6461-8.566213.4774-0.62345.5343-3.2761-6.0086-5.24710.8659-3.3104-0.8139-4.5972QC'd by Sigma DiscoveryCPRInactive04.95490.6911-27.7726
Inactive01.3310.4841-18.2848-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-15.4341-15.6941-0.6359-0.217-0.01279.76010.47981.0579-3.8901-4.4074-0.2904-14.3809-1.6368-26.0707-15.5655-15.4341QC'd by Sigma DiscoveryCPRCytotoxic68.589696.936120Single point of activity-4.16374.95490.9116-96.8607
Cytotoxic68.589648.251420Single point of activity-4.16374.50450.669-42.75145.5-30 0 0 0 0 0 0 0 0 0 0 1 0 0 0-32.76366.68717.171221.5873-4.0029-2.3442-2.24135.53994.60832.4453-0.50548.148-24.60336.40680.6319-32.7636QC'd by Sigma DiscoveryCPRCytotoxic68.589648.174420Single point of activity-4.16374.95490.9289-45.8879
Inactive00.30.7121-33.8051140 0 0 0 0 0 0 0 0 0 0 1 0 0 0-24.382310.43845.12726.81657.22591.8658-8.6709-16.2528-6.24420.3161-1.6373-7.5312-91.6148-26.0875-17.5667-24.3823QC'd by Sigma DiscoveryCPRInactive0
Cytotoxic30.637967.376140Partial curve; high efficacy-4.51370.90.775-65.03912.337-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-60.304212.047412.9559-2.1973-12.63497.3969-3.88253.660712.6478-6.4422-9.9361-12.776-9.7544-22.4301-24.4994-60.3042QC'd by Sigma DiscoveryCPRCytotoxic61.130636.052220Partial curve; partial efficacy; poor fit-4.21374.95490.8632-33.5522
Cytotoxic61.1306111.553142Partial curve; high efficacy-4.21373.990.9734-113.6335-2.0804-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-95.65118.3666-2.0713-3.7808-2.35050.04213.1312-0.1348-6.3457-2.025-7.1259-0.3043-6.8314-6.1688-21.3977-95.6511QC'd by Sigma DiscoveryCPRInactive0
Inactive04-12.7888-1.057-2.0848-0.7554-6.8445-0.3896-2.5669-0.3877-3.83473.37538.0661-13.2548-2.828516.492-3.484-12.7888QC'd by Sigma DiscoveryCPRInactive01.69240.56086
Cytotoxic68.5896120.709842Partial curve; high efficacy-4.16374.95490.9332-122.3541-1.6443-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-99.4749-0.52770.547410.1427-1.25254.012-10.9614-1.4029-7.26650.8155-18.27654.3116-4.27371.9509-11.5455-99.4749QC'd by Sigma DiscoveryCPRInactive0
Inactive04.95490.6075-28.619-440 0 0 0 0 0 0 0 0 0 0 0 0 0 0-28.4325-14.8758-0.7818-11.7063-0.11123.04971.97010.8638-15.4171-14.52550.3742.40541.2793-11.955-27.2415-28.4325QC'd by Sigma DiscoveryCPRInactive0
Inactive04.95490.6053-25.3863340 0 0 0 0 0 0 0 0 0 0 0 0 0 0-19.9053-3.0798-0.16165.81434.36872.6264-2.68023.478213.64463.777-0.6631-2.940811.09824.56250.5366-19.9053QC'd by Sigma DiscoveryCPRInactive0
Inactive04-2.2887-9.33222.806-1.96982.835-19.1802-2.244-2.376111.6639-4.3953-0.88963.7875-1.1556-17.5934-15.146-2.2887QC'd by Sigma DiscoveryCPRInactive04.95490.74112
Cytotoxic68.5896121.561120Single point of activity-4.16374.95490.9451-122.6489-1.0878-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-100.2033-11.91628.5759-4.0103-8.04752.09744.9269-4.8191-8.6034.1695-6.8431-3.09872.96934.092-4.7679-100.2033QC'd by Sigma DiscoveryCPRInactive0
Inactive00.60.4241-16.80689.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-12.33918.7614-0.1122-2.521314.32534.912525.50638.89340.001311.5099-6.67791.0565-0.13852.7506-11.651-12.339QC'd by SIGMACytotoxic20Single point of activity
Inactive00.50.4566-0.24781040 0 0 0 0 0 0 0 0 0 0 0 0 0 02.05936.68268.657811.23617.42261.45222.14479.27011.79030.5244-3.08084.58743.84151.4091-6.45652.0593QC'd by Sigma DiscoveryCPRInactive04.0450.6801-25.4596
Inactive04.95490.4416-12.802440 0 0 0 0 0 0 0 0 0 0 0 0 0 0-12.75170.2533-2.853315.69095.351413.8457-0.7219-3.2206-0.93875.440912.5372-1.28440.86326.1393-10.3064-12.7517QC'd by Sigma DiscoveryCPRInactive0
Inactive01.64360.3324-17.01442.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-10.845410.67053.9496.78270.3479-1.2699-8.220512.82270.96571.1019-3.13092.35830.7293-0.3373-3.38-10.8454QC'd by Sigma DiscoveryCPRInactive0
Cytotoxic0.136975.828189Complete curve; high efficacy-6.86371.46410.9678-76.2529-0.4248-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-83.61070.6376-4.1922-1.0881-0.5964-10.0644-14.6504-42.7191-72.2882-55.2459-69.9677-74.6041-73.5035-77.875-80.4615-83.6107QC'd by Sigma DiscoveryCPRCytotoxic0.216966.648687Complete curve; high efficacy-6.66374.95490.9621-68.4642
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL3137724
Protocol: N/A
Comment: Journal: Gastroenterol Clin Biol
Year: 2004
Volume: 28
Issue: 8-9
First Page: 720
Last Page: 759
DOI: 10.1016/s0399-8320(04)95062-2
Standard TypeStandard RelationStandard ValueActivity Comment
Hepatotoxicity (acute)=1references out of a total of 1
Hepatotoxicity (acute)=11references out of a total of 69
Hepatotoxicity (acute)=3references out of a total of 5
Hepatotoxicity (acute)=17references out of a total of 27
Hepatotoxicity (acute)=0references out of a total of 13
Hepatotoxicity (acute)=1references out of a total of 1
Hepatotoxicity (acute)=21references out of a total of 132
Hepatotoxicity (acute)=9references out of a total of 23
Hepatotoxicity (acute)=1references out of a total of 1
Hepatotoxicity (acute)=5references out of a total of 9
Hepatotoxicity (acute)=27references out of a total of 34
Hepatotoxicity (acute)=4references out of a total of 5
Hepatotoxicity (acute)=36references out of a total of 53
Hepatotoxicity (acute)=1references out of a total of 1
Hepatotoxicity (acute)=12references out of a total of 14
Hepatotoxicity (acute)=1references out of a total of 5
Hepatotoxicity (acute)=0references out of a total of 3
Hepatotoxicity (acute)=5references out of a total of 16
Hepatotoxicity (acute)=84references out of a total of 123
Hepatotoxicity (acute)=0references out of a total of 4
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:NON-PROTEIN TARGET
External ID: CHEMBL3137725
Protocol: N/A
Comment: Journal: Gastroenterol Clin Biol
Year: 2004
Volume: 28
Issue: 8-9
First Page: 720
Last Page: 759
DOI: 10.1016/s0399-8320(04)95062-2

Target ChEMBL ID: CHEMBL3879801
ChEMBL Target Name: NON-PROTEIN TARGET
ChEMBL Target Type: NON-MOLECULAR - Target has not been defined at a molecular level, only the non-molecular entity which is affected (e.g., organism, cell line etc)
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
Hepatotoxicity (acute)=0.2%
Hepatotoxicity (acute)=18.2%
Hepatotoxicity (acute)=0%
Hepatotoxicity (acute)=1%
Hepatotoxicity (acute)=0%
Hepatotoxicity (acute)=1.7%
Hepatotoxicity (acute)=0.2%
Hepatotoxicity (acute)=0%
Hepatotoxicity (acute)=0%
Hepatotoxicity (acute)=0%
Hepatotoxicity (acute)=2%
Hepatotoxicity (acute)=0%
Hepatotoxicity (acute)=5%
Hepatotoxicity (acute)=0%
Hepatotoxicity (acute)=0%
Hepatotoxicity (acute)=0%
Hepatotoxicity (acute)=0%
Hepatotoxicity (acute)=0%
Hepatotoxicity (acute)=2%
Hepatotoxicity (acute)=0%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: Ebola screen2_EM141217_green
Protocol: This 1536-well plate assay was adapted from the original 6-wells assay with a modification that eliminated cell wash steps. HeLa cells were plated at 750 cells/well in 3 microl of assay medium (DMEM + 10% FBS) in 1536-well assay plates and incubated for 16 hours at 37 degrees C and 5% CO2. Compounds in the 1536-well drug source plates were added to the 1536-well assay plates in a volume of 23 nl/well via a NX-TR pintool station (WAKO Scientific Solutions, San Diego, CA). Following 1-hour incubation at 37 degrees C with 5% CO2, 1 microl/well of VLP solution was added to the assay plates using a BioRapTR FRD dispenser (the VLP solution was diluted in Opti-MEM to a final concentration of 1:16). Plates were then spinoculated by centrifugation at 1500 rpm at 4 degrees C for 45 minutes followed by incubation at 37 degrees C with 5% CO2 for 4.5 hours. The CCF2-AM beta-lactamase substrate was prepared at 6x concentration following the manufacturer's instruction which was added to assay plates at 1 microl/well. Following a 2-hour incubation at room temperature, dual fluorescence intensities (Ex1 = 405+/-20, Em1 = 460+/-20, and Ex2 = 405+/-20, Em2 = 530+/-20 nm) were measured in an EnVision plate reader (PerkinElmer, Boston, MA). The ratio of fluorescence intensities (Em1/Em2) was calculated to represent the beta-lactamase activity that is proportional to the amount of VLP entry into the host cells.
Comment: The activity score was determined using both AC50, Efficacy and curve class. For a given compound j:
Activity is defined as the ability to inhibit viral entry.

If curve class = 4, activity score = 0 and outcome is set to 1. Compounds of this class have no significant activity points.
If efficacy is negative, activity score = 0 and outcome is set to 1. Compounds with negative efficacies, promote viral entry.

For all other curve classes:

Activity score(j) = [100*((max(Ac50)-Ac50(j))/(max(Ac50)-min(Ac50))) + 100*(1-(max(efficacy)-efficacy(j))/(max(efficacy)-min(efficacy))) ]/2

Compounds with Activity scores > 70% are deemed active, and the activity outcome is set to 2.

Note that this scoring scheme only applies to the ratio of blue/green fluorescence intensities because it is this ratio that represents the activity of Bla inside cells. Separate uploads of blue and green data exist in this assay group but information on activity should not be derived from these.

Refer to the following recent publication for more detail regarding active compounds:

Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs

Jennifer Kouznetsova, Wei Sun, Carles Marti nez-Romero, Gregory Tawa, Paul Shinn, Catherine Z Chen,
Aaron Schimmer, Philip Sanderson, John C McKew, Wei Zheng and Adolfo Garci a-Sastre

Emerging Microbes and Infections (2014) 3, e84; doi:10.1038/emi.2014.88
NCGC sample nbumberSample NameSupplierAc50Curve ClassEfficacyChannelChannel typeConc0Conc1Conc2Conc3Conc4Conc5Conc6Conc7Conc8Conc9Conc10Data0Data1Data2Data3Data4Data5Data6Data7Data8Data9Data10
10NEROLMicrosource12.589254124-28.228greenused to calculate ratio0.462.311.557.59.1270994759.61618564-3.7770449-15.60632145
3Phenol redLabotest0.707945784419.263greenused to calculate ratio0.462.311.557.5-9.385966028.828293685.796660949.22493965
4Aminoquinuride dihydrochlorideLabotest0.707945784418greenused to calculate ratio0.462.311.557.53.4615238822.8010761516.029539420.72614656
3Pyridoxamine DihydrochlorideBosche15.848931924-11.767greenused to calculate ratio0.462.311.557.53.2822761710.932088973.29047462-4.38930637
7CarzenideLabotest0.630957345411.002greenused to calculate ratio0.462.311.557.5-14.81373825-4.81206699-6.89129672-12.75493009
9PridinolSpecs102.236.664greenused to calculate ratio0.462.311.557.51.799217293.4608488822.2949210337.40401694
4ProcodazoleVitas0.6309573454-21.162greenused to calculate ratio0.462.311.557.511.00151234-9.702208834.56604819-14.71822198
3L-LeucineBosche0.891250938414.333greenused to calculate ratio0.231.155.7528.7-10.277274430.797956196.033257572.21607206
6FenticlorVitas3.162277664-28.657greenused to calculate ratio0.462.311.557.51.97467363-4.86579376-26.3812188411.38643713
6CHLORPROTHIXENE HYDROCHLORIDEMicrosource39.810717065-98.319greenused to calculate ratio0.462.311.557.58.229873113.4401888532.34629485-69.99258758
9Cyclobenzaprine hydrochlorideMicrosource15.848931922.1107.682greenused to calculate ratio0.462.311.557.5-15.91101847-4.2171917225.3285511382.99755874
8Phosphonoacetic acidSIGMA14-15.333greenused to calculate ratio0.462.311.557.57.40981797-5.05293193-1.67180124-11.11044314
17DomperidoneMicrosource25.118864322.1125.472greenused to calculate ratio0.462.311.557.5-10.68996778-0.4700079216.1055883196.36730961
4PifexoleBionet0.6309573454-9.778greenused to calculate ratio0.462.311.557.5-0.02107281-10.25290078-6.57120927-2.6114683
15WY-14643SIGMA3.981071706419.845greenused to calculate ratio0.462.311.557.5-1.53727228-0.6332131222.4891074413.55929131
14OXAPROZINMicrosource39.81071706418.153greenused to calculate ratio0.462.311.557.55.23106550.41003145-0.5438345216.85882561
6Topotecan hydrochloridePrestwick31.62277662.11429.488greenused to calculate ratio0.462.311.557.533.64911259138.5512222284.01020061141.705944
12AZELAIC ACIDMicrosource10417.221greenused to calculate ratio0.462.311.557.5-7.26743084-1.90015675-1.269343046.54169513
13AmoxapineEnzo8.9125093812.194.86greenused to calculate ratio0.462.311.557.5-4.771443380.0424582366.6559176193.16864781
14R-(+)-AtenololVitas104-16.344greenused to calculate ratio0.462.311.557.5-9.75671331-3.63184443-17.25199222-4.91153437
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: DT40653
Protocol: Tox21 Assay Protocol Summary:

300 DT40 wild type cells in 5 uL/well were dispensed into white, solid-bottom 1536-well plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37 C/5% CO2 for approximately 0.5 hour, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred into the assay plate by a pintool work station (Kalypsys, San Diego, CA). The assay plates were incubated at 37 C/5% CO2 for 40 hours. After 5 uL per well of CellTiter-Glo reagent was added into each well of the assay plates, the plates were incubated for 30 min at room temperature and the luminescence intensity of the plates was measured using a ViewLux (PerkinElmer, Shelton, CT) plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000044240 uM-Replicate_1Activity at 0.0000098920 uM-Replicate_1Activity at 0.0000221200 uM-Replicate_1Activity at 0.0000618460 uM-Replicate_1Activity at 0.0001391192 uM-Replicate_1Activity at 0.0002694481 uM-Replicate_1Activity at 0.0005944760 uM-Replicate_1Activity at 0.00124 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00616 uM-Replicate_1Activity at 0.014 uM-Replicate_1Activity at 0.031 uM-Replicate_1Activity at 0.069 uM-Replicate_1Activity at 0.154 uM-Replicate_1Activity at 0.343 uM-Replicate_1Activity at 0.767 uM-Replicate_1Activity at 1.711 uM-Replicate_1Activity at 3.817 uM-Replicate_1Activity at 8.521 uM-Replicate_1Activity at 18.17 uM-Replicate_1Activity at 31.39 uM-Replicate_1Activity at 68.35 uM-Replicate_1Activity at 94.96 uM-Replicate_1Activity at 260.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Cytotoxic26.603236.966420Partial curve; partial efficacy-4.57512.72020.8066-39.4664-2.5-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-32.472-0.25570.1894-1.0942-0.5827-4.2967-5.868-6.7254-11.93875.14311.8075-4.2794-0.4027-4.0199-15.1045-32.472QC'd by BIOMOLCytotoxic29.849326.509520Partial curve; partial efficacy; poor fit-4.52512.63840.9875-26.5095
Inactive01.86170.797812.5-1.95440 0 0 0 0 0 0 0 0 0 0 0 0 0 013.436-3.4844-0.2195-0.0323-3.9215-4.0814-0.0401-0.8641-1.671-6.21177.13323.394912.058516.39137.133513.436QC'd by LabotestInactive0
Cytotoxic33.491572.589320Single point of activity-4.47514.95490.87-70.09812.4912-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-61.7558-5.4321-0.79632.7012-4.9918-9.0E-40.18971.83576.58097.28190.48664.686-3.50518.42064.2376-61.7558QC'd by NIEHSCytotoxic33.491548.466820Single point of activity-4.47514.95490.915-47.5343
Cytotoxic33.491562.335220Single point of activity-4.47514.95490.9666-60.31812.0171-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-52.91061.26516.74810.56595.4752-0.56413.2722-2.04112.0693-0.9569-1.23341.81252.32623.2022-1.746-52.9106QC'd by SigmaAldrichCytotoxic33.491555.158120Single point of activity-4.47514.95490.9353-53.8129
Cytotoxic0.059689.024292Complete curve; high efficacy-7.22511.78850.992-89.7743-0.75-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-79.2674-0.2675-0.0127-3.3186-0.3113-8.6624-24.8555-49.0768-77.442-90.0161-91.8738-92.0934-92.3604-91.6897-87.2484-79.2674QC'd by SigmaAldrichCytotoxic0.094489.564392Complete curve; high efficacy-7.02511.86170.9962-91.4613
Cytotoxic6.682427.545720Partial curve; partial efficacy; poor fit-5.17512.25260.861-25.54572-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-26.28819.49086.5142-4.21044.75951.44771.72043.2832-0.4826-3.55211.5616-1.0976-1.442-21.2425-19.2902-26.2881QC'd by BIOMOLInactive03.24750.9525-18.8964
Cytotoxic23.710193.126841Partial curve; high efficacy-4.62513.92950.9489-91.0412.0858-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-85.2443-3.1984-0.199713.89730.60014.4648-8.30652.45650.811-0.2967-0.07760.088610.98955.4259-31.5062-85.2443QC'd by BIOMOLCytotoxic29.8493108.411840Partial curve; high efficacy-4.52514.0950.9921-108.5943
Inactive02.24810.5195-8.526140 0 0 0 0 0 0 0 0 0 0 0 0 0 112.5751-5.85510.12813.73894.13328.24181.27954.25414.65918.42590.13073.147412.08273.9666.749912.5751QC'd by ART-CHEMInactive02.25260.48479.5
Cytotoxic9.439234.203321Complete curve; partial efficacy-5.02513.1320.894-32.31981.8834-1.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-31.61375.31591.7117-0.85858.78-0.0810.7177-0.76264.06551.1951-4.8016-3.6366-0.459-14.2043-30.7093-31.6137QC'd by MicrosourceCytotoxic26.603248.471820Partial curve; partial efficacy-4.57512.53340.9934-48.0851
Inactive04-16.177-0.1697-9.1792-4.21641.9066-5.3806-0.96160.4121-5.1331-3.3638-0.05870.4161-5.1357-5.4857-1.2925-16.177QC'd by TocrisInactive04.44950.918310
Cytotoxic10.590985.872682Complete curve; high efficacy-4.97513.92950.9788-84.34711.5254-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-83.19184.19197.6194-2.25542.112711.554-1.9447-0.363-1.4443-5.1393-0.2045-0.4497-1.9204-25.8199-80.5151-83.1918QC'd by BIOMOLCytotoxic18.8336109.803841Partial curve; high efficacy-4.72512.33320.9775-108.1925
Inactive0410.93317.2308-0.76461.9030.8854-12.36610.0538-0.03730.03780.85910.1617-0.68821.54178.41924.24810.9331QC'd by DPISMRInactive02.40640.437310
Inactive03.92950.545916.5-1.032140 0 0 0 0 0 0 0 0 0 0 0 0 0 015.0573-1.0016-2.8234-2.88181.553-4.404-7.94341.5739-2.1443-4.82762.255.35516.2847-6.12956.377615.0573QC'd by TimtecInactive00.70.44975.5
Cytotoxic29.8493110.252640Partial curve; high efficacy-4.52512.30310.9779-109.67690.5757-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-83.08850.20916.1543-0.0464-5.63920.8022-1.55-1.65864.52973.84694.02740.9875-0.3079-12.105-32.034-83.0885QC'd by SigmaAldrichCytotoxic23.7101107.138841Partial curve; high efficacy-4.62513.1320.9922-106.8899
Cytotoxic4.216370.168183Complete curve; high efficacy-5.37511.82650.9542-75.4788-5.3107-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-66.79042.2008-11.44290.78810.9581-3.3197-4.8289-11.2303-7.4383-13.5817-10.6197-19.4834-33.1317-70.7599-75.9063-66.7904QC'd by SigmaAldrichCytotoxic6.682485.17583Complete curve; high efficacy-5.17512.25260.9899-85.1455
Inactive040.61421.36820.7153-0.4571-0.0959-0.8039-4.1432-4.6019-4.3611-0.5841.49151.5429-6.74321.21242.11860.6142QC'd by Toronto ResearchInactive0
Inactive02.24810.6569-25.4435040 0 0 0 0 0 0 0 0 0 0 0 0 0 1-6.9489-9.0935-1.1970.4962-0.2828-0.2884-0.6514-0.4859-0.9558-0.834612.2159-0.8399-4.0992-10.64-20.7863-6.9489QC'd by MicrosourceInactive03.990.9151-12.2781
Cytotoxic11.883290.050282Complete curve; high efficacy-4.92512.47290.973-88.31971.7305-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-87.10032.5615-9.7822-0.0524-0.0447.70862.0062.3996-2.72396.63640.75558.2888-9.0916-27.0183-69.093-87.1003QC'd by SigmaAldrichCytotoxic16.7855111.787642Partial curve; high efficacy-4.77512.25260.9888-110.5514
Inactive045.64962.63765.96770.68332.59292.6537-0.6376-1.73942.60582.96495.1854-1.38641.1535-2.51674.08825.6496QC'd by MicrosourceInactive0
Cytotoxic0.013384.417393Complete curve; high efficacy-7.87513.06540.9777-79.41735-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-65.1036-0.246612.5138-0.0588-0.1182-44.5452-81.5515-76.6214-76.487-79.8263-80.1839-83.5104-84.3071-81.9727-77.6097-65.1036QC'd by SigmaAldrichCytotoxic0.018881.862693Complete curve; high efficacy-7.72513.1320.9924-80.8961
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL3137726
Protocol: N/A
Comment: Journal: Gastroenterol Clin Biol
Year: 2004
Volume: 28
Issue: 8-9
First Page: 720
Last Page: 759
DOI: 10.1016/s0399-8320(04)95062-2
Standard TypeStandard RelationStandard ValueActivity Comment
Hepatotoxicity (cytolytic)=0references out of a total of 1
Hepatotoxicity (cytolytic)=6references out of a total of 69
Hepatotoxicity (cytolytic)=1references out of a total of 5
Hepatotoxicity (cytolytic)=8references out of a total of 27
Hepatotoxicity (cytolytic)=0references out of a total of 13
Hepatotoxicity (cytolytic)=1references out of a total of 1
Hepatotoxicity (cytolytic)=7references out of a total of 132
Hepatotoxicity (cytolytic)=3references out of a total of 23
Hepatotoxicity (cytolytic)=0references out of a total of 1
Hepatotoxicity (cytolytic)=3references out of a total of 9
Hepatotoxicity (cytolytic)=9references out of a total of 34
Hepatotoxicity (cytolytic)=3references out of a total of 5
Hepatotoxicity (cytolytic)=27references out of a total of 53
Hepatotoxicity (cytolytic)=1references out of a total of 1
Hepatotoxicity (cytolytic)=3references out of a total of 14
Hepatotoxicity (cytolytic)=1references out of a total of 5
Hepatotoxicity (cytolytic)=0references out of a total of 3
Hepatotoxicity (cytolytic)=0references out of a total of 16
Hepatotoxicity (cytolytic)=53references out of a total of 123
Hepatotoxicity (cytolytic)=0references out of a total of 4
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: ARN311
Protocol: Tox21 Assay Protocol Summary:

AR-bla cells were dispensed at 2,000 cells/5 uL of assay medium per well into black wall/clear-bottom 1536-well plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at a 37C and 5% CO2 for 4 hr, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a Pintool station (Kalypsys, San Diego, CA), followed by addition of 1 uL of agonist (R1881) in culture medium using a Bioraptr Flying Reagent Dispenser (FRD) workstation (Beckman Coulter, Indianapolis, IN, USA). The plates were incubated at a 37C and 5% CO2 for 16 h. After 1 uL of LiveBLAzerTM B/G FRET substrate was added using a Bioraptr FRD, the plates were incubated at room temperature for 2 h and fluorescence intensity was measured by an Envision plate reader (PerkinElmer, Shelton, CT).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W460-Activity_Score-Replicate_1W460-Curve_Description-Replicate_1W460-Fit_LogAC50-Replicate_1W460-Fit_HillSlope-Replicate_1W460-Fit_R2-Replicate_1W460-Fit_InfiniteActivity-Replicate_1W460-Fit_ZeroActivity-Replicate_1W460-Fit_CurveClass-Replicate_1W460-Excluded_Points-Replicate_1W460-Max_Response-Replicate_1W460-Activity at 0.0000036780 uM-Replicate_1W460-Activity at 0.0000082250 uM-Replicate_1W460-Activity at 0.0000183900 uM-Replicate_1W460-Activity at 0.0000514202 uM-Replicate_1W460-Activity at 0.0001156673 uM-Replicate_1W460-Activity at 0.0002261535 uM-Replicate_1W460-Activity at 0.0004949824 uM-Replicate_1W460-Activity at 0.00102 uM-Replicate_1W460-Activity at 0.00229 uM-Replicate_1W460-Activity at 0.00510 uM-Replicate_1W460-Activity at 0.011 uM-Replicate_1W460-Activity at 0.025 uM-Replicate_1W460-Activity at 0.057 uM-Replicate_1W460-Activity at 0.127 uM-Replicate_1W460-Activity at 0.284 uM-Replicate_1W460-Activity at 0.634 uM-Replicate_1W460-Activity at 1.415 uM-Replicate_1W460-Activity at 3.154 uM-Replicate_1W460-Activity at 7.040 uM-Replicate_1W460-Activity at 15.11 uM-Replicate_1W460-Activity at 27.01 uM-Replicate_1W460-Activity at 58.48 uM-Replicate_1W460-Activity at 78.95 uM-Replicate_1W460-Activity at 216.1 uM-Replicate_1W460-Activity at 765.1 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1Ratio-Activity at 0.0000036780 uM-Replicate_1
Inactive04-0.31012.60345.2328-7.4588-22.40130.375-0.1984-2.3931-1.2564-8.09639.3404-3.06595.9663-1.58734.5199-0.3101104-3.9642
Inactive04.95490.3643-22.3778-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-16.78168.0187-3.6037-16.9815-3.8818-2.29095.01652.79550.20882.48671.7989-1.54061.7447-0.235-0.7352-16.7816104-2.2059
Inactive043.57430.8747-3.9166-24.45945.89297.288-1.3695-3.01450.7455-3.3797-5.98945.1771-6.5534-24.68652.32073.57431047.5783
Inhibitor4.900828.1010Complete curve; partial efficacy-5.35974.95490.9394-35.05232.1161-1.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-28.73956.47820.5836-2.50425.18514.7563-0.0076-2.0536-0.46464.28292.77760.8265-36.8316-41.2003-30.0841-28.73950Complete curve; partial efficacy-5.30974.95490.9573-29.601-1.5-1.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-27.6016
Inactive04.95490.4916-1.809223.566940 0 0 0 0 0 0 0 0 0 0 0 0 0 115.21822.11765.5545-21.01622.15544.6396-7.65691.92745.3607-1.5953-4.5468-0.6799-3.76644.0052-3.946215.2181044.8462
Inactive01.10.6588302.061440 0 0 0 0 0 0 0 0 0 0 0 0 0 025.1973-3.28439.6853-7.44880.23246.60482.10544.31735.821-1.74083.4799.49854.81177.719714.363925.1973103.990.399610.5-1.1740 0 0 0 0 0 0 0 0 0 0 0 0 0 09.5095
Inactive049.77122.536-6.562-5.3417-5.9234-39.9488-5.968110.84588.9255-0.24792.9806-6.8833-4.3579-1.6090.52489.7712104.95490.5937-14.8893140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-11.4453
Inactive04.95490.4788-6.55483.540 0 0 0 0 0 0 0 0 0 0 0 0 0 14.7498-1.96698.88083.7797-1.19723.771-1.813610.85376.00320.95625.55565.91760.0775-8.7957-4.39424.7498104.95490.4162-8.4461040 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.3101
Inactive04-0.6526-2.05915.3448-1.516310.020411.48099.60240.498-2.8963-39.9716-6.1745-8.80585.1369-5.28877.5723-0.6526104-6.969
Inactive04.95490.66612.5-2.425140 0 0 0 0 0 0 0 0 0 0 0 0 0 12.24016.20333.29734.4221-3.8862-9.9376-8.1449-6.8511-1.9679-2.63936.38114.984911.18028.177315.06922.24011041.9909
Cytotoxic38.68696.04760Complete curve; high efficacy; poor fit-5.16240.90.9679-177.45466.148-1.30 0 0 0 0 0 0 0 0 0 1 0 0 0 0-159.8693.34737.22885.9146-7.062810.2393-3.541.646215.78721.384-48.661194.1427-91.3502-99.691-149.1613-159.8690Complete curve; high efficacy; poor fit-5.96242.72020.9288-80.8591.6099-1.30 0 0 0 0 0 0 0 0 0 1 0 0 0 1-28.5303
Inactive04.44950.3508-1.0294640 0 0 0 1 0 0 0 0 0 0 0 0 0 19.47328.76138.5543-0.62945.1568-40.71868.076-9.6078-4.29426.8911-0.0474-2.5230.1723.3311-4.05699.47321040.4281
Inactive04-2.2793-16.1966-0.33634.1517210.08650.3009-24.2384.08051.40143.5487-26.7861-1.9657-20.1052-24.4126-2.7694-2.2793104.95490.479-5.1746-140 0 0 1 0 0 0 0 0 0 0 0 0 0 1-2.7494
Inconclusive0Complete curve; partial efficacy; poor fit-4.71813.57220.8573-36.7503-1.463-1.40 0 0 0 1 0 0 0 0 0 0 0 0 0 0-36.42773.30930.74498.2023-4.0947-36.5254-9.3605-10.5624-1.31474.1105-3.7252-2.4539-2.446-11.8667-32.5393-36.4277102.72020.3396-13.3921-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-3.4638
Inconclusive040.358-5.80154.891-0.6919-11.0079-19.6144-7.4623-14.0156-21.4722-10.8579-10.9036-26.1342.925-6.5462-3.80530.35805-38.8248
Inactive04-0.5281-8.24323.7508-2.013114.742614.78921.06921.9847-2.24831.13697.4486-0.4716-7.2648-0.5094-1.7998-0.5281104-2.7813
Inactive0413.8550.0073-4.1723-6.3962.5792-2.82416.1567-21.5019-29.61284.9675-2.8564-1.19920.5899-22.10866.170313.855104.95490.46645-2.923640 0 0 0 0 0 0 0 0 0 0 0 0 0 09.0459
Inactive0410.291510.321.9833-3.4895-1.877-21.07441.25514.61272.0503-1.5541-16.7527-14.5002-14.25263.41944.086110.2915104.95490.33674-3.212740 0 0 0 0 0 0 0 0 0 0 0 0 0 03.6514
Inactive0410.5698-4.85215.51528.02770.6693-0.41221.17524.28157.796711.6703-2.4145-3.5827-17.7432-1.69017.194110.56981040.1918
Inconclusive0Single point of activity-4.22274.95490.346146.34681.113330 0 0 0 0 0 0 0 0 0 0 0 0 0 036.2338.384418.3726-16.520613.7807-9.255918.1763-8.395215.30761.533-21.84513.56131.7241-8.64971.984936.23310413.1112
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: ARV616
Protocol: Tox21 Assay Protocol Summary:

AR-bla cells were dispensed at 2,000 cells/5 uL of assay medium per well into black wall/clear-bottom 1536-well plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at a 37C and 5% CO2 for 4 hr, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a Pintool station (Kalypsys, San Diego, CA), followed by addition of 1 uL of agonist (R1881) in culture medium using a Bioraptr Flying Reagent Dispenser (FRD) workstation (Beckman Coulter, Indianapolis, IN, USA). The plates were incubated at a 37C and 5% CO2 for 16 h. After 1 uL of LiveBLAzerTM B/G FRET substrate was added using a Bioraptr FRD, the plates were incubated at room temperature for 2 h and fluorescence intensity was measured by an Envision plate reader (PerkinElmer, Shelton, CT). For cell viability readout that measures cytotoxicity, 4 ul/well of CellTiter-Glo reagent was added into the assay plates using a Bioraptr FRD. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux (PerkinElmer) plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000036780 uM-Replicate_1Activity at 0.0000082250 uM-Replicate_1Activity at 0.0000183900 uM-Replicate_1Activity at 0.0000514202 uM-Replicate_1Activity at 0.0001156673 uM-Replicate_1Activity at 0.0002261535 uM-Replicate_1Activity at 0.0004949824 uM-Replicate_1Activity at 0.00102 uM-Replicate_1Activity at 0.00229 uM-Replicate_1Activity at 0.00510 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.284 uM-Replicate_1Activity at 0.634 uM-Replicate_1Activity at 1.415 uM-Replicate_1Activity at 3.154 uM-Replicate_1Activity at 7.040 uM-Replicate_1Activity at 15.11 uM-Replicate_1Activity at 27.01 uM-Replicate_1Activity at 58.48 uM-Replicate_1Activity at 78.95 uM-Replicate_1Activity at 216.1 uM-Replicate_1Activity at 765.1 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive03.990.489514.50.387740 0 0 0 0 0 0 0 0 0 0 0 0 0 013.2432-1.4837-1.6377-3.01028.48310.8069-0.8928-2.96526.0294-1.26660.4119-2.01115.2633-2.51414.891813.2432QC'd by NCIInactive0
Cytotoxic13.448167.03541Partial curve; partial efficacy-4.87132.40640.9483-65.88481.1503-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-59.76121.68940-2.57354.3167-3.07571.9178-6.31482.56240.402502.28668.7363-6.0795-46.5284-59.7612QC'd by NCICytotoxic13.448169.062181Complete curve; high efficacy-4.87132.33320.9121-70.6029
Inactive043.7161-12.2751-2.3002-1.6316-15.18541.85713.3342-2.9699-2.0413-13.1818-11.27081.9534-1.39975.1131.14923.7161QC'd by NCIInactive0
Cytotoxic26.832590.849140Partial curve; high efficacy-4.57134.95490.8098-100.2645-9.4153-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-87.95134.2098-19.4478-12.20980.47056.202-13.0275-8.0765-22.0722-18.7099-9.553-20.4345-22.753-16.0947-14.5884-87.9513QC'd by SigmaAldrichCytotoxic26.8325110.606120Single point of activity-4.57134.95490.9757-108.5139
Cytotoxic6.00741.257822Complete curve; partial efficacy-5.22134.95490.9195-42.3449-1.0871-1.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-38.8534-4.4571-8.2748-4.9404-4.3576-4.27765.7531-3.633-1.35980.4958-0.35669.6775-1.5757-32.4825-46.1934-38.8534QC'd by NCICytotoxic10.682254.444561Complete curve; partial efficacy-4.97131.96730.9226-56.5233
Inconclusive26.8325150.171210Single point of activity-4.57134.95490.961153.07962.908430 0 0 0 0 0 0 0 0 0 0 0 0 0 0134.99081.82296.173310.52991.98726.71850.93511.7089-2.14774.2188-0.774613.82718.41320.8303-0.7732134.9908QC'd by NCIInactive0
Inactive01.22210.41864.5-1.930740 0 0 0 0 0 0 0 0 0 0 0 0 0 04.5856-1.3196-3.69221.36491.0832-0.47954.06122.32967.17138.75533.06883.76594.0884-2.7456.66394.5856QC'd by NCIInactive0
Inconclusive7.562471.092210Partial curve; partial efficacy-5.12130.50.76765.1454-5.94682.20 0 0 0 0 0 0 0 0 0 0 0 0 0 046.6342-12.7974-15.4917-0.52960.2388-0.06146.16276.93520.91150.8063.362617.856616.391350.940121.053146.6342QC'd by NCIInactive00.90.42887.5
Inactive041.29870.26417.9226-0.14278.425418.07622.74773.60225.78683.0364-1.92855.85980.202813.7133.40951.2987QC'd by NCIInactive04.95490.4355-1.0732
Inactive04.95490.7188-15.88482.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-13.18360.6525-7.001912.4053-1.472514.74161.3425-4.94940.5613-16.3729-15.2237-21.154-15.1498-14.4462-14.3984-13.1836QC'd by LabotestInactive04.0950.5528-3.855
Inactive04-20.3003-1.0649-10.444-8.75741.6777-10.2125-0.2685-12.5512-13.1255-0.925-7.2786-11.9660.72411.86010.3951-20.3003QC'd by NCIInactive04.95490.5261-23.8123
Inactive04.95490.39593-2.823940 0 0 0 0 0 0 0 0 0 0 0 0 0 03.5673-4.4366-1.0393-2.2619-0.07424.96018.6841.9313-1.37982.68612.98159.12642.3321-1.23280.89963.5673QC'd by NCIInactive04.95490.3659-17.5729
Inactive03.51170.37556-6.443540 0 0 0 0 0 0 0 0 0 0 0 0 0 06.5687-11.2029-0.0395-5.077916.227812.909711.73155.59741.1191-0.30784.957313.204-1.0463-0.93975.026.5687QC'd by NCIInactive0
Cytotoxic16.930159.884821Partial curve; partial efficacy-4.77133.06540.9188-51.38618.4987-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-46.574-0.8676-0.623810.27414.57089.75410.356513.39938.374912.692113.1394.955512.28047.6603-22.9522-46.574QC'd by NCICytotoxic21.313867.884841Partial curve; partial efficacy-4.67131.71370.9408-70.3536
Inactive046.959-0.79660.388-1.0081-2.52160.3745-0.9254-0.49080.00549.84677.2309-1.9095-1.85539.9124-2.0026.959QC'd by NCIInactive04.95490.419911
Inactive042.67970.81320.67155.9018-12.1997-1.08692.54263.33172.1845-1.5877-1.7464-0.16223.45931.06253.25792.6797QC'd by NCIInactive00.90.582-33.3132
Inactive040.6948-5.0672-1.3719-2.8148-0.91130.70280.4556-2.1179-0.7521-3.09620.8353-4.0848-8.6081-7.87880.02230.6948QC'd by NCIInactive0
Inactive042.34697.3341-10.0256-1.419223.5642-8.5631-10.8052-3.591-20.1453-0.5542-4.3357-14.70621.0266-1.0905-3.56012.3469QC'd by ChembridgeInactive01.28760.3307-0.9589
Inactive04-3.4301-3.1069-2.9432-2.5794-6.3741-1.8324-1.6472.01951.609-1.9177-3.2478-5.222-6.2901.2803-3.4301QC'd by NCIInactive0
Inactive04.95490.3885-13.31410.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-11.5118-2.3747-1.76850.3253-8.23524.83090.23524.69012.66612.5173-5.7374.83960.06945.051-0.7597-11.5118QC'd by NCIInactive04.95490.7687-23.7162
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: ARA345
Protocol: Tox21 Assay Protocol Summary:

AR-bla cells were dispensed at 2,000 cells/6 uL/well of assay medium into black wall/clear-bottom 1536-well plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37C and 5% CO2 for 4 h, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a Pintool station (Kalypsys, San Diego, CA). The plates were incubated at 37C and 5% CO2 for 16 h. Then 1 uL of LiveBLAzerTM B/G FRET substrate was added using a Bioraptr Flying Reagent Dispenser (FRD) workstation (Beckman Coulter, Indianapolis, IN, USA). The plates were incubated at room temperature for 2 h, and fluorescence intensity was measured by an Envision plate reader (PerkinElmer, Shelton, CT).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W460-Activity_Score-Replicate_1W460-Curve_Description-Replicate_1W460-Fit_LogAC50-Replicate_1W460-Fit_HillSlope-Replicate_1W460-Fit_R2-Replicate_1W460-Fit_InfiniteActivity-Replicate_1W460-Fit_ZeroActivity-Replicate_1W460-Fit_CurveClass-Replicate_1W460-Excluded_Points-Replicate_1W460-Max_Response-Replicate_1W460-Activity at 0.0000036780 uM-Replicate_1W460-Activity at 0.0000082250 uM-Replicate_1W460-Activity at 0.0000183900 uM-Replicate_1W460-Activity at 0.0000513298 uM-Replicate_1W460-Activity at 0.0001155496 uM-Replicate_1W460-Activity at 0.0002337114 uM-Replicate_1W460-Activity at 0.0005013406 uM-Replicate_1W460-Activity at 0.00101 uM-Replicate_1W460-Activity at 0.00226 uM-Replicate_1W460-Activity at 0.00505 uM-Replicate_1W460-Activity at 0.011 uM-Replicate_1W460-Activity at 0.025 uM-Replicate_1W460-Activity at 0.056 uM-Replicate_1W460-Activity at 0.125 uM-Replicate_1W460-Activity at 0.280 uM-Replicate_1W460-Activity at 0.624 uM-Replicate_1W460-Activity at 1.391 uM-Replicate_1W460-Activity at 3.095 uM-Replicate_1W460-Activity at 6.900 uM-Replicate_1W460-Activity at 15.01 uM-Replicate_1W460-Activity at 29.19 uM-Replicate_1W460-Activity at 62.39 uM-Replicate_1W460-Activity at 79.14 uM-Replicate_1W460-Activity at 216.1 uM-Replicate_1W460-Activity at 765.1 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1Ratio-Activity at 0.0000036780 uM-Replicate_1
Inactive042.6547-0.7130.5183-2.1304-1.9979-1.3265-0.01867.93330.6342-0.1739-0.62145.78417.3104-0.178-7.78592.6547104-3.7851
Inactive042.32568.2060.78711.46461.73150.42748.95695.63553.13353.05-0.77786.510113.61665.19684.14212.3256104-12.1995
Activator18.995930.02560Partial curve; partial efficacy-4.62132.78680.92154.46541.7612.20 0 0 0 0 0 0 0 0 0 0 0 0 0 043.4865-0.3029-0.49880.781111.26170.50915.70490.5268-1.4541-1.24463.5091-0.04480.11754.60116.157343.48650Partial curve; partial efficacy; poor fit-4.72133.19250.842124.5-5.52562.40 0 0 0 0 0 0 0 0 0 0 0 0 0 021.4158
Inactive04-0.0347-9.9873-2.6594-3.1088-0.3377-4.6023-3.692-4.8732-3.2091-0.3806-2.9603-2.7049-2.0287-2.7078-4.4199-0.034710419.5826
Inactive04-3.0982-0.68985.32923.8884-0.5236-0.6926-0.0665-0.01790.06230.6225-0.01212.8929-0.0136.26380.0671-3.0982104-0.058
Activator0.095246.28080Single point of activity-7.07134.95490.994638.71930.012430 0 0 0 0 0 0 0 1 1 1 1 1 1 1-7.8911.05910.73320.2659-1.2397-0.34750.40284.953335.975324.95868.10683.1498-1.567-1.4611-9.018-7.8910Complete curve; partial efficacy-7.02134.95490.935156.861410.58061.20 0 0 0 0 0 0 0 0 1 1 1 1 1 11.9859
Activator23.914570.16480Partial curve; partial efficacy; poor fit-4.62132.72020.943457.80860.94592.40 0 0 0 1 0 0 0 0 0 0 0 0 0 045.6562-1.0317-0.1745.39450.219443.7222-1.1805-5.8784-0.02260.5515.28252.84113.27656.642615.775845.65620Partial curve; high efficacy-4.62134.0950.810970.22490.06012.10 0 0 0 0 0 0 0 0 0 0 0 0 0 061.6926
Inactive04-0.6673-1.46352.2059-0.10010.6518-1.9790.24740.0709-3.6651-2.02110.50780.1094-1.5942-0.2166-1.4096-0.6673101.46410.3579-1-5.240440 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.2755
Inactive04.95490.918711-0.437940 0 0 0 0 0 0 0 0 0 0 0 0 0 08.8709-0.28480.04410.1474-0.1889-0.8305-2.44820.3683-0.4505-0.03670.1234-0.0247-0.2328-0.6585-0.49048.8709100.90.32894-5.857240 0 0 0 0 0 0 0 0 0 0 0 0 0 03.3152
Inactive041.43112.49333.1415-1.4347-0.6951-2.9577-0.15485.14650.1923-0.9057-0.04053.13677.31274.4602-6.46961.4311104-10.1923
Inconclusive04.44950.831416.50.329840 0 0 0 0 0 0 0 0 0 0 0 0 0 015.1543.023-0.00470.0318-0.8095-2.6418-0.00733.1252-0.6141-2.2083-0.12241.3932.2333-2.27025.32415.1540Partial curve; partial efficacy; poor fit-4.62134.0950.71920.5-0.60832.40 0 0 0 0 0 0 0 0 0 0 0 0 0 017.7834
Activator26.832536.12090Partial curve; partial efficacy; poor fit-4.67131.10.844321.49582.40 0 0 0 0 0 0 0 0 0 0 0 0 0 024.97210.59651.95030.5658-0.48080.4727-1.67022.251.19386.2013.92882.9774.918811.35138.676724.97210Single point of activity-4.57134.95490.895234-2.120930 0 0 0 0 0 0 0 0 0 0 0 0 0 030.3051
Inactive01.46410.624412.51.463440 0 0 0 0 0 0 0 0 0 0 0 0 0 010.4167-0.55140.01974.80125.9584-0.8638-0.0453-0.07061.48992.3896-0.76474.52240.82814.64997.782210.41671048.965
Inactive04.95490.597170.740440 0 0 0 0 0 0 0 0 0 0 0 0 0 06.07977.7111-0.0960.17431.623-3.96631.7402-0.65390.2819-0.27796.62437.06165.35719.67176.21496.07971042.9632
Inactive040.05040.05030.33210.3741-0.88310.70860.743713.5848-2.956-0.040.6316-0.27470.2085-0.9317-5.02210.0504103.51170.697212-1.376840 0 0 0 0 0 0 0 0 0 0 0 0 0 09.6003
Inactive04.95490.5151-12.03081.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-10.8591.10191.43572.73238.02021.79190.0334-4.95640.1170.62880.06953.5324-0.1651-0.10014.8039-10.859103.92950.4602-13.0918040 0 0 0 0 0 0 0 0 0 0 0 0 0 0-11.7432
Inactive04.95490.3517-1.127240 0 0 0 0 0 0 0 0 0 0 0 0 0 13.82333.9732-2.00965.51243.0247-0.01220.55981.88060.4643.8758-0.28-2.6058-2.04710.0558-0.01653.8233104-1.1763
Inconclusive15.08923.504-0.08610.50272.7158-3.1697-2.8957-0.2353-0.01494.66570.18430.35262.0111-2.86430.2611.87883.9696-0.08610Partial curve; partial efficacy; poor fit-4.87131.66040.9538-22.7891-1.5-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-20.6576
Inconclusive04.95490.7209-2.7152140 0 0 0 0 0 0 0 0 0 0 0 0 0 10.09050.36180.74711.1205-0.38111.42562.0678-0.18930.08741.98230.175-2.9381-3.5127-3.2857-0.61470.09050Partial curve; partial efficacy; poor fit-4.57134.95490.855226-4.23722.40 0 0 0 0 0 0 0 0 0 0 0 0 0 021.8381
Inactive04-0.630.1249-0.77332.204815.13662.89312.38250.15032.077917.27650.08482.06247.5723-0.4211.8017-0.63104-11.6985
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:846 靶标:N/A
External ID: 5mMGluc_INS1E_InsulinRelease_40mMGluc_SP
Protocol: N/A
Comment: N/A
Activity at 2 uMActivity at 10 uM
1.051.35
-1.2-2.5
0.6-0.4
1.10
2.050.15
-1.2-0.5
1.150.95
-0.4-2
0.7-1.2
-2.3-2.4
0.50.9
1.91.9
-1.16.2
-0.9-0.3
2.24.1
2.61.85
35.9
2.60.5
17.6
0.80.8
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: ERR985
Protocol: Tox21 Assay Protocol Summary:

The ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30-minute incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-2.5265-7.1483-6.3353-8.6464-2.6851-3.55893.2191-3.1242-5.8134-5.6348-5.47660.4473-0.0628-2.5265QC'd by SIGMAInactive0-4.274510.6363
Inactive00043.9024-0.01911.091.23652.36520.00372.0670.4851-0.4224-1.0393-0.4413.17850.34623.9024QC'd by SigmaAldrichInactive0
Inactive00040.8889-4.98190.1870.7854-0.1677-2.0871-0.80150.24410.7043-8.80280.1379-2.37921.85830.8889QC'd by ChemServiceInactive0-7.06644.95490.4482
Inhibitor50.390553.327221Partial curve; partial efficacy-4.29773.06540.9802-53.3433-0.0161-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-46.8509-1.3968-0.7491.0621-2.87011.05283.12180.0760.9249-0.49840.7261-1.3704-19.9808-46.8509QC'd by SigmaAldrichInactive0
Inhibitor70.827737.733910Partial curve; partial efficacy; poor fit-4.14981.46410.7102-39.7339-2-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-29.77821.0091-5.79512.7551.2254-6.9293.33021.728-8.1392-0.7165-6.4259-8.7096-8.3826-29.7782QC'd by SigmaAldrichInhibitor70.827741.854910Single point of activity-4.14984.50450.8302
Inhibitor61.503849.916621Partial curve; partial efficacy-4.21113.1320.892-53.3018-3.3852-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-42.2741-8.1807-7.61190.23321.57810.17121.3858-3.7535-3.206-6.6036-4.2950.0288-15.3692-42.2741QC'd by SIGMAInactive0
Inhibitor52.384150.532421Partial curve; partial efficacy-4.28082.40640.9534-51.6847-1.1523-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-40.2915-0.3854-0.06330.2042-1.816-8.719-1.02010.9052-1.1643-1.4537-2.6853-2.4432-20.0028-40.2915QC'd by SIGMAInhibitor58.775939.524221Partial curve; partial efficacy-4.230810.8135
Inactive0004-9.709-4.4881-6.0445-8.8766-4.0388-0.5862-4.6549-8.3113-5.6134-4.8338-4.5642-0.5579-3.4555-9.709QC'd by Alfa AesarInactive0-4.15283.990.694
Inactive00041.66471.2462-0.14863.91093.85360.66890.332-0.85721.14780.26430.82850.06271.34331.6647QC'd by SV ChembiotechInactive0-4.16373.92950.6564
Inactive0-6.2164.95490.70982-6.490740 0 0 0 0 0 0 0 0 0 0 0 0 0 06.5913-5.6041-9.9923-0.3428-7.6059-8.1832-4.6842-7.94470.1162.2630.2481.13570.77486.5913QC'd by SigmaAldrichInactive0
Inactive0-4.16644.95490.6737-25.7581-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.0484-0.84940.9603-8.21540.11392.05482.69681.41610.7927-9.70141.13732.2368-2.4398-21.0484QC'd by ChemServiceInactive0-4.36642.33320.8792
Inactive0-8.56773.1320.69960.5-9.217540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.1871-8.0979-1.72310.81240.29791.59360.956-0.5761.2867-4.1414-0.48432.01310.0104-0.1871QC'd by SIGMAInactive0
Inactive00045.07940.37572.19050.57630.92270.78453.46994.04961.90151.38273.96340.9117-0.60225.0794QC'd by SIGMAInactive0-4.96862.40640.6273
Inactive0-6.16074.95490.57915.5-2.430540 0 0 0 0 0 0 0 0 0 0 0 0 0 07.1812-3.6421-0.044-0.36213.4152-5.3209-0.5383-7.85872.63685.21583.6992.344410.63857.1812QC'd by City ChemicalInhibitor54.870797.99941Partial curve; high efficacy-4.26071.78850.9628
Inactive0004-7.623-2.2142-5.4178-2.8594-1.2478-3.2961-1.8162-3.3949-3.2651-2.4468-13.60120.62040.0323-7.623QC'd by SIGMAInactive0
Inactive0-7.13754.0950.34570-4.700140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-1.0759-3.7616-3.6914-6.6307-6.3734-2.2758-1.4469-2.07440.5601-2.1426-0.4933-0.57645.1155-1.0759QC'd by SIGMAInactive0-4.58753.29750.926
Inactive0-6.92270.30.66969.5-12.317940 0 0 0 0 0 0 0 0 0 0 0 0 0 010.1368-8.154-8.9165-0.0326-1.7004-6.75864.0282-0.75942.5751-1.1314-0.72269.25986.41410.1368QC'd by SIGMAActivator26.751674.08270Partial curve; high efficacy-4.57272.18760.9777
Inactive0-8.31644.95490.36241-4.006940 0 0 0 0 0 0 0 0 0 0 0 0 0 00.262-4.04751.1113-0.82860.46322.60630.59311.42180.5483-1.23861.81471.70282.46480.262QC'd by SIGMAInactive0-8.81644.95490.6203
Inactive0-4.86070.50.827124-3.343540 0 0 0 0 0 0 0 0 0 0 0 0 0 10.3215-3.1196-2.8382-4.3087-0.9342-1.40680.1964-2.25525.21846.34245.162110.173116.8440.3215QC'd by LKT LabActivator9.757633.8970Complete curve; partial efficacy-5.01073.06540.9367
Inactive0-7.82850.70.757422.5-441 0 0 0 0 0 0 0 0 0 0 0 0 0 13.832412.68164.022614.57444.428120.650914.83922.328422.246920.362223.860820.325322.23313.8324QC'd by SIGMAInactive0-4.42850.80.8451
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: ERR504
Protocol: Assay Protocol Summary:

The ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30-minute incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Activator0.769618.541110Partial curve; partial efficacy; poor fit-6.11370.40.4771201.45892.40 0 0 0 0 0 0 0 0 0 1 1 1 1 18.43542.60297.16556.98426.77576.23584.39893.727414.10836.104412.34916.28710.24048.4354QC'd by SIGMAInactive0-7.46371.10.4107
Activator0.001518.544Complete curve; partial efficacy-8.81374.95490.845716.5-21.20 0 0 0 0 0 0 0 0 0 0 1 0 1 112.76338.520316.029918.960814.610214.569714.66815.484519.340417.405215.435716.74874.776812.7633QC'd by AcrosInactive0
Inactive040 0 0 0 0 0 0 0 0 0 0 0 0 0 0-11.4538.53828.60629.13179.549110.755911.43756.467911.275510.13049.21297.3275-0.1191-11.453QC'd by SIGMAInactive0-4.36422.40640.8668
Inactive000417.43489.84064.73143.893717.43064.73392.71741.799421.142216.61518.79213.32233.134217.4348QC'd by Sigma DiscoveryCPRInactive0
Inactive000417.41599.11946.7603-2.39424.5125-5.07691.71712.688120.52570.113721.134-0.09350.75717.4159QC'd by EnamineInactive0-4.46372.35310.6137
Inactive0-8.51372.40640.34146.5-2.869340 0 0 0 0 0 0 0 0 0 0 0 0 0 09.2286-0.79294.86514.6489.82256.79684.62743.882111.065210.47076.49230.8715-0.7419.2286QC'd by SIGMAInactive0
Inhibitor3.063824.51160Complete curve; partial efficacy; poor fit-5.51374.95490.4049-18.61465.897-1.40 0 0 1 1 0 0 0 0 0 0 0 0 0 0-11.6821-3.038721.1044-20.78423.7169-18.207310.98469.041514.7886-15.2892-21.1562-17.0848-22.0042-11.6821QC'd by SIGMAInactive0
Activator0.001935.242610Complete curve; partial efficacy; poor fit-8.71424.95490.546629.4733-5.76921.40 0 0 0 0 0 0 0 0 0 0 1 1 1 1-35.059810.398831.296228.151536.89384.846829.689133.269131.780835.498622.02484.7913-29.1164-35.0598QC'd by SIGMAInactive0-4.31423.51170.6226
Inactive0004-0.31614.47693.98640.77972.2321.48744.16990.43690.07470.80680.3965-3.2133-3.9851-0.3161QC'd by SIGMAInactive0-4.71374.95490.3304
Inhibitor54.482733.50530Partial curve; high efficacy-4.26373.92950.9608-34.0053-0.5-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-30.00440.50840.4104-0.8948-3.2842-0.42840.0932-3.308-1.82040.56451.2561.479-9.8714-30.0044QC'd by Sigma DiscoveryCPRInhibitor68.589649.00410Single point of activity-4.16374.50450.9035
Inactive0-6.31374.95490.40220.5-2.854340 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.9062-1.42020.2852-3.8028-4.0452-3.8452-3.7145-3.80550.63741.33431.7137-3.28390.5803-2.9062QC'd by MP BiomedicalsInactive0
Inhibitor61.130658.88120Partial curve; high efficacy-4.21373.19250.9781-59.7265-0.8453-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-47.5201-0.605-1.4306-2.7189-0.8465-0.0963-1.1087-1.55290.5068-0.225-0.0391-7.585-12.7325-47.5201QC'd by SIGMAInhibitor61.130669.99940Partial curve; partial efficacy-4.21373.990.9846
Inhibitor48.508455.41370Partial curve; high efficacy-4.31423.06540.992-53.97671.437-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-46.95211.59250.5164-0.94190.64010.73652.10781.92572.71730.23973.6782-1.5898-20.1662-46.9521QC'd by SIGMAInhibitor54.427380.68770Partial curve; high efficacy-4.26422.47290.9773
Inactive00041.1920.359-0.3975-0.251.0086-0.1111.15210.61861.1885-1.45780.6853-0.92120.6021.192QC'd by SIGMAInactive0
Inactive00040.2182-3.0991-1.93151.3572-2.42631.55190.1835-0.68480.605-0.3437-2.1085-0.74640.05991.72430.2182QC'd by LightBiologicalsInactive0
Activator68.589630.210110Single point of activity-4.16373.24750.923330-0.210130 0 0 0 0 0 0 0 0 0 0 0 0 0 021.8495-0.3001-1.0271-2.0701-0.01770.97450.4274-1.8475-0.9875-0.00953.49112.8063.96521.8495QC'd by SIGMAInactive0-4.46371.92820.7837
Activator17.228923.958720Partial curve; partial efficacy-4.76370.60.7544240.04132.20 0 0 0 0 0 0 0 0 0 0 0 0 0 1-1.99880.30040.8704-1.63220.2766.3859-0.80141.77834.025210.31816.43328.494618.8419-1.9988QC'd by LightBiologicalsActivator24.336535.974310Single point of activity-4.61374.0950.8673
Inactive00040.8624-0.4215-2.3373-2.43560.2408-1.76690.8666-1.7395-2.0022-1.4521-1.4395-0.981-0.53890.8624QC'd by LightBiologicalsInactive0-4.51374.95490.8869
Inactive0-4.11374.95490.654990.039740 0 0 0 0 0 0 0 0 0 0 0 0 0 06.5998-0.8326-1.8287-1.08391.30271.03891.22330.81780.8549-1.37240.03750.73910.19056.5998QC'd by SIGMAInactive0-4.56374.95490.8448
Inactive0-4.56374.50450.4774.5-1.13740 0 0 0 0 0 0 0 0 0 0 0 0 0 1-3.7168-1.8447-2.9517-3.0308-1.8846-0.48982.2361-1.7012-0.2024-2.7129-0.6292-0.32113.7485-3.7168QC'd by SIGMAInactive0-4.11374.95490.7344
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:AR protein [Homo sapiens]
External ID: MDAN535
Protocol: Please refer to other AIDs 743042 and 743041 for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the AR antagonist mode assay (AID 743042) and cell viability counter screen (AID 743041). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Activity SummaryAR ActivityAR Potency (uM)AR Efficacy (%)Viability ActivityViability Potency (uM)Viability Efficacy (%)Sample Source
inactiveinactive0inactive0NCI
inconclusive agonistinconclusive agonistinactive0NCI
inconclusive antagonist (cytotoxic)active antagonist18.12455735-111.5015527active antagonist20.3992366-95.33077837NCI
inactiveinactive0inactive0NCI
inconclusive antagonist (cytotoxic)active antagonist33.49145963-71.97733202active antagonist33.49145963-45.59717193SigmaAldrich
inconclusive antagonist (cytotoxic)active antagonist24.63773286-89.63619394inconclusive antagonist33.49145963-42.65251674NCI
inactiveinactive0inactive0NCI
inactiveinactive0inactive0NCI
inactiveinactive0inactive0NCI
inactiveinactive0active antagonist30.2961402-37.60775273NCI
inactiveinactive0inconclusive antagonistLabotest
active antagonistactive antagonist28.72548756-74.97879422inconclusive antagonist32.33061121-27.15821987NCI
active antagonistactive antagonist27.64399095-64.36631028inactive0NCI
inactiveinactive0inactive0NCI
inconclusive antagonist (cytotoxic)inconclusive antagonist33.49145963-64.79576401active antagonist32.7130197-37.67340069NCI
inactiveinactive0inactive0NCI
inactiveinactive0inactive0NCI
inactiveinactive0inactive0NCI
inactiveinactive0inactive0Chembridge
inconclusive agonistinconclusive agonistinactive0NCI
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: ZIK159
Protocol: Assay Protocol Summary:

The medium for SNB-19 cells is composed of RPMI 1640 (ATCC, Cat.# 30-2001), 10% fetal bovine serum (FBS) (GE healthcare Life Sciences, Cat.# SH30071.03), and 1% Pen/Strep (Gibco, Cat.# 15140-122). A Caspase-Glo 3/7 assay kit (catalog number G8092; Promega, Madison, WI) was used to detect caspase-3 activity induced by Zika virus infection in human cells. The reagent mixture was reconstituted as described in the protocol from the manufacturer. Polystyrene tissue culture treated and PDL coated white plates were obtained from Greiner Bio-One (Monroe, NC). Cells were seeded in 384- or 1536-well assay plates and cultured at 37 C with 5% CO2 for 16 to 20 hours. The typical cell seeding density in the 1536-well plate assay is 250 cells/well in 3ul medium for SNB-19 cells in tissue culture treated plates. Compounds were added to cells and incubated for one hour before addition of ZIKV solution to cells (2 FFU/cell). After incubation at 37 C with 5% CO2 for 6 hours, the reagent mixture of Caspase-Glo 3/7 assay kit was added to each well, followed by incubation at room temperature for 30 minutes. The luminescence intensity of the assay plates was measured using a ViewLux plate reader (PerkinElmer). Data were normalized by using the cell-containing wells without ZIKV as a negative control (0% induction of caspase 3/7 activity) and wells containing ZIKV infected cells (Caspase-3 activity induced) as a positive control (100% induction of caspase 3 activity). The percentage inhibitions of the increased Caspase-3 activity by small molecule inhibitors were then calculated.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001529332 uMActivity at 0.0003637214 uMActivity at 0.0006049985 uMActivity at 0.0007847206 uMActivity at 0.00233 uMActivity at 0.00410 uMActivity at 0.00702 uMActivity at 0.012 uMActivity at 0.021 uMActivity at 0.043 uMActivity at 0.064 uMActivity at 0.189 uMActivity at 0.345 uMActivity at 0.568 uMActivity at 0.973 uMActivity at 1.726 uMActivity at 4.529 uMActivity at 9.061 uMActivity at 15.16 uMActivity at 20.54 uMActivity at 45.68 uMActivity at 92.75 uMActivity at 177.7 uMActivity at 231.2 uMCompound QC
Inactive0-6.57924.95490.3504-2.229914.585140 0 0 0 0 0 0 0 0 0 0-5.356915.474625.14691.32891.457930.092112.8619-9.5062-12.2483-4.443920.4415-5.3569QC'd by BIOMOL
Inactive00040.140559.29224.527917.63713.780410.6882-1.5038-3.37094.203930.3994-1.99860.1405QC'd by BIOMOL
Inactive0-8.32924.95490.7822-3.268722.540 0 0 0 0 0 0 0 0 0 0-5.221915.927728.3896-3.44590.9788-0.6642-4.0601-8.14096.6432-8.9739-5.0251-5.2219QC'd by BIOMOL
Inactive0-7.17923.06540.4254932.145740 0 0 0 0 0 0 0 0 0 135.30295.277541.434433.152350.303620.24367.33299.210316.67199.450714.423135.3029QC'd by BIOMOL
Inactive0-8.37924.95490.35830.9315.540 0 0 0 0 0 0 0 0 0 119.319111.410119.1762-0.614-5.8917-0.005821.4835-3.85571.8137-0.8127-2.822419.3191QC'd by BIOMOL
Activator26.3506106.31810Single point of activity-4.57924.95490.950195.6321-10.685930 0 0 0 0 0 0 0 0 0 089.5669-8.1996-4.634-16.5004-16.3027-20.3551-20.1104-2.4639-1.956-4.3704-4.164789.5669QC'd by BIOMOL
Inactive0-9.02924.95490.39864-15.151240 0 0 0 0 0 0 0 0 0 011.3272-9.70937.84233.37613.399312.5003-0.1871-0.4744-2.70083.131-0.583111.3272QC'd by BIOMOL
Inactive0-4.47920.80.6034-34.4978-440 0 0 0 0 0 0 0 0 0 0-27.0815-0.6401-2.5148-2.2817-11.00811.0964-8.2348-11.6629-9.9639-6.098-9.2602-27.0815QC'd by BIOMOL
Inactive0004-0.534621.15938.357233.008610.588322.210240.91430.450915.303915.248315.763-0.5346QC'd by BIOMOL
Inactive0-7.37924.95490.72140.194224.863440 0 0 0 0 0 0 0 0 0 04.066615.530928.052423.038933.3812-2.1843-9.34578.111511.7564-7.393-1.86714.0666QC'd by BIOMOL
Inactive0004-29.782-16.4018-13.9219-14.5268-17.1479-18.872416.6048-0.8381-12.8788-19.3078-27.9636-29.782QC'd by BIOMOL
Inactive0004-9.6121-3.3856-4.2081-0.1463-6.8307-5.50433.9502-1.1496-1.2765-3.5332-1.7407-9.6121QC'd by BIOMOL
Activator0.331733.60330Complete curve; partial efficacy; poor fit-6.47920.70.714330.0135-3.58981.40 0 0 0 0 0 0 0 0 0 022.2786-3.1933-2.4551-4.04170.021512.07325.324119.20397.398643.355928.542722.2786QC'd by BIOMOL
Inactive0004-9.58580.041-18.54712.7931-0.1637-0.4717-3.0273-11.8154-12.2288-9.8437-6.1918-9.5858QC'd by BIOMOL
Inactive00043.544242.3006-2.999222.3937.6161-4.116332.17070.342-5.177242.8575-0.91733.5442QC'd by BIOMOL
Inactive0-6.37924.95490.3244-0.6421040 0 0 1 0 0 0 0 0 0 15.11119.82912.00793.113638.3079-0.532125.7035-1.3518-3.035-0.42124.22735.1111QC'd by BIOMOL
Inactive0-6.87924.95490.39070.6238.540 0 0 0 0 0 0 0 0 0 17.33186.6121-0.51588.08089.177318.9883-0.89744.13632.4077-2.3975-0.54117.3318QC'd by BIOMOL
Inactive0-7.62922.25260.46726-9.673540 0 0 0 0 0 0 0 0 0 04.0434-5.2371-12.2279-11.2597-1.22923.2718-0.865126.0229-0.0171-0.60298.95184.0434QC'd by BIOMOL
Inactive0004-0.5003-6.954428.7797-7.1636-6.6411.8449-16.4193-9.0529-12.5437-4.3363-10.7171-0.5003QC'd by BIOMOL
Inactive00049.9428-15.654318.1375-12.36-2.562816.0422-19.5863-8.3403-1.4148-7.26780.13079.9428QC'd by BIOMOL